BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images, please do not report the images to the Image Problem Mailbox.

M·H

PCT/US99/13959

PATENT COOPERATION TREATY

From the INTERNATIONAL BUREAU

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

To:

Assistant Commissioner for Patents
United States Patent and Trademark Office
Box PCT
Washington, D.C.20231
ÉTATS-UNIS D'AMÉRIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 10 March 2000 (10.03.00)	
International application No. PCT/US99/13959	**Applicant's or agent's file reference** 1151-4153PC1
International filing date (day/month/year) 21 June 1999 (21.06.99)	**Priority date** (day/month/year) 20 June 1998 (20.06.98)
Applicant WANG, Chang, Yi et al	

1. The designated Office is hereby notified of its election made:

[X] in the demand filed with the International Preliminary Examining Authority on:

18 January 2000 (18.01.00)

[ ] in a notice effecting later election filed with the International Bureau on:

2. The election [X] was

[ ] was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO **34, chemin des Colombettes** **1211 Geneva 20, Switzerland**	Authorized officer Olivia RANAIVOJAONA
Facsimile No.: (41-22) 740.14.35	Telephone No.: (41-22) 338.83.38

Form PCT/IB/331 (July 1992)

3158076

PATENT COOPERATION TREATY

From the
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

To: MARIA C. H. LIN
MORGAN & FINNEGAN, L.L.P.
345 PARK AVENUE
NEW YORK, NY 10154

WRITTEN OPINION
CASE 1161-4153PC1 ATTY UN
DUE AUG 5, 2000
1 Mo. Call Up JULY 5, 2000
BY TOA

PCT

WRITTEN OPINION

(PCT Rule 66)

Applicant's or agent's file reference 1151-4153PC1	Date of Mailing *(day/month/year)* 05 JUN 2000
	REPLY DUE within TWO months from the above date of mailing

International application No.	International filing date *(day/month/year)*	Priority date *(day/month/year)*
PCT/US99/13959	21 JUNE 1999	20 JUNE 1998

International Patent Classification (IPC) or both national classification and IPC
IPC(7): C07K 16/46; A61K 39/44 and US Cl.: 530/387.1, 403; 424/180.1, 193.1

Applicant
UNITED BIOMEDICAL INC.

1. This written opinion is the first (first, etc.) drawn by this International Preliminary Examining Authority.

2. This opinion contains indications relating to the following items:

- I [X] Basis of the opinion
- II [ ] Priority
- III [X] Non-establishment of opinion with regard to novelty, inventive step or industrial applicability
- IV [ ] Lack of unity of invention
- V [X] Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI [ ] Certain documents cited
- VII [ ] Certain defects in the international application
- VIII [ ] Certain observations on the international application

3. The applicant is hereby invited to reply to this opinion.

When? See the time limit indicated above. ~~The applicant may, before the expiration of that time limit, request this Authority to grant an extension., see Rule 66.2(d).~~

How? By submitting a written reply, accompanied, where appropriate, by amendments, according to Rule 66.3. For the form and the language of the amendments, see Rules 66.8 and 66.9.

Also For an additional opportunity to submit amendments, see Rule 66.4.
For the examiner's obligation to consider amendments and/or arguments, see Rule 66.4 *bis*.
For an informal communication with the examiner, see Rule 66.6.

If no reply is filed, the international preliminary examination report will be established on the basis of this opinion.

4. The final date by which the international preliminary examination report must be established according to Rule 69.2 is: 20 OCTOBER 2000

Name and mailing address of the IPEA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231	Authorized officer MARIANNE DIBRINO for Lillian Colin
Facsimile No. (703) 305-3230	Telephone No. (703) 308-0196

Form PCT/IPEA/408 (cover sheet) (January 1994)★

WRITTEN OPINION

International application No.
PCT/US99/13959

I. Basis f the pinion

1. This opinion has been drawn on the basis of *(Substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this opinion as "originally filed".)*:

[X] the international application as originally filed.

[X] the description, pages (See Attached) , as originally filed.
pages _____ , filed with the demand.
pages _____ , filed with the letter of _____.

[X] the claims, Nos. (See Attached) , as originally filed.
Nos. _____ , as amended under Article 19.
Nos. _____ , filed with the demand.
Nos. _____ , filed with the letter of _____.

[X] the drawings, sheets/~~fig~~ (See Attached) , as originally filed.
sheets/~~fig~~ _____ , filed with the demand.
sheets/~~fig~~ _____ , filed with the letter of _____.

2. The amendments have resulted in the cancellation of:

[X] the description, pages NONE

[X] the claims, Nos. NONE

[X] the drawings, sheets/~~fig~~ NONE

3. [ ] This opinion has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the ~~Supplemental Box~~ Additional observations below (Rule 70.2(c)).

4. Additional observations, if necessary:
NONE

WRITTEN OPINION

International application No.
PCT/US99/13959

III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

The question whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been and will not be examined in respect of:

☐ the entire international application.

☒ claims Nos. 28

because:

☐ the said international application, or the said claim Nos. _ relate to the following subject matter which does not require international preliminary examination *(specify)*.

☐ the description, claims or drawings *(indicate particular elements below)* or said claims Nos. _ are so unclear that no meaningful opinion could be formed *(specify)*.

☐ the claims, or said claims Nos. _ are so inadequately supported by the description that no meaningful opinion could be formed.

☒ no international search report has been established for said claims Nos. 28.

WRITTEN OPINION

International application No.
PCT/US99/13959

V. Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. STATEMENT

Novelty (N)	Claims	3-27	YES
	Claims	1, 2	NO
Inventive Step (IS)	Claims	NONE	YES
	Claims	1-27	NO
Industrial Applicability (IA)	Claims	1-27	YES
	Claims	NONE	NO

2. CITATIONS AND EXPLANATIONS

Claims 1 and 2 lack novelty under PCT article 33(2) as being anticipated by Burt et al (Molecular Immunology). Burt et al teach that IgE plays an important role in type 1 immediate hypersensitivity reactions due to its ability to bind reversibly to high affinity receptors on mast cells and basophils. Burt et al teach rat IgE-CH3 domain peptides of 18 and 19 amino acid residues in length. Burt et al teach a synthetic peptide corresponding to residues 414-428 is a region of the rat IgE-CH3 domain that is involved in IgE binding to its receptor on mast cells. Burt et al further teach that antibodies produced against said peptide could inhibit binding of IgE to its receptor on mast cells. These peptides are "immunologically functional analogs" of the SEQ ID NOs of instant claims 1 and 2.

Claims 1 and 2 lack novelty under PCT article 33(2) as being anticipated by Burt et al (Eur. J. Immunology) teach a rat IgE-CH3 domain peptide, P129, residues 414-428 can compete with rat IgE for binding to rat mast cells. These peptides are "immunologically functional analogs" of the SEQ ID NOs of instant claims 1 and 2.

Claims 1-27 lack an inventive step under PCT Article 33(3) as being obvious over Burt et al (Molecular Immunology) or Burt et al (Eur. J. Immunology) in view of Ladd et al (U.S. Patent No. 5,759,551). Burt et al and Burt et al have been discussed supra. Burt et al or Burt et al do not teach SEQ ID NOs 5-8 or 84. Ladd et al teach synthetic peptides of the formula: (A)n-(Th)m-(B)o-LHRH, wherein A is independently an amino acid alpha-NH2, a tripalmitoyl cystein group, an invasin domain or an immunostimulatory analog of the corresponding invasin domain (including SEQ ID NO: 13 of the instant application, especially amino acid residues 1-16 of SEQ ID NO: 35 of Ladd et al), B is an amino acid, each Th is independently a sequence of amino acids that comprises a helper T celll epitope or an immune enhancing analog or segment thereof, LHRH is leuteinizing hormone releasing hormone or an immunogenic analog thereof, and n is from 1 to about 10, m is from 1 to about 4 and O is from 0 to about 10 (Continued on Supplemental Sheet.)

Supplemental Box
(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of: Boxes I - VIII

TIME LIMIT:

The time limit set for response to a Written Opinion may not be extended. 37 CFR 1.484(d). Any response received after the expiration of the time limit set in the Written Opinion will not be considered in preparing the International Preliminary Examination Report.

I. BASIS OF OPINION:

This opinion has been drawn on the basis of the description,
pages, 1-81 AND SEQUENCE PAGES 1-62, as originally filed.
pages, NONE, filed with the demand.
and additional amendments:
NONE

This opinion has been drawn on the basis of the claims,
numbers, 1-28, as originally filed.
numbers, NONE, as amended under Article 19.
numbers, NONE, filed with the demand.
and additional amendments:
NONE

This opinion has been drawn on the basis of the drawings,
sheets, NONE , as originally filed.
sheets, NONE, filed with the demand.
and additional amendments:
NONE

V. 2. REASONED STATEMENTS - CITATIONS AND EXPLANATIONS (Continued):
(especially column 12, lines 20-44). Ladd et al further teach that these elements of the synthetic peptides can be covalently joined in any order (especially column 4, lines 19-38). Ladd et al teach that said peptides can be about 20 to about 90 amino acid residues in length (especially column 4, lines 19-21). Ladd et al teach Th epitopes that are SSAL (especially column 10, lines 22-48). Ladd et al teach Th epitopes with the amino acid sequence of SEQ ID NO: 10, 61 and 62 of the instant claims (SEQ ID NO: 19, 20 and 21 of Ladd et al, respectively). Ladd et al teach linkers, including Gly-Gly(especially column 9, lines 62-67 and column 10, lines 1-6).
Ladd et al teach carrier proteins conjugated to said peptides (especially column 3, lines 10-17). Ladd et al further teach branched and unbranched polymers comprising said peptides, the branched polymers comprising a lysine, trilysine or heptalysine (especially column 13, lines 22-38 and column 14, lines 1-2). Ladd et al also teach pharmaceutical compositions comprising said peptide, and methods for administration wherein an immunologically effective amount of said peptide is between about 0.5 ug to about 1 mg/Kg body weight per dose (especially claim 12). Ladd et al do not teach said peptides, compositions thereof and methods of administration wherein the peptides are the peptides of the instant application. It would have been prima facie obvious at the time the invention was made to identify correlative amino acid residues in human or other mammal IgE-CH3 regions, to make correlative synthetic overlapping peptides of the size taught by Burt et al, i.e., of "between about 25 and between about 29 amino acids in length" (including SEQ ID NOs 5-8 or 84), and to optimize said peptides to obtain the optimal peptides of desired immune function, i.e., to make peptides corresponding to the region of the CH3 domain of IgE important for binding to the IgE receptor on mast cells for the purpose of making antibodies with blocking function to alleviate type I immediate hypersensitivity reactions. It would have been prima facie obvious at the time the invention was made to substitute the peptides of Burt et al for the LHRH peptides of Ladd et al. One of ordinary skill in the art at the time the invention was made would have been motivated to do this in order to stimulate an effective immune response to the IgE-CH3 region peptides. It would have been obvious to attach Cys residues to the ends of the peptides in order to couple them to proteins such as carrier proteins. Claim 20 is included because a skilled artisan at the time the invention was made would have known that KLH is a common protein used as a carrier coupled to haptens or to peptides. Claim 23 is included because a skilled artisan at the time the invention was made would have known that a bifunctional cross-linking agent could be used to make peptide conjugate polymers. Claim 14 is included because SEQ ID NO: 22 of the instant application is of the formula Inv-linker-Th-linker-Cys-peptide-Cys, and the Inv, linkers and Th regions are taught by Ladd et al.

Supplemental Box
(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of: Boxes I - VIII

Claims 1-27 meet the criteria set out in PCT Article 33 (4), because the claimed peptides, compositions and method are useful for stimulating an immune response for the production of antibodies to the IgE-CH3 region.

NEW CITATIONS

US 5,579,551 A (LADD et al) 02 JUNE 1998, see entire document.

1151-4153 PC1
LIN

PATENT COOPERATION TREATY

From the
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

RECEIVED
DOCKET DEPT.

To: MARIA C. H. LIN
MORGAN & FINNEGAN, L.L.P.
345 PARK AVENUE
NEW YORK, NY 10154

2000 OCT -5 P 12:28

MORGAN & FINNEGAN

PCT

NOTIFICATION OF TRANSMITTAL OF INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Rule 71.1)

Date of Mailing *(day/month/year)*	29 SEP 2000
Applicant's or agent's file reference: 1151-4153PC1	IMPORTANT NOTIFICATION

International application No.	International filing date *(day/month/year)*	Priority Date *(day/month/year)*
PCT/US99/13959	21 JUNE 1999	20 JUNE 1998

Applicant
UNITED BIOMEDICAL INC.

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.

2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.

3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

4. REMINDER

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices)(Article 39(1))(see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

Name and mailing address of the IPEA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231	Authorized officer MARIANNE DIBRINO
Facsimile No. (703) 305-3230	Telephone No. (703) 308-0196

Form PCT/IPEA/416 (July 1992)★

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 1151-4153PC1	FOR FURTHER ACTION	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)
International application No. PCT/US99/13959	International filing date *(day/month/year)* 21 JUNE 1999	Priority date *(day/month/year)* 20 JUNE 1998
International Patent Classification (IPC) or national classification and IPC IPC(7): C07K 16/46; A61K 39/44 and US Cl.: 530/387.1, 403; 424/180.1, 193.1		
Applicant UNITED BIOMEDICAL INC.		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.

2. This REPORT consists of a total of 5 sheets.

   [ ] This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority. (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

   These annexes consist of a total of 1 sheets.

3. This report contains indications relating to the following items:

   I [X] Basis of the report

   II [ ] Priority

   III [ ] Non-establishment of report with regard to novelty, inventive step or industrial applicability

   IV [ ] Lack of unity of invention

   V [X] Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

   VI [ ] Certain documents cited

   VII [ ] Certain defects in the international application

   VIII [X] Certain observations on the international application

Date of submission of the demand	Date of completion of this report
18 JANUARY 2000	25 AUGUST 2000
Name and mailing address of the IPEA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer MARIANNE DIBRINO Telephone No. (703) 308-0196

Form PCT/IPEA/409 (cover sheet) (July 1998)*

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.
PCT/US99/13959

I. Basis of the report

1. With regard to the **elements** of the international application:*

☐ the international application as originally filed

☒ the description:
pages (See Attached) , as originally filed
pages _____ , filed with the demand
pages _____ , filed with the letter of _____

☒ the claims:
pages (See Attached) , as originally filed
pages _____ , as amended (together with any statement) under Article 19
pages _____ , filed with the demand
pages _____ , filed with the letter of _____

☒ the drawings:
pages (See Attached) , as originally filed
pages _____ , filed with the demand
pages _____ , filed with the letter of _____

☒ the sequence listing part of the description:
pages (See Attached) , as originally filed
pages _____ , filed with the demand
pages _____ , filed with the letter of _____

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.
These elements were available or furnished to this Authority in the following language _____ which is:

☐ the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).

☐ the language of publication of the international application (under Rule 48.3(b)).

☐ the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

☒ contained in the international application in printed form.

☒ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☐ furnished subsequently to this Authority in computer readable form.

☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☐ The statement that the information recorded in computer readable form is identical to the writen sequence listing has been furnished.

4. ☒ The amendments have resulted in the cancellation of:

☒ the description, pages NONE

☒ the claims, Nos. NONE

☒ the drawings, sheets/~~fig~~ NONE

5. ☐ This report has been drawn as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**

** Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).*

***Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.*

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.
PCT/US99/13959

V. Reasoned statement under Article 35(2) with regard t n velty, inventive step or industrial applicability; citations and explanations supporting such statement

1. statement

Novelty (N)	Claims	3-28	YES
	Claims	1, 2	NO
Inventive Step (IS)	Claims	3-28	YES
	Claims	1, 2	NO
Industrial Applicability (IA)	Claims	1-28	YES
	Claims	NONE	NO

2. citations and explanations (Rule 70.7)

Claims 1 and 2 lack novelty under PCT article 33(2) as being anticipated by Burt et al (Molecular Immunology). Burt et al teach that IgE plays an important role in type 1 immediate hypersensitivity reactions due to its ability to bind reversibly to high affinity receptors on mast cells and basophils. Burt et al teach rat IgE-CH3 domain peptides of 18 and 19 amino acid residues in length. Burt et al teach said peptides inhibit the binding of IgE to the IgE receptor on mast cells. Burt et al teach a synthetic peptide corresponding to residues 414-428 is a region of the rat IgE-CH3 domain that is involved in IgE binding to its receptor on mast cells. Burt et al further teach that antibodies produced against said peptide could inhibit binding of IgE to its receptor on mast cells. These peptides are "immunologically functional analogs" of the SEQ ID NOs of instant claims 1 and 2.

Applicant's arguments in the amendment filed 7/6/00 have been fully considered but are not persuasive.

As regards Applicant's comments in said amendment filed 7/6/00, the disclosure of the instant application on page 20 at lines 14-21 is that an "IgE-CH3 domain antigen" or "IgE-CH3 domain peptide" is modified from a segment of the CH3 domain of the epsilon heavy chain of human IgE (e.g., amino acids 413-435 of SEQ ID NO: 1 or SEQ ID NO: 5) or the homologous sequence from other species (e.g., SEQ ID NOS: 6-8 and 84). However, there are no amino acid residues in SEQ ID NO: 1 numbered 413-435. SEQ ID NO: 1 consists of amino acid residues 1-325. In addition, there is no subsequence in SEQ ID NO: 1 that corresponds to SEQ ID NO: 5. The disclosure of the instant application on page 37 at lines 2-14 is that SEQ ID NOS: 5-8 and 84 are both crossreactive and immunologically functional analogs of IgE-CH3 domain antigen peptides that may further comprise analogs capable of illiciting immune responses crossreactive with the IgE-CH3 peptides. For the purpose of Examination, claims are given their broadest reasonable interpretation. The term "immunologically functional analog" is not defined in the instant disclosure.
(Continued on Supplemental Sheet.)

VIII. Certain observations on the internati nal applicati n

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

Claims 1-28 are objected to under PCT Rule 66.2(a)(v) as lacking clarity under PCT Article 6 because the claims 1-28 are indefinite for the following reason(s):

a. it is not clear what the claim limitation "an IgE-CH3 domain antigen peptide" means.

b. it is not clear what the claim limitation "immunologically functional analogs" means.

Supplemental Box
(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of: Boxes I - VIII

I. BASIS OF REPORT:

This report has been drawn on the basis of the description,
page(s) 1-18 and 20-81
page(s) NONE, filed with the demand.
and additional amendments:
Page 19, filed with the letter of 13 December 1999.

This report has been drawn on the basis of the claims,
page(s) 82-87, as originally filed.
page(s) NONE, as amended under Article 19.
page(s) NONE, filed with the demand.
and additional amendments:
NONE

This report has been drawn on the basis of the drawings,
page(s) NONE , as originally filed.
page(s) NONE, filed with the demand.
and additional amendments:
NONE

This report has been drawn on the basis of the sequence listing part of the description:
page(s) 1-62, as originally filed.
pages(s) NONE, filed with the demand.
and additional amendments:
NONE

V. 2. REASONED STATEMENTS - CITATIONS AND EXPLANATIONS (Continued):
The peptides of Burt et al compete with IgE for binding to the IgE receptor and so meet the claim limitation "immunologically functional analog".

Claims 1 and 2 lack novelty under PCT article 33(2) as being anticipated by Burt et al (Eur. J. Immunology) teach a rat IgE-CH3 domain peptide, P129, residues 414-428 can compete with rat IgE for binding to rat mast cells. These peptides are "immunologically functional analogs" of the SEQ ID NOs of instant claims 1 and 2.

Applicant's arguments filed 06 July 2000 have been fully considered but are not persuasive.

The discussion applied supra to the objection under Burt et al (Molecular Immunology) apply here as well.

Claims 1-28 meet the criteria set out in PCT Article 33 (4), because the claimed peptides, compositions and method are useful for stimulating an immune response for the production of antibodies to the IgE-CH3 region.

NEW CITATIONS

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 1151-4153PC1	FOR FURTHER ACTION	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)
International application No. PCT/US99/13959	International filing date *(day/month/year)* 21 JUNE 1999	Priority date *(day/month/year)* 20 JUNE 1998
International Patent Classification (IPC) or national classification and IPC IPC(7): C07K 16/46; A61K 39/44 and US Cl.: 530/387.1, 403; 424/180.1, 193.1		
Applicant UNITED BIOMEDICAL INC.		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.

2. This REPORT consists of a total of 5 sheets.

   [ ] This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority. (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

   These annexes consist of a total of 1 sheets.

3. This report contains indications relating to the following items:

   I [X] Basis of the report

   II [ ] Priority

   III [ ] Non-establishment of report with regard to novelty, inventive step or industrial applicability

   IV [ ] Lack of unity of invention

   V [X] Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

   VI [ ] Certain documents cited

   VII [ ] Certain defects in the international application

   VIII [X] Certain observations on the international application

Date of submission of the demand	Date of completion of this report
18 JANUARY 2000	25 AUGUST 2000
Name and mailing address of the IPEA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer MARIANNE DIBRINO Telephone No. (703) 308-0196

Form PCT/IPEA/409 (cover sheet) (July 1998)*

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.
PCT/US99/13959

I. Basis of the r port

1. With regard to the elements of the international application:*

☐ the international application as originally filed

☒ the description:
pages (See Attached) , as originally filed
pages _____ , filed with the demand
pages _____ , filed with the letter of _____

☒ the claims:
pages (See Attached) , as originally filed
pages _____ , as amended (together with any statement) under Article 19
pages _____ , filed with the demand
pages _____ , filed with the letter of _____

☒ the drawings:
pages (See Attached) , as originally filed
pages _____ , filed with the demand
pages _____ , filed with the letter of _____

☒ the sequence listing part of the description:
pages (See Attached) , as originally filed
pages _____ , filed with the demand
pages _____ , filed with the letter of _____

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.
These elements were available or furnished to this Authority in the following language _____ which is:

☐ the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).

☐ the language of publication of the international application (under Rule 48.3(b)).

☐ the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

☒ contained in the international application in printed form.

☒ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☐ furnished subsequently to this Authority in computer readable form.

☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☐ The statement that the information recorded in computer readable form is identical to the writen sequence listing has been furnished.

4. ☒ The amendments have resulted in the cancellation of:

☒ the description, pages NONE

☒ the claims, Nos. NONE

☒ the drawings, sheets/~~fig~~ NONE

5. ☐ This report has been drawn as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**

** Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).*

***Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.*

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.
PCT/US99/13959

V. Reasoned statement under Article 35(2) with regard to novelty, inv ntive step r industrial applicability; citations and explanati ns supporting such statement

1. statement

Novelty (N)	Claims	3-28	YES
	Claims	1, 2	NO
Inventive Step (IS)	Claims	3-28	YES
	Claims	1, 2	NO
Industrial Applicability (IA)	Claims	1-28	YES
	Claims	NONE	NO

2. citations and explanations (Rule 70.7)

Claims 1 and 2 lack novelty under PCT article 33(2) as being anticipated by Burt et al (Molecular Immunology). Burt et al teach that IgE plays an important role in type 1 immediate hypersensitivity reactions due to its ability to bind reversibly to high affinity receptors on mast cells and basophils. Burt et al teach rat IgE-CH3 domain peptides of 18 and 19 amino acid residues in length. Burt et al teach said peptides inhibit the binding of IgE to the IgE receptor on mast cells. Burt et al teach a synthetic peptide corresponding to residues 414-428 is a region of the rat IgE-CH3 domain that is involved in IgE binding to its receptor on mast cells. Burt et al further teach that antibodies produced against said peptide could inhibit binding of IgE to its receptor on mast cells. These peptides are "immunologically functional analogs" of the SEQ ID NOs of instant claims 1 and 2.

Applicant's arguments in the amendment filed 7/6/00 have been fully considered but are not persuasive.

As regards Applicant's comments in said amendment filed 7/6/00, the disclosure of the instant application on page 20 at lines 14-21 is that an "IgE-CH3 domain antigen" or "IgE-CH3 domain peptide" is modified from a segment of the CH3 domain of the epsilon heavy chain of human IgE (e.g., amino acids 413-435 of SEQ ID NO: 1 or SEQ ID NO: 5) or the homologous sequence from other species (e.g., SEQ ID NOS: 6-8 and 84). However, there are no amino acid residues in SEQ ID NO: 1 numbered 413-435. SEQ ID NO: 1 consists of amino acid residues 1-325. In addition, there is no subsequence in SEQ ID NO: 1 that corresponds to SEQ ID NO: 5. The disclosure of the instant application on page 37 at lines 2-14 is that SEQ ID NOS: 5-8 and 84 are both crossreactive and immunologically functional analogs of IgE-CH3 domain antigen peptides that may further comprise analogs capable of illiciting immune responses crossreactive with the IgE-CH3 peptides. For the purpose of Examination, claims are given their broadest reasonable interpretation. The term "immunologically functional analog" is not defined in the instant disclosure.
(Continued on Supplemental Sheet.)

VIII. Certain bservations on the international applicati n

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

Claims 1-28 are objected to under PCT Rule 66.2(a)(v) as lacking clarity under PCT Article 6 because the claims 1-28 are indefinite for the following reason(s):

a. it is not clear what the claim limitation "an IgE-CH3 domain antigen peptide" means.

b. it is not clear what the claim limitation "immunologically functional analogs" means.

Supplemental Box
(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of: Boxes I - VIII

I. BASIS OF REPORT:

This report has been drawn on the basis of the description,
page(s) 1-18 and 20-81
page(s) NONE, filed with the demand.
and additional amendments:
Page 19, filed with the letter of 13 December 1999.

This report has been drawn on the basis of the claims,
page(s) 82-87, as originally filed.
page(s) NONE, as amended under Article 19.
page(s) NONE, filed with the demand.
and additional amendments:
NONE

This report has been drawn on the basis of the drawings,
page(s) NONE , as originally filed.
page(s) NONE, filed with the demand.
and additional amendments:
NONE

This report has been drawn on the basis of the sequence listing part of the description:
page(s) 1-62, as originally filed.
pages(s) NONE, filed with the demand.
and additional amendments:
NONE

V. 2. REASONED STATEMENTS - CITATIONS AND EXPLANATIONS (Continued):
The peptides of Burt et al compete with IgE for binding to the IgE receptor and so meet the claim limitation "immunologically functional analog".

Claims 1 and 2 lack novelty under PCT article 33(2) as being anticipated by Burt et al (Eur. J. Immunology) teach a rat IgE-CH3 domain peptide, P129, residues 414-428 can compete with rat IgE for binding to rat mast cells. These peptides are "immunologically functional analogs" of the SEQ ID NOs of instant claims 1 and 2.

Applicant's arguments filed 06 July 2000 have been fully considered but are not persuasive.

The discussion applied supra to the objection under Burt et al (Molecular Immunology) apply here as well.

Claims 1-28 meet the criteria set out in PCT Article 33 (4), because the claimed peptides, compositions and method are useful for stimulating an immune response for the production of antibodies to the IgE-CH3 region.

NEW CITATIONS

follows the Rothbard sequence and the 1, 4, 5, 8 rule:

1			5				10						15		
Asp	Leu	Ser	Asp	Leu	Lys	Gly	Leu	Leu	Leu	His	Lys	Leu	Asp	Gly	Leu
Glu	Ile		Glu	Ile	Arg		Ile	Ile	Ile		Arg	Ile	Glu		Ile
	Val			Val			Val	Val	Val			Val			Val
	Phe			Phe			Phe	Phe	Phe			Phe			Phe

Charged residues Glu or Asp are added at position 1 to increase the charge surrounding the hydrophobic face of the Th. The hydrophobic face of the amphipathic helix is then maintained by hydrophobic residues at 2, 5, 8, 9, 10, 13 and 16, with variability at 2, 5, 8, 9, 10, 13, and 16 to provide a facade with the capability of binding to a wide range of MHC restriction elements. The net effect of the SSAL feature is to enlarge the range of immune responsiveness to an artificial Th (WO 95/11998).

Peptide immunogens that have been designed with the peptide technologies and peptide design elements discussed above, *i.e.*, precise epitope mapping, cyclic constraint, and the incorporation of promiscuous Th epitopes or idealized promiscuous Th, and idealized SSAL Th epitopes, are the basis for the effective synthetic peptide IgE immunogens of the present invention. Such peptides are preferred for appropriate targeting and safety due to effective presentation of the IgE effector site by optimized positioning and cyclization, and for immunopotency due to broadly reactive Th responsiveness.

REQUE

The undersigned requests that the present international application be processed according to the Patent Cooperation Treaty.

International Application

International Filing Date

Name of receiving Office and "PCT International Application"

Applicant's or agent's file reference *(if desired) (12 characters maximum)* 1151-4153PC1

Box No. I TITLE OF INVENTION

PEPTIDE COMPOSITION AS IMMUNOGEN FOR THE TREATMENT OF ALLERGY

Box No. II APPLICANT

Name and address: *(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)*

UNITED BIOMEDICAL INC.
25 Davids Drive
Hauppauge, New York 11788
US

☐ This person is also inventor.

Telephone No.
(516) 273-2828

Facsimile No.
(516) 273-1717

Teleprinter No.

State *(that is, country)* of nationality: US

State *(that is, country)* of residence: US

This person is applicant for the purposes of: ☐ all designated States ☒ all designated States except the United States of America ☐ the United States of America only ☐ the States indicated in the Supplemental Box

Box No. III FURTHER APPLICANT(S) AND/OR (FURTHER) INVENTOR(S)

Name and address: *(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)*

WANG, Chang Yi
47 Snake Hill Road
Cold Spring Harbor, New York 11724
US

This person is:

☐ applicant only

☒ applicant and inventor

☐ inventor only *(If this check-box is marked, do not fill in below.)*

State *(that is, country)* of nationality: US

State *(that is, country)* of residence: US

This person is applicant for the purposes of: ☐ all designated States ☐ all designated States except the United States of America ☒ the United States of America only ☐ the States indicated in the Supplemental Box

☐ Further applicants and/or (further) inventors are indicated on a continuation sheet.

Box No. IV AGENT OR COMMON REPRESENTATIVE; OR ADDRESS FOR CORRESPONDENCE

The person identified below is hereby/has been appointed to act on behalf of the applicant(s) before the competent International Authorities as: ☒ agent ☐ common representative

Name and address: *(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)*

LIN, Maria C.H.
Morgan & Finnegan, L.L.P.
345 Park Avenue
New York, New York 10154
US

Telephone No.
(212) 758-4800

Facsimile No.
(212) 751-6849

Teleprinter No.
421792

☐ Address for correspondence: Mark this check-box where no agent or common representative is/has been appointed and the space above is used instead to indicate a special address to which correspondence should be sent.

FURTHER APPLICANT(S) AND/OR (FURTHER) INVENTOR(S)

If none of the following sub-boxes is used, this sheet should not be included in the request.

Name and address: *(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)*

WALFIELD, Alan M.
45 Schiller Avenue
Huntington Station, New York 11746
US

This person is:

- [ ] applicant only
- [X] applicant and inventor
- [ ] inventor only *(If this check-box is marked, do not fill in below.)*

State *(that is, country)* of nationality: US

State *(that is, country)* of residence: US

This person is applicant for the purposes of:

- [ ] all designated States
- [ ] all designated States except the United States of America
- [X] the United States of America only
- [ ] the States indicated in the Supplemental Box

Name and address: *(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)*

This person is:

- [ ] applicant only
- [ ] applicant and inventor
- [ ] inventor only *(If this check-box is marked, do not fill in below.)*

State *(that is, country)* of nationality:

State *(that is, country)* of residence:

This person is applicant for the purposes of:

- [ ] all designated States
- [ ] all designated States except the United States of America
- [ ] the United States of America only
- [ ] the States indicated in the Supplemental Box

Name and address: *(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)*

This person is:

- [ ] applicant only
- [ ] applicant and inventor
- [ ] inventor only *(If this check-box is marked, do not fill in below.)*

State *(that is, country)* of nationality:

State *(that is, country)* of residence:

This person is applicant for the purposes of:

- [ ] all designated States
- [ ] all designated States except the United States of America
- [ ] the United States of America only
- [ ] the States indicated in the Supplemental Box

Name and address: *(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)*

This person is:

- [ ] applicant only
- [ ] applicant and inventor
- [ ] inventor only *(If this check-box is marked, do not fill in below.)*

State *(that is, country)* of nationality:

State *(that is, country)* of residence:

This person is applicant for the purposes of:

- [ ] all designated States
- [ ] all designated States except the United States of America
- [ ] the United States of America only
- [ ] the States indicated in the Supplemental Box

- [ ] Further applicants and/or (further) inventors are indicated on another continuation sheet.

DESIGNATION OF STATES

The following designations are hereby made under Rule 4.9(a) *(mark the applicable check-boxes; at least one must be marked)*:

Regional Patent

- ☒ AP **ARIPO Patent:** GH Ghana, GM Gambia, KE Kenya, LS Lesotho, MW Malawi, SD Sudan, SZ Swaziland, UG Uganda, ZW Zimbabwe, and any other State which is a Contracting State of the Harare Protocol and of the PCT
- ☒ EA **Eurasian Patent:** AM Armenia, AZ Azerbaijan, BY Belarus, KG Kyrgyzstan, KZ Kazakhstan, MD Republic of Moldova, RU Russian Federation, TJ Tajikistan, TM Turkmenistan, and any other State which is a Contracting State of the Eurasian Patent Convention and of the PCT
- ☒ EP **European Patent:** AT Austria, BE Belgium, CH and LI Switzerland and Liechtenstein, CY Cyprus, DE Germany, DK Denmark, ES Spain, FI Finland, FR France, GB United Kingdom, GR Greece, IE Ireland, IT Italy, LU Luxembourg, MC Monaco, NL Netherlands, PT Portugal, SE Sweden, and any other State which is a Contracting State of the European Patent Convention and of the PCT
- ☒ OA **OAPI Patent:** BF Burkina Faso, BJ Benin, CF Central African Republic, CG Congo, CI Côte d'Ivoire, CM Cameroon, GA Gabon, GN Guinea, GW Guinea-Bissau, ML Mali, MR Mauritania, NE Niger, SN Senegal, TD Chad, TG Togo, and any other State which is a member State of OAPI and a Contracting State of the PCT *(if other kind of protection or treatment desired, specify on dotted line)* .....

National Patent *(if other kind of protection or treatment desired, specify on dotted line)*:

- ☒ AL Albania .....
- ☒ AM Armenia .....
- ☒ AT Austria .....
- ☒ AU Australia .....
- ☒ AZ Azerbaijan
- ☒ BA Bosnia and Herzegovina .....
- ☒ BB Barbados
- ☒ BG Bulgaria .....
- ☒ BR Brazil .....
- ☒ BY Belarus .....
- ☒ CA Canada
- ☒ CH and LI Switzerland and Liechtenstein
- ☒ CN China .....
- ☒ CU Cuba .....
- ☒ CZ Czech Republic .....
- ☒ DE Germany .....
- ☒ DK Denmark .....
- ☒ EE Estonia .....
- ☒ ES Spain .....
- ☒ FI Finland .....
- ☒ GB United Kingdom
- ☒ GD Grenada
- ☒ GE Georgia .....
- ☒ GH Ghana .....
- ☒ GM Gambia
- ☒ HR Croatia .....
- ☒ HU Hungary .....
- ☒ ID Indonesia
- ☒ IL Israel .....
- ☒ IN India .....
- ☒ IS Iceland
- ☒ JP Japan .....
- ☒ KE Kenya .....
- ☒ KG Kyrgyzstan .....
- ☒ KP Democratic People's Republic of Korea .....
- ☒ KR Republic of Korea .....
- ☒ KZ Kazakhstan .....
- ☒ LC Saint Lucia
- ☒ LK Sri Lanka
- ☒ LR Liberia
- ☒ LS Lesotho .....
- ☒ LT Lithuania
- ☒ LU Luxembourg
- ☒ LV Latvia
- ☒ MD Republic of Moldova .....
- ☒ MG Madagascar .....
- ☒ MK The former Yugoslav Republic of Macedonia .....
- ☒ MN Mongolia
- ☒ MW Malawi .....
- ☒ MX Mexico .....
- ☒ NO Norway
- ☒ NZ New Zealand .....
- ☒ PL Poland .....
- ☒ PT Portugal .....
- ☒ RO Romania
- ☒ RU Russian Federation .....
- ☒ SD Sudan
- ☒ SE Sweden
- ☒ SG Singapore
- ☒ SI Slovenia .....
- ☒ SK Slovakia .....
- ☒ SL Sierra Leone
- ☒ TJ Tajikistan .....
- ☒ TM Turkmenistan .....
- ☒ TR Turkey .....
- ☒ TT Trinidad and Tobago .....
- ☒ UA Ukraine .....
- ☒ UG Uganda .....
- ☒ US United States of America .....
  Continuation-in-part .....
- ☒ UZ Uzbekistan .....
- ☒ VN Viet Nam .....
- ☒ YU Yugoslavia .....
- ☒ ZW Zimbabwe .....

Check-boxes reserved for designating States (for the purposes of a national patent) which have become party to the PCT after issuance of this sheet:

- ☒ .ZA .South .Africa .....
- ☒ .AE .United .Arab. .Emirates.....
- ☐ .....

Precautionary Designation Statement: In addition to the designations made above, the applicant also makes under Rule 4.9(b) all other designations which would be permitted under the PCT except any designation(s) indicated in the Supplemental Box as being excluded from the scope of this statement. The applicant declares that those additional designations are subject to confirmation and that any designation which is not confirmed before the expiration of 15 months from the priority date is to be regarded as withdrawn by the applicant at the expiration of that time limit. *(Confirmation of a designation consists of the filing of a notice specifying that designation and the payment of the designation and confirmation fees. Confirmation must reach the receiving Office within the 15-month time limit.)*

Supplemental Box *If the S[redacted]mental Box is not used, this sheet should not be [redacted]ed in the request.*

1. If, in any of the Boxes, the space is insufficient to furnish all the information: in such case, write "Continuation of Box No. ..." [indicate the number of the Box] and furnish the information in the same manner as required according to the captions of the Box in which the space was insufficient, in particular:

(i) if more than two persons are involved as applicants and/or inventors and no "continuation sheet" is available: in such case, write "Continuation of Box No. III" and indicate for each additional person the same type of information as required in Box No. III. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below;

(ii) if, in Box No. II or in any of the sub-boxes of Box No. III, the indication "the States indicated in the Supplemental Box" is checked: in such case, write "Continuation of Box No. II" or "Continuation of Box No. III" or "Continuation of Boxes No. II and No. III" (as the case may be), indicate the name of the applicant(s) involved and, next to (each) such name, the State(s) (and/or, where applicable, ARIPO, Eurasian, European or OAPI patent) for the purposes of which the named person is applicant;

(iii) if, in Box No. II or in any of the sub-boxes of Box No. III, the inventor or the inventor/applicant is not inventor for the purposes of all designated States or for the purposes of the United States of America: in such case, write "Continuation of Box No. II" or "Continuation of Box No. III" or "Continuation of Boxes No. II and No. III" (as the case may be), indicate the name of the inventor(s) and, next to (each) such name, the State(s) (and/or, where applicable, ARIPO, Eurasian, European or OAPI patent) for the purposes of which the named person is inventor;

(iv) if, in addition to the agent(s) indicated in Box No. IV, there are further agents: in such case, write "Continuation of Box No. IV" and indicate for each further agent the same type of information as required in Box No. IV;

(v) if, in Box No. V, the name of any State (or OAPI) is accompanied by the indication "patent of addition," or "certificate of addition," or if, in Box No. V, the name of the United States of America is accompanied by an indication "continuation" or "continuation-in-part": in such case, write "Continuation of Box No. V" and the name of each State involved (or OAPI), and after the name of each such State (or OAPI), the number of the parent title or parent application and the date of grant of the parent title or filing of the parent application;

(vi) if, in Box No. VI, there are more than three earlier applications whose priority is claimed: in such case, write "Continuation of Box No. VI" and indicate for each additional earlier application the same type of information as required in Box No. VI;

(vii) if, in Box No. VI, the earlier application is an ARIPO application: in such case, write "Continuation of Box No. VI", specify the number of the item corresponding to that earlier application and indicate at least one country party to the Paris Convention for the Protection of Industrial Property for which that earlier application was filed.

2. If, with regard to the precautionary designation statement contained in Box No. V, the applicant wishes to exclude any State(s) from the scope of that statement: in such case, write "Designation(s) excluded from precautionary designation statement" and indicate the name or two-letter code of each State so excluded.

3. If the applicant claims, in respect of any designated Office, the benefits of provisions of the national law concerning non-prejudicial disclosures or exceptions to lack of novelty: in such case, write "Statement concerning non-prejudicial disclosures or exceptions to lack of novelty" and furnish that statement below.

Continuation of Box No. V

Continuation-in-part of U.S. patent application number 09/100,287 filed on 20 June 1998

Box No. VI PRIORITY CLAIM

☐ Further priority claims are indicated in the Supplemental Box.

Filing date of earlier application (day/month/year)	Number of earlier application	Where earlier application is: national application: country	regional application:* regional Office	international application: receiving Office
item (1) 20 June 1998 (20.06.98)	09/100,287	US		
item (2)				
item (3)				

☒ The receiving Office is requested to prepare and transmit to the International Bureau a certified copy of the earlier application(s) *(only if the earlier application was filed with the Office which for the purposes of the present international application is the receiving Office)* identified above as item(s): (1)

* *Where the earlier application is an ARIPO application, it is mandatory to indicate in the Supplemental Box at least one country party to the Paris Convention for the Protection of Industrial Property for which that earlier application was filed (Rule 4.10(b)(ii)). See Supplemental Box.*

Box No. VII INTERNATIONAL SEARCHING AUTHORITY

Choice of International Searching Authority (ISA) *(if two or more International Searching Authorities are competent to carry out the international search, indicate the Authority chosen; the two-letter code may be used)*: ISA / US

Request to use results of earlier search; reference to that search *(if an earlier search has been carried out by or requested from the International Searching Authority)*: Date *(day/month/year)* Number Country *(or regional Office)*

Box No. VIII CHECK LIST; LANGUAGE OF FILING

This international application contains the following number of sheets:

request	5
description (excluding sequence listing part)	81
claims	6
abstract	1
drawings	--
sequence listing part of description	62
Total number of sheets	155

This international application is accompanied by the item(s) marked below:

1. ☒ fee calculation sheet (in duplicate)
2. ☒ separate signed power of attorney (unexecuted)
3. ☐ copy of general power of attorney; reference number, if any:
4. ☐ statement explaining lack of signature
5. ☐ priority document(s) identified in Box No. VI as item(s):
6. ☐ translation of international application into (language):
7. ☐ separate indications concerning deposited microorganism or other biological material
8. ☒ nucleotide and/or amino acid sequence listing in computer readable form
9. ☒ other *(specify)*: Transmittal Letter; check for $3,460

Figure of the drawings which should accompany the abstract: 1

Language of filing of the international application: English

Box No. IX SIGNATURE OF APPLICANT OR AGENT

Next to each signature, indicate the name of the person signing and the capacity in which the person signs (if such capacity is not obvious from reading the request).

Maria C.H. Lin
Agent for Applicants

For receiving Office use only

1. Date of actual receipt of the purported international application:
2. Drawings: ☐ received: ☐ not received:
3. Corrected date of actual receipt due to later but timely received papers or drawings completing the purported international application:
4. Date of timely receipt of the required corrections under PCT Article 11(2):
5. International Searching Authority (if two or more are competent): ISA /
6. ☐ Transmittal of search copy delayed until search fee is paid.

For International Bureau use only

Date of receipt of the record copy by the International Bureau:

PCT

FEE CALCULATION SHEET

Annex to the Request

For receiving Office use only

International application No.

Date stamp of the receiving Office

Applicant's or agent's file reference: 1151-4153PC1

Applicant: UNITED BIOMEDICAL INC., et al.

CALCULATION OF PRESCRIBED FEES

1. TRANSMITTAL FEE . . . . . $240 [T]

2. SEARCH FEE . . . . . $450 [S]

International search to be carried out by US

(If two or more International Searching Authorities are competent in relation to the international application, indicate the name of the Authority which is chosen to carry out the international search.)

3. INTERNATIONAL FEE

Basic Fee

The international application contains 155 sheets.

first 30 sheets . . . . . $455 [b1]

125 remaining sheets x $10 additional amount = $1,250 [b2]

Add amounts entered at b1 and b2 and enter total at B . . . . $1,705 [B]

Designation Fees

The international application contains 79 designations.

10 number of designation fees payable *(maximum 10)* x $105 amount of designation fee = $1,050 [D]

Add amounts entered at B and D and enter total at I . . . . . $2,755 [I]

(Applicants from certain States are entitled to a reduction of 75% of the international fee. Where the applicant is (or all applicants are) so entitled, the total to be entered at I is 25% of the sum of the amounts entered at B and D.)

4. FEE FOR PRIORITY DOCUMENT *(if applicable)* . . . . . $15 [P]

5. TOTAL FEES PAYABLE . . . . . $3,460 TOTAL

Add amounts entered at T, S, I and P, and enter total in the TOTAL box

[ ] The designation fees are not paid at this time.

MODE OF PAYMENT

- [ ] authorization to charge deposit account (see below)
- [X] cheque
- [ ] postal money order
- [ ] bank draft
- [ ] cash
- [ ] revenue stamps
- [ ] coupons
- [ ] other *(specify):*

DEPOSIT ACCOUNT AUTHORIZATION *(this mode of payment may not be available at all receiving Offices)*

The RO/ US

- [ ] is hereby authorized to charge the total fees indicated above to my deposit account.
- [X] *(this check-box may be marked only if the conditions for deposit accounts of the receiving Office so permit)* is hereby authorized to charge any deficiency or credit any overpayment in the total fees indicated above to my deposit account.
- [X] is hereby authorized to charge the fee for preparation and transmittal of the priority document to the International Bureau of WIPO to my deposit account.

13-4500
Deposit Account No.

21 June 1999
Date *(day/month/year)*

Signature Maria C.H. Lin

Form PCT/RO/101 (Annex) (January 1999)

See Notes to the fee calculation sheet

Attorney's Docket No. 1151-4153PC1

IN THE UNITED STATES DESIGNATED OFFICE (DO/US)

PCT/US99/13959 21 June, 1999 20 June 1998
INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE PRIORITY DATE CLAIMED
STRUCTURED SYNTHETIC ANTIGEN LIBRARIES AS DIAGNOSTICS, VACCINES AND THERAPEUTICS
TITLE OF INVENTION
UNITED BIOMEDICAL, INC.
APPLICANT(S) FOR DO/US

BOX PCT
COMMISSIONER OF PATENTS AND TRADEMARKS
WASHINGTON, D.C. 20231
ATTENTION: Marianne DiBrino, Ph.D.

RESPONSE TO WRITTEN OPINION

Sir:

This is in response to the Preliminary International Report issued on September 29, 2000.

The Examiner has maintained her opinion that claims 1-2 lack novelty as being anticipated by Burt et al. Molecular Immunology, 1987, 24:179-189; and that claims 3-27 lack inventive step in view of Burt et al. in combination with Ladd et al. US Patent 5,759,551.

Reconsideration and withdrawal of the opinion is requested for the following reasons.

The Examiner indicated that SEQ ID NO:1 consists of 1-325 amino acids. This is based on the arbitrary numbering system required by the Sequence Listing rules. However, the numbering system of the IgE is in accordance with that published by Dorrington and Bennich Immunol. Rev., 1978, 41:3-25 and is presented in Table 1 of the specification on Table 1, pages 66-68. Based on the published numbering system, SEQ ID NO:1 is AA224-AA547 of IgE.

SEQ ID NO: 5 in the present invention is identified as corresponding to IgE AA413- AA435 with two cysteines added to the amino and carboxy terminal and a serine instead of a cysteine at AA418. The amino acid sequence of SEQ ID NO: 5 is, therefore, as follows:

CGETYQSRVTHPHLPRALMRSTTKC

SEQ ID NO: 6 is the corresponding analog from dog IgE:

CGETYYSRVTHPHLPKDIVRSIAKC

SEQ ID NO: 7 is the corresponding analog from rat IgE:

CGEGYQSRVDHPHFPKPIVRSITKC

SEQ ID NO: 8 is the corresponding analog from mouse IgE:

CGYGYQSIVDRPDFPKPIVRSITKC

SEQ ID NO: 84 is the corresponding analog from horse IgE:

CGETYKSTVSHPDLPREVVRSIAKC

These sequences are underscored in Table 1.

The amino acid sequences of the Burt et al. peptides are presented in Table 1 of the cited reference and in Burt et al. Eur. J. Immunol., 1987, 17:437-440. Burt et al. peptide AA414-AA435 is designated as p129 therein.

A comparison of SEQ ID NO:5 of the present application with the Burt et al. peptides are presented in the table below.

SEQ ID NO:5	CGETYQSRVTHPHLPRALMRSTTKC
Burt et al. AA378-396, p130	ESEENITVTWVTWVRETKKSIG
Burt et al. AA414-428, p129	SILVPVDAKDWIEGEG
Burt et al. AA459-472, P124	YVFLPPEEEEKDKR
SEQ ID NO:5	CGETYQSRVTHPHLPRALMRSTTKC
Burt et al. AA491-503, p128	LQDSKLIPKSQHS
Burt et al. AA522-535, p122	RLEVTKALWTWTKQ
Burt et al. AA542-557, p123	HEALREPRKLERTJSK
Burt et al. AA560-571, p131	GNTSLRPSQASM

Based on the comparison, it is clear that the Burt et al. peptides are entirely different from the peptides of the present invention. They are not even analog peptides because they are from different regions of the IgE. Burt et al.

appears to have taken the rat IgE sequence with the numbering as reported by Hellman et al., Nucleic Acids Res., 1982, 10:6041-6049. If the Dorrington and Bennich numbering system were applied, p129 would be AA401-AA415. The Burt et al. references were discussed in the present application on pages12-13.

The standard for lack of novelty is that every element of the claimed invention is to be found in the cited reference. According to this standard, the maintenance of the lack of novelty rejection for Claims 1-2 cannot be understood and should be withdrawn.

Not only are the claimed peptides totally different from that disclosed be Burt et al., none of Burt et al.'s peptides can be immunologically functional analogs of the claimed peptides because they are not immunologically functional analogs as defined on page 37 of the specification, lines 3-13. SEQ ID NOs: 5, 6, 7, 8 and 84 are defined as cross reactive and immunologically functional analogs and may include conservative substitutions, additions, deletions, or insertions of from one to about four amino acid residues of SEQ ID Nos.: 5, 6, 7, 8 and 84. Burt et al. are entirely different peptides. They contain more than four amino acids that are different from the claimed peptides.

Secondly, the antibodies produced against the peptides of the present invention do not cause an anaphylactic reaction in cells already sensitized by IgE. See page 54 lines 1-20. Whereas the antibodies produced using Burt et al.'s peptides do result in anaphylactic histamine release. See p. 386 column 2 of Burt et al. Mol. Immunol. The increased histamine release indicates that the animal can undergo anaphylactic shock which may result in death and is very dangerous. For this reason, Burt et al. actually teaches away from the claimed invention.

Thirdly, Burt et al. teaches that Burt et al. peptide p129 is 1000 fold less potent than intact rat IgE in binding to rat mast cells. (See page 438 column 1 of Burt et al. Eur. J. Immunol. This data shows that p129 is not a useful antagonist. Again, this teaches away from the usefulness of a synthetic peptide for allergy treatment.

A discussion of the above was had with the Examiner. The courtesy extended by the Examiner is deeply appreciated.

575639_1

The Commissioner is hereby authorized to charge any additional fees which may be required for this amendment, including all fees pursuant to 37 C.F.R. § 1.17 for its timely consideration, or credit any overpayment to Deposit Account No. 13-4500. Order No.: 1151-4153PC1. A Duplicate Copy Of This Sheet Is Attached.

Respectfully submitted

Maria C.H. Lin
Registration No. 29,323

Date: October 13, 2000
Morgan & Finnegan
345 Park Avenue
New York, New York 10154
Tel. No. (212) 758-4800
Fax. No. (212) 751-6849

VERIFIED CERTIFICATION OF EXPRESS MAILING DATE
(INTERNATIONAL APPLICATION (37 CFR 1.10(c))

I declare that on 13, October 2000 I deposited with the United States Postal Service in an envelope "Express Mail, Post Office to Addressee", bearing Label Number EL 704 519 047US addressed to the "Commissioner for Patents, BOX PCT, Washington, D.C. 20231" directed to the attention of MaryAnne DiBrino

Francisco Garcia
(Typed or printed name of person mailing paper)

(Signature of person mailing paper)

follows the Rothbard sequence and the 1, 4, 5, 8 rule:

1 5 10 15

Asp-Leu-Ser-Asp-Leu-Lys-Gly-Leu-Leu-Leu-His-Lys-Leu-Asp-Gly-Leu

Glu Ile Glu Ile Arg Ile Ile Ile Arg Ile Glu Ile

Val Val Val Val Val Val Val

Phe Phe Phe Phe Phe Phe Phe

Charged residues Glu or Asp are added at position 1 to increase the charge surrounding the hydrophobic face of the Th. The hydrophobic face of the amphipathic helix is then maintained by hydrophobic residues at 2, 5, 8, 9, 10, 13 and 16, with variability at 2, 5, 8, 9, 10, 13, and 16 to provide a facade with the capability of binding to a wide range of MHC restriction elements. The net effect of the SSAL feature is to enlarge the range of immune responsiveness to an artificial Th (WO 95/11998).

Peptide immunogens that have been designed with the peptide technologies and peptide design elements discussed above, *i.e.*, precise epitope mapping, cyclic constraint, and the incorporation of promiscuous Th epitopes or idealized promiscuous Th, and idealized SSAL Th epitopes, are the basis for the effective synthetic peptide IgE immunogens of the present invention. Such peptides are preferred for appropriate targeting and safety due to effective presentation of the IgE effector site by optimized positioning and cyclization, and for immunopotency due to broadly reactive Th responsiveness.

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 16/46, A61K 39/44 — A1

(11) International Publication Number: WO 99/67293

(43) International Publication Date: 29 December 1999 (29.12.99)

(21) International Application Number: PCT/US99/13959

(22) International Filing Date: 21 June 1999 (21.06.99)

(30) Priority Data:
09/100,287 20 June 1998 (20.06.98) US

(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application
US 09/100,287 (CIP)
Filed on 20 June 1998 (20.06.98)

(71) Applicant *(for all designated States except US)*: UNITED BIOMEDICAL INC. [US/US]; 25 Davids Drive, Hauppauge, NY 11788 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: WANG, Chang, Yi [US/US]; 47 Snake Hill Road, Cold Spring Harbor, NY 11724 (US). WALFIELD, Alan, M. [US/US]; 45 Schiller Avenue, Huntington Station, NY 11746 (US).

(74) Agent: LIN, Maria, C., H.; Morgan & Finnegan, L.L.P., 345 Park Avenue, New York, NY 10154 (US).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: PEPTIDE COMPOSITION AS IMMUNOGEN FOR THE TREATMENT OF ALLERGY

(57) Abstract

The invention provides peptides comprising a sequence homologous to a portion of the third constant domain of the epsilon heavy chain of IgE, covalently linked to either (1) a carrier protein, or (2) a helper T cell epitope, and optionally to other immunostimulatory sequences as well. The invention provides for the use of such peptides as immunogens to elicit the production in mammals of high titer polyclonal antibodies, which are specific to a target effector site on the epsilon heavy chain of IgE. The peptides are expected to be useful in pharmaceutical compositions, to provide an immunotherapy for IgE–mediated allergic diseases.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	**ES**	Spain	**LS**	Lesotho	**SI**	Slovenia
AM	Armenia	**FI**	Finland	**LT**	Lithuania	**SK**	Slovakia
AT	Austria	**FR**	France	**LU**	Luxembourg	**SN**	Senegal
AU	Australia	**GA**	Gabon	**LV**	Latvia	**SZ**	Swaziland
AZ	Azerbaijan	**GB**	United Kingdom	**MC**	Monaco	**TD**	Chad
BA	Bosnia and Herzegovina	**GE**	Georgia	**MD**	Republic of Moldova	**TG**	Togo
BB	Barbados	**GH**	Ghana	**MG**	Madagascar	**TJ**	Tajikistan
BE	Belgium	**GN**	Guinea	**MK**	The former Yugoslav Republic of Macedonia	**TM**	Turkmenistan
BF	Burkina Faso	**GR**	Greece			**TR**	Turkey
BG	Bulgaria	**HU**	Hungary	**ML**	Mali	**TT**	Trinidad and Tobago
BJ	Benin	**IE**	Ireland	**MN**	Mongolia	**UA**	Ukraine
BR	Brazil	**IL**	Israel	**MR**	Mauritania	**UG**	Uganda
BY	Belarus	**IS**	Iceland	**MW**	Malawi	**US**	United States of America
CA	Canada	**IT**	Italy	**MX**	Mexico	**UZ**	Uzbekistan
CF	Central African Republic	**JP**	Japan	**NE**	Niger	**VN**	Viet Nam
CG	Congo	**KE**	Kenya	**NL**	Netherlands	**YU**	Yugoslavia
CH	Switzerland	**KG**	Kyrgyzstan	**NO**	Norway	**ZW**	Zimbabwe
CI	Côte d'Ivoire	**KP**	Democratic People's Republic of Korea	**NZ**	New Zealand		
CM	Cameroon			**PL**	Poland		
CN	China	**KR**	Republic of Korea	**PT**	Portugal		
CU	Cuba	**KZ**	Kazakstan	**RO**	Romania		
CZ	Czech Republic	**LC**	Saint Lucia	**RU**	Russian Federation		
DE	Germany	**LI**	Liechtenstein	**SD**	Sudan		
DK	Denmark	**LK**	Sri Lanka	**SE**	Sweden		
EE	Estonia	**LR**	Liberia	**SG**	Singapore		

PEPTIDE COMPOSITION AS IMMUNOGEN FOR THE TREATMENT OF ALLERGY

FIELD OF THE INVENTION

The present invention relates to the use of peptide conjugate compositions as an immunogen, with each peptide conjugate contained therein comprising a target antigenic site on the third constant domain (CH3) of the epsilon (ε) heavy chain of IgE, with said target antigenic site covalently linked to (1) a carrier protein through chemical coupling, or (2) a helper T cell epitope and other immunostimulatory sequences through chemical coupling or through direct synthesis, for the treatment of allergy.

More particularly, the present invention relates to the use of such peptide conjugate compositions as an immunogen to elicit the production, in mammals including humans, of high titer polyclonal antibodies specific to a target effector site on the CH3 domain of the ε heavy chain of IgE, and to the use of such composition as a pharmaceutical to provide an immunotherapy for IgE-mediated allergic diseases.

BACKGROUND OF THE INVENTION

In the immune system of humans and other mammals, IgE mediates type I hypersensitivities. These are the allergic responses to certain foods, drugs, and environmental allergens which are manifested by such symptoms as allergic rhinitis, asthma, allergic

dermatitis, and anaphylaxis. Existing strategies to treat allergic diseases are of limited utility, consisting of attempts to either desensitize the atopic individual to an identified allergen or to ameliorate an ongoing allergic reaction with therapeutic compounds. Limitations to allergen-based desensitization immunotherapy include difficulties in identifying the allergen involved and the adverse reactions frequently caused by the use of the identified allergen (World Health Organization and International Union of Immunological Societies Working Group, *Lancet*, 1989; i:259-261). Other treatments for the relief of allergies employ therapeutic compounds to block the acute inflammatory cascade that is responsible for allergic reactions. These compounds include anti-histamines, decongestants, β_2 agonists, and corticosteroids. Anti-histamines, decongestants, and β_2 agonists act on events downstream of IgE in the allergic cascade, making them palliative remedies which address allergic symptoms rather than preventative treatments which must act on events closer to the initiation of IgE-mediated allergic reactions. These palliative remedies provide relief that is short term and partial, frequently accompanied by adverse side effects. Many patients with severe allergies are effectively treated with corticosteroids. Steroid therapy reduces inflammation but is broadly immunosuppressive.

To avoid the shortcomings of the known therapeutic drugs, it would be more desirable to prevent allergic responses by selective intervention targeted to IgE. In common with the other immunoglobulins, IgE has two heavy

chains and two light chains. The ε heavy chain has five domains, a variable VH domain and constant domains CH1 to CH4. The constant domains from both ε chains of an IgE molecule combine to comprise the constant or Fc region of IgE. IgE circulates and becomes attached to effector cells such as basophils and mast cells through a site on the IgE Fc region, becoming bound to a high affinity FcεRI receptor on the cell surface. In an allergic response, allergens (*e.g.*, pollen, dust mite proteins, flea antigens) bind to the antigen-binding sites on the variable region of mast cell or basophil-bound IgE. This action crosslinks the IgE molecules and the underlying FcεRI receptors. The IgE-allergen complexes thereby signal the degranulation of mast cells and basophils with the concomitant release of histamine and the other inflammatory mediators. These mediators produce the symptoms of allergy, up-regulate the production of IgE, and result in heightened sensitivity to the allergen (Davis *et al.*, *Springer Semin Immunopathol*, 1993; **15**: 51-73).

It has been suggested that allergic diseases may be treated by interventions which inhibit the binding of IgE to mast cells and basophils. For example, synthetic peptides corresponding to various sites on the Fc of IgE have been studied as competitive inhibitors for the binding of IgE to the FcεRI receptor. The presumption of the investigators has been that such peptides act as antagonists for sites on IgE that participate in the binding of IgE to the FcεRI receptor, and serve to map portions of the binding site.

The amino acid residues of the competitively inhibiting IgE peptides and of all IgE peptides to follow, including non-human IgE peptide homologues, are indexed in accordance with the numbering for human IgE given by Dorrington and Bennich *(Immunol Rev*, 1978; **41**: 3-25, also accessible at internet location http:/www.pdb.bnl.gov/pdb.bin/pdbids). That human sequence is listed here as SEQ ID NO:1 and is numbered as shown in Table 1. The homologous dog, rat and mouse sequences for IgE (Patel *et al., Immunogenetics*, 1995; **41**: 282-286; Steen *et al., J Mol Biol*, 1984; **177**: 19-32; and, Ishida *et al., EMBO*, 1982; **1**: 1117-1123) are also shown in Table 1 and listed as SEQ ID NOS: 2, 3, and 4 respectively. The animal sequences are shown in register with human IgE. Individual amino acid positions in human IgE, and in homologues from other species, are identified herein according to the numbering system for the amino acid sequences shown in Table 1, unless otherwise specified.

Helm *et al.* (*Nature*, 1988; **331**:180-183) have shown that a 76 amino acid long recombinant polypeptide, spanning the C-terminal CH2 and N-terminal CH3 region of human IgE, from amino acids 301-376, reduces binding of IgE to human mast cells by competitive inhibition. Other studies reported that only the CH3 domain is involved with binding to FcεRI. For example, a rat sequence peptide corresponding to amino acids 401-415 of the human sequence (Table 1) inhibited the binding of rat IgE to rat mast cells (Burt and Stanworth, *Eur J Immunol*, 1987; **17**:437-440). A peptide of residues 419 to 463 from human IgE prevented the sensitization of rat mast cells (Nio *et al.*,

FEBS Lett, 1992; **314**: 229-231). Jardieu and Presta (WO 93/04173) reported on peptides homologous to the CH3 and CH4 regions which may include amino acids 373-390, 420-428, 446-453, and adjacent regions, which differentially bind to the FcεRI receptor. However, high concentrations of all such peptides were required to achieve effective inhibition of IgE binding. These high concentrations are predictive of excessively large doses for significant physiological effect, and are not therapeutically practical.

Anti-IgE antibodies have also been applied as a method for mapping sites on IgE that participate in binding to the FcεRI receptor. Studies with mouse monoclonal antibodies directed against various domains of IgE Fc revealed that anti-IgE monoclonal antibodies with specificities for the CH3 domain inhibit the binding of IgE to its high affinity receptor (Baniyash *et al.*, *Molec Immunol*, 1988; **25**: 705-711; and, Stadler *et al.*, *Immunol Cell Biol*, 1996; **74**: 195-200). These monoclonal antibody studies are in agreement with earlier studies that used polyclonal antipeptide antibodies to map sites that are apparently involved in receptor binding. For example, rabbit antibodies with specificities for IgE amino acid positions 401-415 (Burt *et al.*, *Molec Immunol*, 1987; **24**: 379-389), and 355-368 (Robertson and Liu, *Molec Immunol*, 1988; **25**:103-113) showed specificity for unbound IgE but reacted poorly with receptor-bound IgE.

A canine IgE peptide fragment containing at least five continuous amino acids from dog IgE amino acids 356-479 is useful for the preparation of antibodies for

diagnosis of allergy in dogs (JP 9179795, 1997). Those results are suggestive of surface-exposed effector sites in the CH3 domain of the dog ε chain, but no such effector site is taught nor is a therapeutic application disclosed for the anti-IgE antibodies.

These epitope mapping studies demonstrate most consistently that the CH3 domain of the ε heavy chain can be targeted for interventions aimed at inhibiting the binding of IgE to basophils and mast cells. However, the various studies are quite inconsistent on precise locations for sites on CH3 that are most useful. Also, results from cross-inhibition studies on IgE, with site-specific antibodies (*e.g.*, Burt *et al.*, 1987) have frequently been over-interpreted to signify that they have defined a precise location for the FcεR1 binding site on the ε chain. Interpretation of such cross-inhibition studies is limited because it cannot be assumed that an antibody recognition site is equivalent to a ligand binding site. Antibodies may inhibit by directly binding to the desired target site, but they can also occupy non-continuous effector sites and inhibit ligand binding through steric hindrance or induction of conformational change.

Therefore, the epitope mapping studies have provided empirical observations but have not resolved the binding site for the high affinity receptor within the CH3 domain. In the absence of a defined binding site, no means is available for the reliable prediction of potentially therapeutic synthetic immunogens with immunologic crossreactivities for effector sites that

participate directly or indirectly in binding to FcεR1.

Furthermore, in the absence of X-ray crystallography data for IgE, the available structural models for IgE are not sufficient for the reliable prediction of the sites on IgE that are suitable for anti-IgE interventions. Conflicting structures based on the divulged three-dimensional structure of IgG have been modeled for IgE and for the CH2/CH3 region of IgE that is associated with the interaction between IgE and its high affinity receptor. These models propose various conformationally dependent structures for the site, involving contact with linearly non-adjacent residues of the IgE molecule. Some models for the site suggest interactions between non-contiguous sites on the same ε chain mediated by intramolecular disulfide bonded loops (Helm *et al., Eur J Immunol*, 1991; **21**:1543-1548) or intramolecular loops maintained by electrostatic interactions (Presta *et al.,J Biol Chem*, 1994; **269**: 26368-26373). Other models propose intermolecular interactions between segments of the dimerized ε chains of an IgE molecule (McDonnell *et al., Biochem Soc Trans*, 1997; **25**: 387-392). In fact, experimental observations show that potential contact points comprise several scattered and discontinuous sites on the CH3 domain of the ε chain and make it clear that the three-dimensional structure of the FcεR1 binding site cannot be readily resolved by modeling (Helm *et al.*, 1988; Baniyash *et al.*, 1988; and, Presta *et al.*, 1994). Therefore, the identification of useful synthetic peptide antagonists and immunogens that mimic effector sites on IgE has not been disclosed by

theoretical modeling. In the absence of a structure for IgE resolved by X-ray crystallography, such useful peptide sites can only be arrived at by empirical experimentation.

The concept of treating allergic diseases with anti-IgE antibodies, of specificities that inhibit the binding of IgE to the high affinity receptor on basophils and mast cells, also has been known (Stadler *et al.*, 1996; Davis *et al.*, 1993). Such anti-IgE antibodies are either anaphylactogenic (crosslinking) or non-anaphylactogenic (non-crosslinking). Most such anti-IgE antibodies are anaphylactogenic. They will bind and crosslink IgE on the surface of basophils and mast cells and trigger the release of the pharmacologic mediators of allergy. This crosslinking could lead to anaphylaxis and death.

It is therefore crucial that anti-IgE antibodies for treatment be non-anaphylactogenic. Certain non-anaphylactogenic antibodies retain specificity for the CH3 domain of the ε chain and do not crosslink cell-bound IgE, while displaying inhibitory activity for IgE-mediated histamine release (Davis *et al.*,1993; Stadler *et al.*, 1996). Rup and Kahn (U.S. 4,940,782) report such a non-anaphylactogenic monoclonal antibody that reacts with free rat IgE and rat IgE bound to B cells, but not IgE bound to the rat mast cell FcεR1 receptor. Most significantly, it inhibits the sensitization of rat mast cells. The non-anaphylactogenic antibodies with homologous specificities for human IgE also inhibit sensitization by the same action mode. These anti-human IgE antibodies bind free serum IgE, bind to B cell-bound IgE, fail to bind to IgE attached to the basophil and mast cell high affinity

receptor and prevent sensitization of human cells. These antibodies are presumed to act by specificity for the site on IgE that binds to the FcεR1 receptor (Rup and Kahn, U.S. 4,940,782; Davis *et al.*, 1993; Chang, U.S. 5,420,251; Presta *et al.*, *J Immunol*, 1993; **151**: 2623-2632). In addition, a non-anaphylactogenic anti-human IgE monoclonal antibody with a different specificity has been found that also neutralizes free IgE (Rudolf *et al.*, *J Immunol*, 1996; **157**: 5646-5652). This anti-IgE does not directly bind with the receptor binding site because it also recognizes FcεR1-bound IgE. Apparently, it functions to reduce sensitization of basophils by altering the thermodynamic balance of receptor-bound versus free IgE.

Thus, anti-IgE antibodies that directly bind to the FcεR1 binding site and anti-IgE antibodies that interfere with FcεR1 binding at other effector sites, both serve to block the sensitization of mast cells and basophils by free IgE. These potentially immunotherapeutic antibodies identify CH3 as the domain of IgE that interacts with the high affinity IgE Fc receptor, in agreement with the previous mapping studies. However, a more precise identification of the binding site and alternative useful effector sites such as that described by Rudolf *et al.* remain elusive. Rudolf *et al.* have also used a phage display library to identify mimotope peptides which bind to their anti-IgE monoclonal antibody; however, the peptide mimotopes did not show homology to the primary amino acid sequence of human IgE (Rudolf *et al.*, *J. Immunol.*, 1998; **160**: 3315-3321).

A humanized monoclonal anti-IgE antibody with

apparent specificity for the FcεR1 receptor site is under clinical study in humans for the treatment of allergy by passive immunotherapy (MacGlashan *et al.*, *J Immunol*, 1997; **158**:1438-1445). It has been found that infusion with that antibody, rhuMAb-E25, reduces the serum concentration of IgE in patients, down-regulates the expression of IgE receptor on effector cells, reduces allergic sensitivities to challenge by allergen, and improves the symptoms of asthma and allergic rhinitis. The antibody displays a good safety profile. The clinical trial results establish the feasibility of an anti-IgE approach for the treatment of allergic diseases. But this treatment mode is problematical: Immunotherapy by the anti-IgE invention is accomplished by passive immunization, *i.e.*, by infusion of the antibody. The antibody must be delivered in doses high enough and at frequencies often enough, via inconvenient intravenous or subcutaneous routes, to achieve a continuous pharmacologically effective concentration of antibody. The effective dose is determined by patient body weight, baseline level of free IgE in circulation, and by route of administration. In recent clinical trials, the steady-state concentration required for therapeutic efficacy was achieved by two weekly doses and maintained thereafter by biweekly doses. A full course of treatment for a typical allergy patient would expend a total of 2000-3000 mg of humanized antibody and requires seven to 10 inconvenient intravenous administrations (MacGlashan *et al.*,1997; Boulet *et al.*, *Am J Respir Crit Care Med*, 1997; **155**:1835-1840). The cost for this amount of antibody and the expense and inconvenience of multiple infusions in a hospital setting

suggest that this treatment is too expensive for all but a small proportion of the patient population.

The clinical effectiveness of the monoclonal antibody rhuMAb-E25 establishes the feasibility of immunotherapy by passively administered anti-IgE. It also provides the rationale for an alternative anti-IgE approach by active immunization, if and when such immunogens can be designed.

An anti-IgE treatment affected by active immunization with an IgE immunogen, *i.e.*, by "vaccination" against endogenous IgE, would be preferable on the basis of cost and convenience. "Vaccination" against IgE offers advantages over passive immunization: small amounts of inexpensive immunogen, infrequent and conveniently administered intramuscular injections, and no need to customize murine antibodies for compatibility with the subject species, *i.e.*, to "humanize" antibodies for use in humans, since the procedure uses the patient's own immune system to produce antibodies. However, while the desensitizing monoclonal antibodies cited above may be suggestive of the desirability of IgE immunogens, they do not disclose the identity of safe and effective immunogens. Such immunogens must mimic relevant IgE effector sites with fidelity sufficient to evoke cross-inhibitory antibodies, while retaining site-specificity sufficient to avoid induction of anaphylactogenic antibodies. Moreover, effective IgE immunogens must be highly immunostimulatory. There remains a need for such immunogens, of relevant and safe site-specificity, and of sufficient immunopotency.

IgE immunogens for immunotherapy of allergy must be immunostimulatory so as to evoke levels of anti-IgE sufficient to reduce IgE-mediated sensitization. Such immunogens must be designed to overcome the strong tolerance exhibited towards self molecules. Haba and Nisonoff (*Proc Natl Acad Sci USA*, 1990; **87**:3363-3367) induced an effective anti-IgE response in mice only by immunizations with IgE during a short neonatal window of development, from birth to day 10. Vaccinations initiated beyond this time failed to induce the desired autoimmune response unless the IgE used to immunize the mice had been covalently coupled to a foreign carrier protein, keyhole limpet hemocyanin (KLH). Similarly, a desensitizing anti-IgE response was evoked in rats by a recombinant protein comprising the CH2-CH3 ε chain domains fused to the glutathione-S-transferase protein of *Schistosoma japonicum* (Hellman, *Eur J Immunol*, 1994; **24**:415-420).

Other investigators have been concerned with minimizing the risk of evoking anaphylactogenic anti-IgE antibodies that crosslink IgE already bound to the surface of mast cells and basophils by seeking peptide IgE immunogens of finer site specificity. For example, a peptide corresponding to a site in the CH4 domain of IgE (residues 497-506 of SEQ ID NO:1) was coupled to KLH and used to induce polyclonal antibodies that were effective in suppressing IgE-mediated signal transduction in rat mast cells. However, the peptide-KLH conjugate displayed poor immunostimulatory capabilities which necessitated demonstration of efficacy by passive immunization of rats with peak immune rabbit antiserum (Stanworth *et al.*, *Lancet*, 1990; **336**:1279-1281). The CH4 immunogen of

Stanworth *et al.* was later produced, by the work of the present inventor, as a series of wholly synthetic immunogens by synthesis that provided covalent linkage to promiscuous human T helper epitopes. Immunogenicity of these peptides was improved over that of the original KLH-peptide conjugate, but no evidence was provided for the efficacy of resultant anti-IgE CH4 antibodies (Wang, WO 95/26365). Furthermore, as shown herein in Example 1 (Table 2, entry 34), anti-peptide antibodies with specificity for the previously disclosed CH4 effector site (Stanworth *et al.*, 1990) had no crossreactivity to human IgE. The earlier antipeptide studies of Burt and Stanworth (1987) targeted to the IgE-CH3 401-415 peptide also provided evidence of evoking desensitizing cross-reactivity, but this too required selected peak rabbit antiserum and use of an ill-defined peptide-carrier protein conjugate to observe effects by passive immunization in a rat model. No synthetic peptides have ever been demonstrated to be effective in eliciting the production in immunized hosts of polyclonal antisera capable of inhibition of histamine release.

The improvement of the prior art immunogens discussed above is necessary before a synthetic peptide immunogen of immunogenicity and specificity sufficient for efficacy and safety can be attained. The present invention accomplishes these improvements through incorporation of a collection of additional methods for the identification and design of synthetic peptide immunogens. These methods include: (1) an effective procedure for the identification of an effective target epitope; (2) the means to augment the immunogenicity of a

B cell target epitope by combining it with a peptide comprising broadly reactive promiscuous T helper cell (Th) epitope; (3) the means of enlarging the repertoire of T cell epitopes by application of combinatorial peptide chemistry and thereby further accommodate the variable immune responsiveness of an outbred population; and (4) the stabilization of conformational features by the introduction of cyclic constraints, so as to maximize cross-reactivity to the native molecule.

Synthetic peptides have been used for "epitope mapping" to identify immunodominant determinants or epitopes on the surface of proteins, for the development of new vaccines and diagnostics. Epitope mapping employs a series of overlapping peptides corresponding to regions on the protein of interest to identify sites which participate in antibody-immunogenic determinant interaction. Most commonly, epitope mapping employs peptides of relatively short length to precisely detect linear determinants. A fast method of epitope mapping known under the trademark "PEPSCAN" is based on the simultaneous synthesis of hundreds of overlapping peptides, of lengths of 8 to 14 amino acids, coupled to solid supports. The coupled peptides are tested for their ability to bind antibodies. The PEPSCAN approach is effective in localizing linear determinants, but not for the identification of epitopes needed for mimicry of discontinuous effector sites such as the FcεR1 binding site (Meloen *et al.*, Ann Biol Clin, 1991; **49**:231-242). An alternative method relies on a set of nested and overlapping peptides of multiple lengths ranging from 15 to 60 residues. These longer peptides can be reliably

synthesized by a laborious series of independent solid-phase peptide syntheses, rather than by the rapid and simultaneous PEPSCAN syntheses. The resulting set of long nested and overlapping peptides can then be used for analyses of antibody binding in systems such as experimental immunizations and natural infections, to identify long peptides which best present immunodominant determinants, including simple discontinuous epitopes. This method is exemplified by the studies of Wang for the mapping of immunodominant sites from HTLV I/II (US 5,476,765) and HCV (US 5,106,726); and it was used for the selection of a precise position on the gp120 sequence for optimum presentation of an HIV neutralizing epitope (Wang *et al.*, *Science*, 1991; **254**:285-288).

Peptide immunogens are generally more flexible than proteins and tend not to retain any preferred structure. Therefore it is useful to stabilize a peptide immunogen by the introduction of cyclic constraints. A correctly cyclized peptide immunogen can mimic and preserve the conformation of a targeted epitope and thereby evoke antibodies with cross-reactivities for that site on the authentic molecule (Moore, Chapter 2 in *Synthetic Peptides: A User's Guide*, ed Grant, WH Freeman and Company: New York, 1992, pp 63-67).

Another important factor affecting the immunogenicity of an IgE-derived peptide for an allergy pharmaceutical is its presentation to the immune system by T helper cell epitopes that react with a host's T-helper cell receptors and Class II MHC molecules (Babbitt *et al.*, Nature, 1985; **317**: 359-361). These are often provided by carrier proteins with concomitant disadvantages due to the

difficulties for the manufacture of well-defined peptide-carrier conjugates, misdirection of most antibody response to the carrier, and carrier-induced epitopic suppression (Cease, *Intern Rev Immunol.*, 1990; **7**: 85-107; Schutze *et al.*, *J Immunol.*, 1985; **135**: 2319-2322). Alternatively, T-helper cell epitopes (Th) may also be supplied by synthetic peptides comprising Th sites. Thus, Th epitopes termed promiscuous Th evoke efficient T cell help and can be combined with synthetic B cell epitopes that by themselves are poorly immunogenic to generate potent peptide immunogens (US 5,759,551). Well-designed promiscuous Th/B cell epitope chimeric peptides are capable of eliciting Th responses and resultant antibody responses in most members of a genetically diverse population expressing diverse MHC haplotypes. Promiscuous Th can be provided by specific sequences derived from potent foreign antigens, such as for example measles virus F protein, hepatitis B virus surface antigen, and *Chlamydia trachomatis* major outer membrane protein (MOMP). Many known promiscuous Th, taken from viral and bacterial pathogens, have been shown to be effective in potentiating a poorly immunogenic peptide corresponding to the decapeptide hormone LHRH (US 5,759,551)

Promiscuous Th epitopes derived from foreign pathogens may include, but are not limited to, hepatitis B surface and core antigen helper T cell epitopes (HB_s Th and HB_c Th), pertussis toxin helper T cell epitopes (PT Th), tetanus toxin helper T cell epitopes (TT Th), measles virus F protein helper T cell epitopes (MV_F Th), *Chlamydia trachomatis* major outer membrane protein helper T cell epitopes (CT Th), diphtheria toxin helper T cell epitopes

(DT Th), *Plasmodium falciparum* circumsporozoite helper T cell epitopes (PF Th), *Schistosoma mansoni* triose phosphate isomerase helper T cell epitopes (SM Th), and *Escherichia coli* TraT helper T cell epitopes (TraT Th). The pathogen-derived Th were listed as SEQ ID NOS:2-9 and 42-52 in US 5,759,551; as Chlamydia helper site P11 in Stagg *et al.*, *Immunology*, 1993; **79**;1-9; and as HBc peptide 50-69 in Ferrari *et al.*, *J Clin Invest*, 1991; **88**: 214-222.

Promiscuous Th epitopes range in size from about 15 to about 50 amino acid residues in length (US 5,759,551) and often share common structural features and may contain specific landmark sequences. For example, a common feature is amphipathic helices, which are alpha-helical structures with hydrophobic amino acid residues dominating one face of the helix and with charged and polar resides dominating the surrounding faces (Cease *et al.*, *Proc Natl Acad Sci USA*, 1987; **84**:4249-4253). Th epitopes frequently contain additional primary amino acid patterns such as a Gly or charged residue followed by two to three hydrophobic residues, followed in turn by a charged or polar residue. This pattern defines what are called Rothbard sequences. Also, Th epitopes often obey the 1, 4, 5, 8 rule, where a positively charged residue is followed by hydrophobic residues at the fourth, fifth and eighth positions after the charged residue, consistent with an amphipathic helix having positions 1, 4, 5,and 8 located on the same face. Since all of these structures are composed of common hydrophobic, charged and polar amino acids, each structure can exist simultaneously within a single Th epitope (Partidos et al., *J Gen Virol*, 1991; **72**:1293-1299). Most, if not all, of the promiscuous

T cell epitopes fit at least one of the periodicities described above. These features may be incorporated into the designs of "idealized artificial Th sites".

Useful Th sites may also include combinatorial Th that incorporate selected degenerate sites into the design of the idealized Th sites. In Wang *et al.*(WO 95/11998), a particular class of a combinatorial epitope was designated as a "Structured Synthetic Antigen Library" or SSAL. A Th constructed as an SSAL epitope is composed of positional substitutions organized around a structural framework of invariant residues. The sequence of the SSAL is determined by aligning the primary amino acid sequence of a promiscuous Th, retaining relatively invariant residues at positions responsible for the unique structure of the Th peptide and providing degeneracy at the positions associated with recognition of the diverse MHC restriction elements. Lists of variable and preferred amino acids are available for MHC-binding motifs (Meister *et al.*, *Vaccine*, 1995; **13**: 581-591; Alexander *et al.*, *Immunity*, 1994, 1:751-761).

All members of the SSAL are produced simultaneously in a single solid-phase peptide synthesis in tandem with the targeted B cell epitope and other sequences. The Th library sequence maintains the binding motifs of a promiscuous Th and accommodates reactivity to a wider range of haplotypes. For example, the degenerate Th epitope described in WO 95/11998 as "SSAL1TH1" was modeled after a promiscuous epitope taken from the F protein of measles virus (Partidos *et al.*, 1991). SSAL1TH1 was designed to be used in tandem with an LHRH target peptide. Like the measles epitope, SSAL1TH1

follows the Rothbard sequence and the 1, 4, 5, 8 rule:

1 5 10 15

Asp-Leu-Ser-Asp-Leu-Lys-Gly-Leu-Leu-Leu-His-Lys-Leu-Asp-Gly-Leu

Glu Ile Glu Ile Arg Ile Ile Ile Arg Ile Glu Ile

Val Val Val Val Val Val Val

Phe Phe Phe Phe Phe Phe Phe

Charged residues Glu or Asp are added at position 1 to increase the charge surrounding the hydrophobic face of the Th. The hydrophobic face of the amphipathic helix is then maintained by hydrophobic residues at 2, 5, 8, 9, 10, 13 and 16, with variability at 2, 5, 8, 9, 10, 13, and 16 to provide a facade with the capability of binding to a wide range of MHC restriction elements. The net effect of the SSAL feature is to enlarge the range of immune responsiveness to an artificial Th (WO 95/11998).

Peptide immunogens that have been designed with the peptide technologies and peptide design elements discussed above, *i.e.*, precise epitope mapping, cyclic constraint, and the incorporation of promiscuous Th epitopes or idealized promiscuous Th, and idealized SSAL Th epitopes, are the basis for the effective synthetic peptide IgE immunogens of the present invention. Such peptides are preferred for appropriate targeting and safety due to effective presentation of the IgE effector site by optimized positioning and cyclization, and for immunopotency due to broadly reactive Th responsiveness.

SUMMARY OF THE INVENTION

The present invention provides new synthetic peptide conjugate compositions for the treatment of IgE-mediated allergic diseases by active immunization. The immunization induces the production of high titer non-anaphylactogenic polyclonal antibodies specific to an effector site of IgE in an immunized host. This in turn prevents the triggering and activation of mast cells/basophils and down-regulates IgE synthesis.

Treatment is effected by immunization of the host with the peptide composition, with each peptide contained therein comprising a target antigenic peptide sequence (referred to herein as an "IgE-CH3 domain antigen" or "IgE-CH3 domain antigen peptide") modified from a segment of the CH3 domain of the epsilon (ε) heavy chain of human IgE (*e.g.*, amino acids 413-435 of SEQ ID No:1 or SEQ ID NO:5) or the homologous sequence from other species (*e.g.* SEQ ID NOS:6-8 and 84).

In general, the IgE-CH3 domain antigen is a peptide sequence between about 25 and about 29 amino acids in length, is substantially homologous to the above segment of the CH3 domain of the epsilon heavy chain of a mammalian IgE antibody, and contains two cysteine residues separated by about 23 amino acid residues. In the present context, substantially homologous means that in addition to the two cysteine residues, which may be introduced by insertion or substitution, up to about four other amino acid substitutions (preferably conservative substitutions) may also be made.

Preferably, the target site is modified from that

of the naturally occurring IgE sequences as follows:

(1) by the insertion of a cysteine residue to the N-terminus side of position 413 or homologous position, unless cysteine is already present at positions 413 or 414 in the natural sequence;

(2) by the conservative substitution (preferably of serine) for any native cysteines from positions 415 to 434 of the natural target sequence;

(3) by the insertion of cysteine at the C-terminus side of position 435 or homologous position unless cysteine is already present at positions 435 or 436 in the natural sequence; and

(4) by the formation of a disulfide bond between the retained cysteines so as to produce a cyclic structure. The structures may also comprise 1 to 5 additional amino acids taken from either terminus of the 413-435 segment of IgE, provided that the single disulfide looped structure is preserved.

An optimized IgE-CH3 domain antigen peptide for human IgE, having the sequence Cys-Gly-Glu-Thr-Tyr-Gln-Ser-Arg-Val-Thr-His-Pro-His-Leu-Pro-Arg-Ala-Leu-Met-Arg-Ser-Thr-Thr-Lys-Cys (SEQ ID NO:5) is provided by the present invention. The human IgE target site is cyclized through the unnatural terminal cysteines and a serine residue substitutes for the cysteine residue of the natural sequence. Antibody that is evoked by peptide immunogens comprising this IgE-CH3 domain antigen is crossreactive with human IgE and inhibits the sensitization of human basophils by human IgE.

Likewise, corresponding target sites for IgE of

other species can be derived from the homologous ε chain segment of the relevant species. For example, such target sequences can be taken from the dog, rat and mouse ε sequences shown in Table 1 (SEQ ID NOS: 2, 3 and 4), or the horse IgE-CH3 sequence provided by Navarro *et al.*, *Molec. Immunol.*, 1995, **32**:1-8. Additional IgE-CH3 domain antigen peptides (SEQ ID NOS: 6, 7, 8, and 84), may be derived from these sequences.

Preferably, the IgE-CH3 domain antigens of the invention are rendered more immunogenic via covalent linkage to a carrier protein through chemical coupling, or more preferably via covalent linkage to synthetic immunostimulatory elements, such as promiscuous Th epitopes, through direct synthesis. Specific examples of carrier protein and immunostimulatory elements are provided, *e.g.*, Keyhole Limpet Hemocyanin (KLH) carrier, an artificial Th (SEQ ID NO:9), artificial SSAL Th (SEQ ID NOS:10 and 11), a pathogen-derived Th (SEQ ID NO:12), and an immunostimulatory invasin peptide (Inv) taken from *Yersinia* (SEQ ID NO:13).

Completely synthetic peptide conjugates of the invention may be represented by the formulas:

$(A)_n$-(IgE-CH3 domain antigen)-$(B)_o$-$(Th)_m$-X

or

$(A)_n$-$(Th)_m$-$(B)_o$-(IgE-CH3 domain antigen)-X

or

$(A)_n$-$(B)_o$-$(Th)_m$-$(B)_o$-(IgE-CH3 domain antigen)-X

or

(IgE-CH3 domain antigen)-$(B)_o$-$(Th)_m$-$(A)_n$-X

or

$(Th)_m-(B)_o-(IgE\text{-}CH3\ domain\ antigen)-(A)_n-X$

wherein

each A is independently an amino acid or a general immunostimulatory sequence;

each B is chosen from the group consisting of amino acids,

$-NHCH(X)CH_2SCH_2CO-$, $-NHCH(X)CH_2SCH_2CO(\varepsilon\text{-}N)Lys-$,

$-NHCH(X)CH_2S$-succinimidyl$(\varepsilon\text{-}N)Lys-$, and

$-NHCH(X)CH_2S-$(succinimidyl)$-$;

each Th is independently a sequence of amino acids that constitutes a helper T cell epitope, or an immune enhancing analog or segment thereof;

IgE-CH3 domain antigen is a peptide between about 25 and about 29 amino acids in length, is substantially homologous to one of the segments represented by SEQ ID NOS:5-8 and 84 of the CH3 domain of the epsilon heavy chain of a mammalian IgE antibody, and contains two cysteine residues separated by about 23 amino acid residues;

X is an amino acid α-COOH or α-$CONH_2$;

n is from 0 to about 10;

m is from 1 to about 4; and

o is from 0 to about 10.

More specifically, IgE-CH3 domain antigen is selected from the group consisting of SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, homologous sequences from the epsilon heavy chain of mammalian IgE-CH3 antibodies, and crossreactive and immunologically functional analogs

thereof.

The peptide compositions of the present invention comprises peptide immunogens from about 25 to about 100 amino acid residues, preferably from about 25 to about 80 amino acid residues and more preferably from about 45 to about 65 amino acid residues.

Also provided are adjuvants and/or delivery vehicles and other ingredients routinely incorporated with vaccine formulations, and instructions for dosage such that immunotherapeutic antibodies directed against the targeted IgE effector site are generated. This in turn inhibits the sensitization by circulatory IgE of basophils and mast cells, and thereby prevents the triggering and activation of mast cells/basophils by IgE-allergen complexes. The inhibitory mechanism, mediated by the antibodies and induced by the peptide composition of the present invention, will specifically reduce or eliminate the IgE-mediated pathology while leaving the defensive components of the immune system, *e.g.* IgG, unaffected.

DETAILED DESCRIPTION OF THE INVENTION

This invention is directed to novel peptide and peptide conjugate compositions for the generation of high titer polyclonal antibodies with specificity for a target effector site on the third domain of the Fc portion of IgE, *i.e.*, the CH3 domain of the ε chain.

For convenience, the term "peptide conjugate" as used herein refers to molecules which comprise Th epitopes covalently linked to IgE-CH3 domain antigen peptides,

whether through conventional peptide bonds so as to form a single larger peptide, or through other forms of covalent linkage.

The high site-specificity of the compositions of this invention minimizes the generation of anti-IgE antibodies that can crosslink the bivalent IgE bound to FcεR1 on the basophil/mast cell surface, and thereby evoke the production of non-anaphylactogenic anti-IgE antibodies. Therefore, the invention is further directed to a safe method for the treatment of IgE-mediated allergic diseases in mammals, including humans.

The targeted antigenic sequence was determined by a thorough screening of candidate sites on the CH2 and CH3 domains of human IgE for useful immunoreactivities. CH2 and CH3 sites were selected for synthesis as peptide immunogens based on the disclosures by Helm *et al.* (1988) and Presta *et al.* (1994) that a long region which begins in the carboxyl terminus region of the CH2 domain of IgE and proceeds through the CH3 domain contains potential effector sites. Potential loop structures in the conformation of IgE were deduced from a theoretical model for the three dimensional structure of human IgE made available by the Brookhaven National Laboratory at internet address http://www.pdb.bnl.gov/pdb.bin/pdbids and reported in Helm *et al.* (*Eur J Immunol*, 1991; **21**: 1543-1548). Disulfide-bonded loops were incorporated into the design of selected peptide immunogens so as to mimic the positions of predicted loops, so as to maximize the possibility of crossreactivity between the designed target antigenic peptides and the native IgE molecule. Potential target antigenic sites were synthesized and made

immunogenic either by chemical conjugation to KLH following solid-phase peptide synthesis, or by covalent attachment to promiscuous Th epitopes and other immunostimulatory sequences by continuous synthesis (Table 2). Several sites were synthesized as cyclic peptides, with the incorporation of specific disulfide bonds, so as to stabilize the mobile peptides into conformations that resemble predicted IgE loop structures. Potentially useful effector target sites were then identified by the preparation of hyperimmune sera and testing of the antiserum for crossreactivity to human IgE. Antibodies from sera with high crossreactivity to human IgE were purified and evaluated for ability to inhibit the IgE-mediated sensitization of human basophils in an *in vitro* assay for histamine release. Anti-peptide antibodies evoked by peptides, SEQ ID NOS: 14 and 15 comprising SEQ ID NO:5, displayed strong crossreactivity for IgE (Table 2), and most consistently displayed high inhibitory activity in the histamine release assay (Table 3). The target epitope common to the peptides of SEQ ID NOS:14 and 15 corresponds to a segment of the IgE CH3 domain shown in Table 1. Table 1 shows the amino acid sequence of CH2, CH3 and CH4 domains of the ε heavy chain of the human IgE aligned with the homologous sequences taken from the dog, rat, and mouse. The target site on the human ε chain sequence that was determined to be useful for representation as the IgE-CH3 domain antigens of the invention is underlined in Table 1 and includes human ε chain residues 413-435. Homologous target sequences in the dog, rat, and mouse proteins are also underlined in Table 1. The homologous sequence in the horse is residues

296-318 in the amino acid sequence of Navarro *et al.*, *Molec. Immunol.*, 1995, **32**:1-8.

The underlined target IgE CH3 effector sites, and the derived IgE-CH3 domain antigen peptides of this invention, are short peptide sequences which, when synthesized by themselves, are usually weakly or non-immunogenic, more so for being self-antigens. These short peptides can be immunopotentiated by chemically coupling to a carrier protein, for example, keyhole limpet hemocyanin (KLH). A disadvantage of such "IgE-CH3 domain antigen-carrier protein" based immunogens is the weak immunogenicity of the antigen compared to the large carrier protein, an inherent problem associated with peptide-carrier protein conjugates. The majority of antibodies generated by such a conjugate are non-functional antibodies directed against the carrier protein. The preferred immunogens of the present invention are wholly synthetic peptides which minimize the generation of irrelevant antibodies, and thereby elicit immune responses more focused to the target IgE-CH3 domain antigens, *e.g.*, SEQ ID NOS:5-8 and 84.

However, because the short IgE-CH3 domain antigen peptides of the present invention (*e.g.*, SEQ ID NOS:5-8 and 84) are non-immunogenic T cell-dependent epitopes, they are dependent for immunogenicity on extrinsic Th epitopes. These are provided for the preferred peptides of the invention as covalently linked promiscuous Th epitopes. The immunogens of the invention elicit site-specific immunoreactivity to provide precise targeting of the effector site and thus produce non-crosslinking anti-IgE antibodies. The resultant site-specific antibodies

inhibit sensitization and allergic response but do not induce spontaneous degranulation.

Specific examples are provided in the present invention as embodiments of the immunogenic peptide conjugates of the invention. These examples provide for the linkage of synthetic immunostimulatory elements to IgE-CH3 domain antigen peptides (*e.g.*, SEQ ID NOS:5-8 and 84) such that potent crossreactive antibodies are broadly generated, in a genetically diverse host population, against the targeted site on the IgE CH3 domain. These anti-IgE antibodies are non-anaphylactogenic and specifically directed against IgE (Examples 2 and 3). These antibodies, in turn, lead to inhibition of histamine release and diminished IgE-mediated responses, thus resulting in effective treatment and/or prevention of IgE-mediated allergic diseases.

For active immunization, the term "immunogen" referred to herein relates to a peptide conjugate composition which is capable of inducing antibodies against an effector site present on the third domain of the ε-heavy chain of IgE (*e.g.*, SEQ ID NOS:5-8 and 84), leading to inhibition or suppression of IgE-mediated basophil and mast cell degranulation. The peptide compositions of the present invention include IgE-CH3 domain antigen peptides, preferably linked to carrier proteins via chemical coupling, more preferably IgE-CH3 domain antigen peptides linked to promiscuous helper T cell epitopes (Th epitopes) via chemical coupling, and most preferably wholly synthetic peptides which contain IgE-CH3 domain antigen sequences and promiscuous helper T cell epitope (Th epitope) sequences.

The carrier proteins are covalently attached to the IgE-CH3 domain antigen peptides, preferably with a spacer (*e.g.*, Lys-Lys-Lys), via chemical coupling. The Th peptides (*e.g.*, SEQ ID NOS:9-12) are covalently attached to the IgE-CH3 domain antigen peptides (*e.g.*, SEQ ID NOS:5-8 and 84) either *via* chemical coupling or preferably *via* direct synthesis, preferably with a spacer (*e.g.*, Gly-Gly), so as to be adjacent to either the N- or C-terminus of the IgE-CH3 domain antigen sequences, in order to evoke efficient antibody responses. The immunogen optionally may also comprise a general immunostimulatory amino acid sequence, for example one corresponding to a domain of an invasin protein from the bacteria *Yersinia* spp (Brett *et al.*, *Eur J Immunol*, 1993, **23**: 1608-1614) (SEQ ID NO:13). The general immunostimulatory sequence may comprise an optional spacer through which it is attached to a Th peptide.

The completely synthetic peptides of this invention can be represented by the formulas:

$(A)_n$-(IgE-CH3 domain antigen)-$(B)_o$-$(Th)_m$-X

or

$(A)_n$-$(Th)_m$-$(B)_o$-(IgE-CH3 domain antigen)-X

or

$(A)_n$-$(B)_o$-$(Th)_m$-$(B)_o$-(IgE-CH3 domain antigen)-X

or

(IgE-CH3 domain antigen)-$(B)_o$-$(Th)_m$-$(A)_n$-X

or

$(Th)_m$-$(B)_o$-(IgE-CH3 domain antigen)-$(A)_n$-X

wherein

each A is independently an amino acid or a general

immunostimulatory sequence;

each B is chosen from the group consisting of amino acids, $-NHCH(X)CH_2SCH_2CO-$, $-NHCH(X)CH_2SCH_2CO(\varepsilon\text{-}N)Lys-$, $-NHCH(X)CH_2S$-succinimidyl$(\varepsilon\text{-}N)Lys-$, and $-NHCH(X)CH_2S$-(succinimidyl)-;

each Th is independently a sequence of amino acids that constitutes a helper T cell epitope, or an immune enhancing analog or segment thereof;

IgE-CH3 domain antigen represents the sequence of an IgE-CH3 domain antigen peptide as defined herein (or a crossreactive and immunologically functional analog thereof);

n is from 0 to about 10;

m is from 1 to about 4; and

o is from 0 to about 10.

The peptide immunogen of the present invention comprises from about 25 to about 100 amino acid residues, preferably from about 25 to about 80 amino acid residues and more preferably from about 25 to about 65 amino acid residues.

When A is an amino acid, it can be any non-naturally occurring or any naturally occurring amino acid. Non-naturally occurring amino acids include, but are not limited to, D-α-amino acids, ß-alanine, ornithine, norleucine, norvaline, hydroxyproline, thyroxine, γ-amino butyric acid, homoserine, citrulline and the like. Naturally-occurring amino acids include alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine,

lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine and valine. Moreover, when n is greater than one, and two or more of the A groups are amino acids, then each amino acid may be independently the same or different.

When A is an invasin domain, it is an immune stimulatory epitope from the invasin protein of a *Yersinia* species. This immune stimulatory property results from the capability of this invasin domain to interact with the β1 integrin molecules present on T cells, particularly activated immune or memory T cells. The specific sequence for an invasin domain found to interact with the β1 integrins has been described by Brett *et al.* (*Eur J Immunol*, 1993). A preferred embodiment of the invasin domain (Inv) for linkage to a promiscuous Th epitope has been previously described in US 5,759,551 which is incorporated herein by reference. The Inv domain has the sequence Thr-Ala-Lys-Ser-Lys-Lys-Phe-Pro-Ser-Tyr-Thr-Ala-Thr-Tyr-Gln-Phe (SEQ ID NO:13) or is an immune stimulatory homologue thereof from the corresponding region in another *Yersinia* species invasin protein. Such homologues thus may contain substitutions, deletions or insertions of amino acid residues to accommodate bacterial strain variation, provided that the homologues retain immune stimulatory properties. An immune stimulatory homologue may also comprise an optional spacer through which it is attached to a Th epitope.

In one embodiment, n is 3 and $(A)_3$ is an invasin domain (Inv), glycine and glycine, in that order.

$(B)_o$ is an optional spacer and comprises amino

acids which can be naturally occurring or the non-naturally occurring amino acids as described above. Each B is independently the same or different. The carrier proteins are covalently attached to the peptides with a spacer (*e.g.*, Lys-Lys-Lys) via chemical coupling. The amino acids of B can also provide a spacer, *e.g.*, Gly-Gly or (□-N)Lys, between the promiscuous Th epitope (*e.g.*, SEQ ID NO:9) and the IgE-CH3 peptide (*e.g.*, SEQ ID NO:5) and crossreactive and functional immunological analogs thereof. In addition to physically separating the Th epitope from the B cell epitope, *i.e.*, the IgE-CH3 peptide (*e.g.*, SEQ ID NO:5) and immunological analogs thereof, the spacer can disrupt any artifactual secondary structures created by the joining of the Th epitope with the IgE-CH3 peptide (*e.g.*, SEQ ID NO:5) and crossreactive and functional immunological analogs thereof and thereby eliminate interference between the Th and/or B cell responses. The amino acids of B can also form a spacer which acts as a flexible hinge that enhances separation of the Th and IgE domains. Examples of sequences encoding flexible hinges are found in the immunoglobulin heavy chain hinge region. Flexible hinge sequences are often proline rich. One particularly useful flexible hinge is provided by the sequence Pro-Pro-Xaa-Pro-Xaa-Pro (SEQ ID NO:16), where Xaa is any amino acid, and preferably aspartic acid. The conformational separation provided by the amino acids of B permits more efficient interactions between the presented peptide immunogen and the appropriate Th cells and B cells and thus enhances the immune responses to the Th epitope and the antibody-eliciting epitope and their crossreactive and functional

immunological analogs thereof.

Th is a sequence of amino acids (natural or non-natural amino acids) that comprises a Th epitope. A Th epitope can consist of a continuous or discontinuous epitope. Hence not every amino acid of Th is necessarily part of the epitope. Accordingly, Th epitopes, including analogs and segments of Th epitopes, are capable of enhancing or stimulating an immune response to the IgE-CH3 antigen peptides (*e.g.*, SEQ ID NOS:5-8 and 84, and immunological analogs thereof). Th epitopes that are immunodominant and promiscuous are highly and broadly reactive in animal and human populations with widely divergent MHC types (Partidos *et al.*, 1991; US 5,759,551). The Th domain of the subject peptides has from about 10 to about 50 amino acids and preferably from about 10 to about 30 amino acids. When multiple Th epitopes are present (*i.e.* $m \geq 2$), then each Th epitope is independently the same or different. Th segments are contiguous portions of a Th epitope that are sufficient to enhance or stimulate an immune response to the IgE-CH3 peptide (*e.g.*, SEQ ID NO:5) and immunological analogs thereof.

Th epitopes of the present invention include as examples, but are not limited to, pathogen-derived hepatitis B surface and core antigen helper T cell epitopes (HBs Th and HBc Th), pertussis toxin helper T cell epitopes (PT Th), tetanus toxin helper T cell epitopes (TT Th), measles virus F protein helper T cell epitopes (MVF Th), *Chlamydia trachomatis* major outer membrane protein helper T cell epitopes (CT Th), diphtheria toxin helper T cell epitopes (DT Th), *Plasmodium falciparum* circumsporozoite helper T cell

epitopes (PF Th), *Schistosoma mansoni* triose phosphate isomerase helper T cell epitopes (SM Th), and *Escherichia coli* TraT helper T cell epitopes (TraT Th). The pathogen-derived Th were listed as SEQ ID NOS:2-9 and SEQ ID NOS:42-52 in US 5,759,551; as Chlamydia helper site P11 in Stagg *et al.*, *Immunology*, 1993; **79**:1-9 (also listed here as SEQ ID NO:12); and as HBc peptide 50-69 in Ferrari *et al.*, *J Clin Invest*, 1991; **88**: 214-222, and are incorporated herein by reference.

Exemplary Th sites of the invention also include the artificial Th site termed "Syn Th (1,2,4)" (SEQ ID NO:9), artificial SSAL Th sites "(1,4,9 PALINDROMIC) Th", "IS (1,4,9 PALINDROMIC) LF Th" and "IS (1, 4, 9 PALINDROMIC)LF simplified Th" (SEQ ID NOS:10, 11 and 60), and immunologically functional analogs thereof. Functional Th analogs include immune-enhancing analogs, crossreactive analogs and segments of any of these Th epitopes. Functional Th analogs further include conservative substitutions, additions, deletions and insertions of from one to about 10 amino acid residues in the Th epitope which do not essentially modify the Th-stimulating function of the Th epitope.

The synthetic peptide of this invention are generally about 50 to about 90 amino acids, and comprise

(a) an immunostimulatory invasin domain,

(b) a helper T cell (Th) epitope, and

(c) an IgE-CH3 domain antigen peptide.

More specifically, the synthetic peptides of this invention are described by the formulas

$(A)_n$-$(Th)_m$-$(B)_o$-(IgE-CH3 domain antigen)-X,

$(A)_n$-$(B)_o$-$(Th)_m$-$(B)_o$-(IgE-CH3 domain antigen)-X,

$(A)_n$-(IgE-CH3 domain antigen)-$(B)_o$-$(Th)_m$-X,

(IgE-CH3 domain antigen)-$(B)_o$-$(Th)_m$-$(A)_n$-X, and

$(Th)_m$-$(B)_o$-(IgE-CH3 domain antigen)-$(A)_n$-X.

The Th epitope is attached, optionally through spacer B, to either the N terminus or C terminus of the IgE-CH3 peptide and crossreactive and functional immunological analogs thereof. Preferred peptide immunogens of this invention are the peptides containing the IgE-CH3 domain antigen peptides (*e.g.*, SEQ ID NO:5) (or immunological analogs thereof) and Th peptides, and optionally Inv (SEQ ID NO:13). In a more preferred embodiment the Th epitope is an HBs Th, HBc Th, MV_F Th, PT Th, TT Th, CT Th (*e.g.*, SEQ ID NO:12) or artificial Th (SEQ ID NOS:9-11 and 60), or functional immunogenic analogue thereof, and optionally, A is Inv (SEQ ID NO:13) attached through a $(B)_o$ spacer such as Gly-Gly or (□-N)Lys.

The structure of the IgE-CH3 domain antigen comprises a peptide sequence taken from the CH3 domain of human IgE (amino acids 413-435 of SEQ ID No:1) or the homologous sequences from other species (*e.g.*, SEQ ID NOS:6-8 and 84) and subjected to the following modifications:

the target site is modified from that of the naturally occurring IgE sequences by the insertion of a cysteine residue to the N-terminus side of position 413 or homologous position unless cysteine is already present at positions 413 or 414 in the natural sequence,

the substitution for the native cysteine of

position 418 or corresponding position of an homologous non-human sequence or any other cysteine of the native target sequence by serine (unless said native cysteines are present at positions 413 or 414 and 435 or 436),

the insertion of cysteine at C-terminus side of position 435 or homologous position unless cysteine is already present at positions 435 or 436 in the natural sequence, and

the formation of a disulfide bond between the retained cysteines so as to produce a cyclic structure.

Said cyclic structures also comprise 1 to 5 additional amino acids taken from either terminus of the 413-435 segment of IgE provided that the single disulfide looped structure is preserved. An optimized target antigen for human IgE of sequence Cys-Gly-Glu-Thr-Tyr-Gln-Ser-Arg-Val-Thr-His-Pro-His-Leu-Pro-Arg-Ala-Leu-Met-Arg-Ser-Thr-Thr-Lys-Cys (SEQ ID NO:5) is provided by the present invention. The human IgE target antigen is cyclized through the unnatural terminal cysteines and the first serine residue substitutes for the cysteine residue of the natural sequence. Antibody that is evoked by peptide immunogens comprising this IgE-CH3 domain antigen is crossreactive with human IgE and inhibits the sensitization of human basophils by human IgE.

Likewise, corresponding IgE-CH3 domain antigen sequences for IgE of other species can be derived from the homologous ε chain segment of the relevant species. For example, such target sequences can be taken from the dog, rat and mouse ε chain sequences shown in Table 1 as SEQ ID NOS:2, 3 and 4, and the equine sequence published by

Navarro *et al.*, and IgE-CH3 domain antigen sequences such as SEQ ID NOS:6, 7, 8 and 84 can be derived.

Crossreactive and immunologically functional analogs of the IgE-CH3 domain antigen peptides (*e.g.*, SEQ ID NOS:5-8 and 84) according to the invention, may further comprise conservative substitutions, additions, deletions, or insertions of from one to about four amino acid residues, provided that the resulting peptide analogs are capable of eliciting immune responses crossreactive with the IgE-CH3 peptides (*e.g.*, SEQ ID NOS:5-8 and 84). The conservative substitutions, additions, and insertions can be accomplished with natural or non-natural amino acids as defined herein.

Peptide compositions which contain mixtures of the subject peptide immunogens with two or more of the Th epitopes may enhance immunoefficacy in a broader population and thus provide an improved immune response to the IgE-CH3 domain antigen (*e.g.*, SEQ ID NOS:5-8 and 84).

The peptide immunogens of this invention can be made by chemical synthesis methods which are well known to the ordinarily skilled artisan. See, for example, Fields *et al.*, Chapter 3 in *Synthetic Peptides: A User's Guide*, ed. Grant, W. H. Freeman & Co., New York, NY, 1992, p. 77. When a peptide immunogen includes a SSAL Th, the coupling of the alternative amino acids at a given variable position is accomplished by providing a mixture of the amino acids specified for that position. Hence, peptides can be synthesized using the automated Merrifield techniques of solid phase synthesis with the α-NH_2 protected by either *t*-Boc or Fmoc chemistry using side

chain protected amino acids on, for example, an Applied Biosystems Peptide Synthesizer Model 430A or 431.

After complete assembly of the desired peptide immunogen, the resin is treated according to standard procedures to cleave the peptide from the resin and deblock the functional groups on the amino acid side chains. The free peptide is purified, for example by HPLC, and characterized biochemically, for example, by amino acid analysis, mass spectrometry, and/or by sequencing. Purification and characterization methods for peptides are well known to those of ordinary skill in the art.

Other chemical means to generate the synthetic peptide constructs of the invention containing IgE and Th sites include the ligation of haloacetylated and cysteinylated peptides through the formation of a "thioether" linkage. For example, a cysteine can be added to the C terminus of a Th-containing peptide and the thiol group of cysteine may be used to form a covalent bond to an electrophilic group such as an N chloroacetyl-modified or a maleimide-derivatized α- or ε-NH_2 group of a lysine residue attached to the N-terminus of an IgE-CH3 peptide (*e.g.*, SEQ ID NO:5) or crossreactive and functional immunological analogs thereof. In this manner, a construct with Th-(IgE-CH3 domain antigen) or its reverse, (IgE-CH3 domain antigen)-Th, may be obtained.

The subject immunogen may also be polymerized. Polymerization can be accomplished for example by reaction of the immunogen with a cross-linking agent, for example by reaction between glutaraldehyde and the -NH_2 groups of

lysine residues, using routine methodology. By another method, a synthetic immunogen, such as for example "A-Th_m-spacer-(IgE-CH3 domain antigen)", can be polymerized or co-polymerized with another immunogen by utilization of an additional cysteine added to the N-terminus of the synthetic immunogen. The thiol group of the N-terminal cysteine can be used for the formation of a "thioether" bond with haloacetyl-modified amino acid or a maleimide-derivatized α-NH_2 or ε-NH_2 group of a lysine residue that is attached to the N-terminus of a branched poly-lysyl core molecule (*e.g.*, K_2K, K_4K_2K or $K_8K_4K_2K$). The subject immunogen may also be prepared as a branched polymer through synthesis of the desired peptide construct directly onto a branched poly-lysyl core resin (Wang *et al.*, *Science*, 1991; **254**: 285-288).

Alternatively, the longer synthetic peptide immunogens can be synthesized by well-known recombinant DNA techniques. Many standard manuals on molecular cloning technology provide detailed protocols to produce the peptides of the invention by expression of recombinant DNA and RNA. To construct a gene encoding a peptide of this invention (*e.g.*, immunogenic peptides comprising SEQ ID NOS:5-8 and 84, and other species-specific homologs), the amino acid sequence is reverse translated into a nucleic acid sequence, preferably using optimized codon usage for the organism in which the gene will be expressed. Next, a gene encoding the peptide is made, typically by synthesizing overlapping oligonucleotides which encode the peptide and necessary regulatory elements. The synthetic gene is assembled and inserted into the desired expression vector. The synthetic nucleic

acid sequences encompassed by this invention include those which encode the peptides of the invention, immunologicaly functional homologs, and nucleic acid constructs characterized by changes in the non-coding sequences that do not alter the immunogenic properties of the peptide encoded thereby. Nucleic acids which comprise sequences that encode the peptides of this invention are also provided. The synthetic gene is inserted into a suitable cloning vecor and recombinants are obtained and characterized. The peptide is then expressed under conditions appropriate for the selected expression system and host. The peptide is purified and characterized by standard methods.

The nucleic acids of this invention may themselves be useful as components of so-called "DNA vaccines". In this embodiment of the invention, expression of the immunogenic peptides of the invention is induced in the patient's own cells, by introduction into those cells of nucleic acids which encode the peptides. Methods of making and using DNA vaccines are disclosed in US Patents 5,580,859, 5,589,466, and 5,703,055; see also WO 97/02840 and W. McDonnell and F. Askari, *New Engl. J. Med.*, 1996, **334**:2-45, all of which are incorporated herein by reference. Such methods of making and using the peptides and peptide conjugates of this invention are contemplated to be within the scope of this invention.

The efficacy of any peptide composition of the present invention can be established by *in vitro* assay in which a host animal is immunized with a peptide composition of the invention and the resulting antibodies are shown to inhibit the sensitization of basophils and

mastcells by IgE, as shown in Examples 2 and 6. Efficacy can be established *in vivo* by injecting a host with a species-appropriate peptide composition (for example, immunizing mice with a formulation of immunogens comprising SEQ ID NOS:24 and/or 25) followed by monitoring the humoral immune response to the IgE-CH3 peptide and crossreactive and functional immunological homologues thereof, as detailed in Example 5.

Another aspect of this invention provides a peptide composition comprising an immunologically effective amount of one or more of the peptide immunogens of this invention in a pharmaceutically acceptable delivery system. Accordingly, the subject peptides can be formulated as a pharmaceutical composition using adjuvants, pharmaceutically acceptable carriers, or other ingredients routinely provided in vaccine compositions. Among the ingredients that can be used in this invention are adjuvants or emulsifiers including alum, incomplete Freund's adjuvant, liposyn, saponin, squalene, L121, emulsigen, monophosphoryl lipid A (MPL), QS21, ISA51, ISA35, ISA 206, and ISA 720, as well as other known efficacious adjuvants and emulsifiers. The formulations include formulations for immediate release and/or for sustained release, and for induction of systemic immunity and/or induction of localized mucosal immunity, which may be accomplished by, for example, immunogen entrapment by or coadministration with microparticles. Such formulations are readily determined by one of ordinary skill in the art, and methods for the preparation, preservation, and sterilization of such formulations are known to those skilled in the art.

The present pharmaceuticals can be administered by any convenient route including subcutaneous, oral, intramuscular, or other parenteral or enteral route. Similarly the pharmaceuticals can be administered as a single dose or multiple doses. Immunization schedules are readily determined by the ordinarily skilled artisan.

The pharmaceutical composition of the instant invention contain an effective amount of one or more of the peptide immunogens of the present invention and a pharmaceutically acceptable carrier. Such a composition in a suitable dosage unit form generally contains about 0.5 μg to about 1 mg of the immunogen per kg body weight. When delivered in multiple doses, it may be conveniently divided into an appropriate amount per dosage unit form. For example, an initial dose, *e.g.* 0.2-2.5 mg; preferably 1 mg, of immunogen represented as a peptide composition of the present invention, may be administered by injection, preferably intramuscularly, followed by repeat (booster) doses. Dosage will depend on the age, weight and general health of the patient as is well known in the vaccine and therapeutic arts.

The immune response to synthetic IgE-CH3 peptide immunogens may be improved by delivery through entrapment in or on biodegradable microparticles of the type described by O'Hagan *et al.* (*Vaccine*, 1991; **9**:768-771). The immunogens can be encapsulated with or without an adjuvant in biodegradable microparticles, to potentiate immune responses, including localized mucosal immunity which may be especially applicable to mucosally localized allergic reactions, and to provide time-controlled release for sustained or periodic responses, for oral

administration, and for topical administration (O'Hagan *et al.*, 1991; Eldridge *et al.*, *Molec. Immunol.*, 1991; **28**: 287-294).

The pharmaceutical compositions of this invention are used in a manner similar to that of vaccines, for the prevention of atopic allergic reactions including allergic rhinitis, those of food allergies, asthma, anaphylaxis, flea allergy dermatitis, and other IgE-mediated hypersensitivities.

All patents and literature references referenced hereinabove are incorporated herein by reference.

Specific peptide and peptide conjugate immunogens are provided in the following examples to illustrate the invention. These examples are for purpose of illustration only, and are not to be construed as limiting the scope of the invention in any manner.

EXAMPLE 1

IDENTIFICATION OF POTENTIAL EFFECTOR SITES ON THE HUMAN IgE MOLECULE

Peptide Design

Sites within the CH2 and CH3 domains of ε heavy chain of human IgE were selected for mimicry by peptides, in accordance with the disclosures of Helm *et al.* (1988) and Presta *et al.* (1994) that a long segment of the ε chain which overlaps both these domains participates in binding IgE to the FcεR1 receptor. The sequences of such sites were synthesized as target site peptides and rendered into antigens by (1) attaching them through

chemical coupling to large carrier proteins such as KLH or (2) constructing peptides where promiscuous Th and Inv (SEQ ID NO:13) were linked to the amino terminal of the target sites. Specific sites within these domains were selected as peptides for cyclization based on predictions by the Brookhaven 3-dimensional model for human IgE (http:www.pdb.bnl.gov/pdb.bin/pdbids) of surface-exposed loops. Specified cyclic constraints were installed into the design of those peptides so as to maximize the crossreactions between the antigens and the native IgE molecule. Accordingly, several of the synthetic constructs were synthesized with introduced cysteines not found in the native sequence to produce disulfide bond loops of specified position, in mimicry of loop structures predicted by the Brookhaven model. In some cases naturally occurring cysteines were substituted with serines so as to prevent the formation of conformations not favored by the model.

The constructs are listed in Table 2. Peptides marked by * in the description column of Table 2 are cyclized by cysteine disulfide bonds. Cysteine residues that have been inserted into the native sequence for cyclization are denoted in the amino acid sequences of Table 2 by parentheses, other residues that have been inserted, substituted for a native residue, or are natural cysteines that participate in disulfide bonds are indicated in the amino acid sequences of Table 2 by underlining. Other peptides are linear. Peptides labeled by "a" in the third column represent the IgE-CH2/3 or -CH3 antigen peptide, chemically linked to KLH carrier protein by conventional glutaraldehyde or MBS (m-Maleimidobenzoyl-

N-hydroxysuccinimide ester, Pierce Chemical Co., catalogue No. 22510) coupling reactions. Peptides marked by "b" in the third column were synthesized as IgE antigen peptides in tandem with the Th sites shown. Th sites used include the HBs_{19-32} Th taken from hepatitis B virus, the MVf Th taken from measles virus, and $PT_{149-146}$ Th taken from pertussis toxin as referenced in US 5,759,551, the CT Th termed P11 (Stagg *et al.*, 1993) and novel artificial Th sites termed "1,4,9 PALINDROMIC Th" (SEQ ID NO:10), "IS(1,4,9 PALINDROMIC)LF Th" (SEQ ID NO:11), "IS(1,4,9 PALINDROMIC)LF simplified Th" (SEQ ID NO:60), and "Syn Th (1,2,4)" (SEQ ID NO:9). Peptides marked by "c" are variants of the "b" constructs synthesized in tandem with the Inv domain immunostimulatory peptide (SEQ ID NO:13).

The "b" and "c" constructs were also synthesized with Gly-Gly spacers for separation of the IgE-CH2/3 or -CH3 target antigen site from the Th site, and separation of the Th from the Inv immunostimulatory site. The "b" and "c" constructs in Table 2 had the Th and/or Inv domains attached to the amino terminal of the IgE target site. The peptide immunogens of Table 2 were screened as candidate target antigenic peptides for the treatment of allergy, by the hyperimmunization of animals followed by testing of the hyperimmune sera for crossreactivity to human IgE.

Specific Procedures for the Screening of Candidate Target Antigenic Peptides:

1. Synthesis of IgE-CH3 domain antigen Peptides and Conjugates.

Peptides listed in Table 2 were synthesized by the

Merrifield solid-phase synthesis technique on Applied Biosystems automated peptide synthesizers using Fmoc chemistry. When a peptide immunogen included a SSAL Th, the coupling of one of the alternate amino acids at a given variable position was accomplished by providing a mixture of amino acids at equivalent molar ratios. After complete assembly of the desired peptide, the resin was treated according to standard procedure using trifluoroacetic acid to cleave the peptide from the resin and deblock the protecting groups on the amino acid side chains. For cyclic peptides, the cleaved peptides were dissolved in 15% DMSO in water for 48 hours to facilitate intradisulfide bond formation between cysteines.

2. Experimental Immunizations.

Rats or guinea pigs were immunized intramuscularly with experimental peptide immunogens. The dose was 100 µg of peptide suspended in a volume of 0.5 ml. The first dose was administered with Complete Freunds Adjuvant. Subsequent doses were administered in Incomplete Freunds Adjuvant. Animals received injections on weeks 0, 3, 6, and 10 or 0, 2, 4, and 8. Test bleeds were taken at biweekly intervals and reactivities were determined by IgE peptide ELISA and crossreactivities by human IgE ELISA.

3. ELISA Assays.

Peptide ELISAs for determination of anti-IgE peptide reactivity were conducted in peptide-coated 96-well microtiter plates coated by 1 hr incubation at 37°C with an appropriate "a" target antigen site peptide without carrier at 0.5 µg/mL using 100 µL per well in 10 mM $NaHCO_3$ buffer, pH 9.5. For determination of anti-human

IgE crossreactivity, human IgE ELISAs were conducted in human IgE-coated 96-well microtiter plates coated in a likewise fashion with a human IgE myeloma protein (American Biosystems, Inc. cat. no. A113) at 5 μg/mL. The peptide or human IgE-coated wells were incubated with 250 μL of 3% by weight of gelatin in PBS, at 37°C for 1 hr to block non-specific protein binding sites, washed three times with PBS containing 0.05% by volume TWEEN 20 and then dried. Test samples were serially diluted with PBS containing 20% by volume normal goat serum, 1% by weight gelatin and 0.05% by volume TWEEN 20. 100 μL of the diluted sample was added to each of the wells and allowed to react for 1 hr at 37°C. The wells were then washed six times with 0.05% by volume TWEEN 20 in PBS to remove unbound labeled antibodies. 100 μL of horseradish peroxidase labeled anti-rat IgG goat antibody or anti-guinea pig IgG goat antibody at predetermined optimal dilution in 1% by volume normal goat serum, 0.05% by volume TWEEN 20 in PBS were added to each well and incubated at 37°C for 30 minutes. The wells were washed six times with 0.05% by volume TWEEN 20 in PBS to remove unbound labeled antibody conjugate and reacted with 100 μL of the substrate mixture containing 0.04% by weight orthophenylenediamine (OPD) and 0.12% by volume hydrogen peroxide in sodium citrate buffer pH 5.0, for 15 minutes. Reactions were stopped by the addition of 100 μL of 1.0 M H_2SO_4 and the absorbance at A_{492} was measured. ELISA titers, expressed as $\log_{10}$ of reciprocal dilution, were calculated based on linear regression analysis of the absorbances, with cutoff A_{492} set at 0.5. This cutoff

value was rigorous as the values for diluted normal guinea pig control samples run with each assay were less than 0.15.

Results.

Candidate target antigen sites are described in Table 2. They are shown either as "a" peptides attached to KLH carrier or as "b" peptides attached to synthetic Th sites or as "c" peptides attached to synthetic Th and Inv. Either rats or guinea pigs were immunized as described in Specific Procedures above and hyperimmune antisera collected at week 8 were analyzed by anti-peptide ELISA and anti-human IgE ELISA as described in Specific Procedures.

Many of the CH2/3 and CH3 peptide immunogens were immunogenic, as they evoked anti-peptide antibodies with titers in the range of $\log_{10}$ 2-5. The CH2/3 antigenic target sites comprising long segments of the human ε chain from 301-376 (numbering scheme of Table 1) were all strongly crossreactive with human IgE, as shown by $\log_{10}$ titers on the anti-human IgE ELISA of greater than 3. Crossreactivity was lost for some CH3 peptides which initiated at position 342 and beyond (*e.g.*, entries 21 and 22). However, for CH3 peptides which included a relatively short region comprising 354-372, crossreactivity was largely restored (e.g, entries 27, 28, and 29) with the exception of entry 31 (354-368). Another short region of crossreactivity is seen in entry 20 (cyclic peptide spanning positions 374-385).

As evidenced by the lack of crossreactivity of

entries 14, 17, 23, 24, 25, and 26, a stretch of sequence that extends from 365 to 413 is devoid of crossreactivity, despite overlap with the 354-372 region of crossreactivity and a crossreactive region represented by entry 20 (374-385). Interestingly, the short crossreactivities exemplified by entries 27, 28, 29 (354-372) and 20 (374-385) are lost in the conformation of the long cyclized peptide entry 17 (365-396), despite their overlap in those crossreactive regions. Crossreactive sites which overlap non-crossreactive sites are again to be found beyond a region that starts around position 399 and extends to position 445, as shown by the crossreactivities of entries 15 and 30, and the weak crossreactivities of entries 19 (432-445) and 23 (404-413). It is significant that of two similarly cyclized peptides which include position 418, 15 (413-435) and 18 (404-434), only entry 15 (SEQ ID NO:5), in which the cysteine at position 418 has been substituted by serine, is crossreactive with human IgE. A CH4 site that corresponds to an IgE effector site described by Stanworth (Stanworth *et al.*, *Lancet*, 1990; **336**:1279-1281) failed to show crossreactivity (entry 34).

These results demonstrate that crossreactivity for IgE peptides is a complex phenomenon influenced by conformational features, and cannot be predicted from a straightforward analysis of overlapping linear peptides. Candidate IgE-CH3 domain antigens were selected from among the conjugates shown to be crossreactive with human IgE in Table 2 and used for further analyses.

EXAMPLE 2

IDENTIFICATION OF EFFECTOR SITE ON THE HUMAN IgE MOLECULE

IgE-CH3 domain antigen peptides were selected for further analysis from among those peptide conjugates of Table 2 that exhibited high affinity crossreactivities to human IgE, as evidenced by anti-IgE titers for their respective antisera of greater than $\log_{10}=3$. Guinea pig hyperimmune sera were produced as described above. Guinea pig IgG antibodies were purified from the hyperimmune sera by protein A affinity chromatography and analyzed by a functional assay for determination of ability of anti-IgE to inhibit the sensitization of human basophils by allergen-specific IgE. The endpoint of the assay is expressed as per cent inhibition of IgE-mediated histamine release.

Guinea pig IgG antibodies were purified from serum by Protein A affinity chromatography (ImmunoPure® Immobilized Recomb® Protein A, Pierce) and the eluted antibodies were prepared at a standard concentration of 8 mg/ml in 25 mM PIPES buffer, 0.15 M NaCl, pH 7.2. A control antibody preparation was prepared from the pooled serum of guinea pigs immunized with an irrelevant peptide immunogen. These antibodies were used in assays that measure the reduction in IgE-mediated sensitization of human basophils. Human basophils were prepared from the venous blood of volunteers using centrifugation through Percoll density gradients (MacGlashan. *J Allergy Clin Immunol, 1993; **91**:605-615*). The banded leukocytes were collected, washed, and resuspended in 0.1 ml of PAGCM buffer as described (MacGlashan, 1993) except that the PAGCM buffer used to suspend the cells was made up with

water containing 44% D_2O. The IgE used for the assay was allergen-specific, either human BPO-specific IgE or chimeric human IgE specific for HIV glycoprotein gp120. The allergen-specific IgE used for sensitization at 0.25 µg/ml was preincubated with an equal volume of purified guinea pig antibody at 8 mg/ml, total volume 0.1 ml, for 15 minutes at 37°C, prior to being added to the basophils. The antibody mixture was added to the cells and incubated for 20 minutes to allow for sensitization of the cells by uncomplexed IgE. The sensitized cells were then stimulated by addition of the allergen, either BPO_{21}-HSA or a gp120 polypeptide as described (MacGlashan, 1993).

After an appropriate incubation period (usually 45 minutes), the cells were separated from the supernatant and the supernatant assayed for histamine content by an automated fluorimetric technique (Siraganian, *Anal Biochem*, 1974; **57**: 383-394). All reactions were performed in duplicate. The percentage of histamine release was calculated from the ratio of sample to total histamine after spontaneous release was subtracted from both. Results are expressed as per cent inhibition of histamine release, as determined from the ratio of histamine release by experimental antibody to histamine release by the control antibody of irrelevant specificity. Histamine release assays on human basophils were kindly performed under coded conditions by Dr. Donald W. MacGlashan, The Johns Hopkins University School of Medicine, Johns Hopkins Asthma and Allergy Center, Baltimore.

Results

The results for inhibition of histamine release

assays are shown in Table 3 for guinea pig anti-peptide antibodies that displayed crossreactivities for human IgE of $\log_{10}$ >3. Determinations were made from antibodies purified from 8 week bleeds, except for antibodies against peptide entries 15b and 15c which were also characterized from serum collected on week 12. The inhibition results shown for anti-15b and anti-15c antibodies, of 61% and 71%, were made on the antibodies purified from bleeds taken on weeks 8 and 12, respectively. Separate animals had been immunized with 15b and 15c, but antibodies from both sets of animals had been pooled for the 8 and 12 week results shown in Table 3. (The guinea pigs of these groups had received an additional dose of peptide conjugate on week 10 and so had retained high antibody levels for the 12 week bleed). The significant inhibitory reactivity of the anti-15 antibodies was unexpected in comparison to the reactivities of the IgE crossreactive antibodies evoked by the remainder of the peptides shown in Table 3. These other IgE-CH3 domain antigenic peptides failed to provide inhibition, or presented levels of inhibition for histamine release that were negligible and non-reproducible.

Histamine release inhibition results and IgE crossreactivities for antibodies elicited by IgE-CH3 domain antigen peptides that overlap with the antigenic site (SEQ ID NO:5) of peptide entries 15b (SEQ ID NO:14) and 15c (SEQ ID NO:15) may be compared. The IgE antigens represented by peptide entries 19, 23, 24, and 33 comprise short overlaps with the entry 15 antigen sequence (SEQ ID NO:5). They compare unfavorably to entry 15 for crossreactivity to IgE, and are devoid of inhibitory

activity. The IgE antigen sequence (SEQ ID NO:44) of entry 18 comprises the entire antigen sequence of entry 15, except that (1) the carboxyl terminal lysine is deleted, (2) the naturally occurring cysteine at position 418 is retained, and (3) there are nine additional N-terminal amino acids. It is non-crossreactive with IgE and fails to inhibit histamine release. In contrast, the immunogens of entry 15, having antigen SEQ ID NO:5, provide unexpected reactivities. The IgE-CH3 domain antigen sequence of entry 15, with a cyclic structure specified by introduced terminal cysteines, and with no contribution from the cysteine at position 418 (which has been replaced), provides an antigen that is crossreactive with IgE and elicits antibodies which inhibit IgE sensitization.

Antibodies elicited by entry 15b (SEQ ID NO:14) and 15c (SEQ ID NO:15) were prepared from 13 week bleeds and tested individually. By week 13, both crossreactivity for IgE, as determined by IgE ELISA, and per cent inhibition of histamine release had diminished from the values of week 12. Nevertheless, antibodies from both preparations were found to be individually effective in reducing histamine release: anti-15b inhibited 28% and anti-15c inhibited 20%.

The extent by which histamine release was inhibited by either of these antibodies was dose dependent, as evidenced by the effect of dilution on the antibodies. When a preparation of anti-15b from week 13 was assayed at full concentration (8 mg/ml), then at 1:3 and 1:9 dilutions, per cent inhibition of histamine release was 28%, 21%, and 14% respectively.

A preparation of guinea pig anti-15b was tested by direct challenge of IgE-sensitized basophils, in the absence of allergen, as an evaluation of its ability to crosslink receptor-bound IgE and induce degranulation. Histamine release by anti-15b was equivalent to the level of spontaneous histamine release by the donor cells. This indicates that antibody of specificity for the SEQ ID NO:5 IgE antigen is non-anaphylactogenic. Thus, active immunization with peptide conjugate immunogens comprising the IgE-CH3 domain antigen SEQ ID NO:5 (SEQ ID NOS:14 and 15) elicits non-anaphylactogenic anti-IgE antibodies that inhibit IgE-mediated sensitization without themselves causing histamine release. These actively evoked polyclonal antibodies display specificity for an IgE effector site that has not been described by previous studies, including prior studies of therapeutic and non-anaphylactogenic anti-IgE monoclonal antibodies intended for treatment of allergy by passive immunization (U.S. 4,940,782, U.S. 5,420,251, and Presta *et al.*, 1993).

EXAMPLE 3

ISOTYPE SPECIFICITY AND POTENTIAL FOR IMMUNOSUPPRESSION

The polyclonal antibodies elicited by active immune response to SEQ ID NOS:14 and 15 were examined for specificity to IgE in comparison to IgG. Anti-15b guinea pig antibodies described in Example 2 that were prepared from the 12 week bleed were subjected to a parallel comparison of crossreactivities to IgE and IgG, by the IgE ELISA described in Example 1 and by a similar IgG ELISA.

For the IgE ELISA, plates were coated with the human IgE myeloma at 5 μg/ml. For the IgG ELISA, the plates were coated with human purified IgG (Sigma reagent grade human IgG), also at 5 μg/ml. The purified guinea pig anti-15b was tested for reactivities in both ELISAs at concentrations of 0.5 and 0.1 μg/ml. Results were compared to antibodies purified from control guinea pig serum and to a "no antibody" control. The A_{490} values for anti-15b antibody on IgE were 1.126 at 0.5 μg/ml and 0.344 at 0.1 μg/ml. The A_{490} values for anti-15b antibody on IgG were equal to control antibody and background values. There was no crossreactivity of the guinea pig anti-15b to human IgG. The peptide composition of the invention did not evoke antibodies that recognize IgG antibodies, and therefore are isotype specific for IgE. They will suppress IgE-mediated allergic reactions and not result in undesirable immunosuppression of IgG protective antibody responses.

EXAMPLE 4

REPRESENTATIVE PEPTIDE CONJUGATES OF THE INVENTION

The immunogenic peptide conjugates of the invention shown in Table 4A, which are wholly synthetic peptides, were synthesized by the solid-phase method outlined in Example 1. Each peptide in the Table can be represented by the formula $(A)_n$-$(Th)_m$-$(B)_o$-(IgE-CH3 domain antigen)-X, but peptides of the other formulas disclosed above are understood to be encompassed within the peptides of this invention. The IgE-CH3 domain antigen sequence is SEQ ID NO:5, 6, or 8 in the peptides of Table 4A, but it

is understood that homologous IgE-CH3 domain antigen sequences from other mammalian species are encompassed within the peptides of this invention. The immunogenic peptides comprise Th sites derived from foreign pathogens (*e.g.*, SEQ ID NO:20, 87), and also artificial Th (*e.g.*, SEQ ID NOS:14, 18, 21 and 90). In addition to the examples shown in Table 4A, other pathogen-related Th may be selected from among the promiscuous Th sites exemplified in Table 5, and artificial Th may be selected from among the Th sites exemplified in Table 6. Each peptide of this example has Gly-Gly or (□-N)Lys spacers between immunogenic elements, but peptides of the invention may have other spacers (*e.g.*, SEQ ID NO:16) or no spacers.

Peptides of these examples also comprise an optional Inv immunostimulatory site (*e.g.*, SEQ ID NOS:15-19 and 22). It is understood however that the invention is not limited to Inv as an additional immunostimulatory element. As shown by the KLH conjugate, peptide conjugates of the invention also include an IgE-CH3 domain antigen coupled to a carrier protein.

Materials and methods

Representative peptide constructs of the invention as listed in Table 4A (SEQ ID NOS: 18, 85, 87, 88, 90 and 91) were synthesized, cleaved, cyclized and purified as described in Example 1. The peptide constructs were formulated for immunization into small animals such as guinea pigs, or into larger animals such as pigs or baboons for evaluation of their immunogenicities. Peptides were suspended in a volume of 0.5 mL containing

representative emulsifiers or adjuvants such as ISA51, ISA720, DDA or monophosphoryl lipid A (MPL). The dose was 100 µg of peptide for guinea pigs or 300 µg of peptide for swine or baboons and the animals were immunized intramuscularly.

Animals received injection on weeks 0, 3 and 6 or 0, 2 and 4 weeks as specified in Table 4B. Test bleeds from 8 weeks post initial immunization were evaluated for crossreactivities to IgE by human IgE or dog IgE ELISA as described in Example 1, except that for the dog IgE ELISA a dog IgE myeloma protein (Bethyl Laboratories Inc., Montgomery TX) was used for plate coating at 1 µg/mL, and horseradish peroxidase labeled protein A/G reagent (Pierce Chemical Co., Rockford IL) at a predetermined optimal dilution was used as the tracer for detection of dog IgE. The peptide-induced crossreactivities were also evaluated for capacity to inhibit IgE-mediated histamine release. Guinea pig, pig, or baboon IgG were purified from representative immune sera by protein A affinity chromatography and analyzed by functional assay for determination of ability to inhibit the sensitization of human basophils by allergen-specific IgE, as described in details in Example 2. The endpoint of the assay is expressed as per cent inhibition of IgE-mediated histamine release in comparison to control antibody of the same species that was raised with specificity for an irrelevant antigen, as shown in Table 4B.

Results

The representative peptide constructs were of relevant immunogenicity, as all peptides tested elicited

strong site-directed cross reactivities to the corresponding human IgE or dog IgE, as shown by Log_{10} titers on the anti-human IgE or anti-dog IgE ELISAs of greater than 3 (Table 4B). Inhibition of IgE-mediated sensitization was observed for guinea pig, pig, and baboon antibodies as evaluated by the ability of the anti-IgE peptide antibodies to inhibit histamine release by basophils. This functional crossreactivity by the baboon antibodies is noteworthy insomuch as the neutralization of human IgE by the baboon IgG is nearly a human system. Thus, the efficacy of a peptide construct of the invention, as an agent for the immunotherapy of allergy by active immunization, is indicated in a model that is nearly homologous for species of peptide and target species.

EXAMPLE 5

IMMUNIZATION OF MICE AND EVALUATION OF IN VIVO EFFICACY

Efficacy of peptides of SEQ ID NOS:24 and 25 (37b and 38b) is evaluated with five groups of 16 mice by the immunization and sensitization protocol outlined below.

Groups of 16 mice (Balb/c), female, 8-10 weeks old, are immunized subcutaneously with the indicated peptide composition of the invention. The mice are given 20 µg/0.2ml doses on weeks 0, 3, 6, and 11. The first dose is prepared with Complete Freunds Adjuvant, subsequent doses with Incomplete Freunds Adjuvant. The mice are sensitized to a hapten conjugate, diphenylated KLH (DNP-KLH), on weeks 7 and 10. Sensitization is

accomplished by intraperitoneal administration of DNP-KLH in 0.4% Alum, 5 μg/0.2ml/dose. Mock immunizations and sensitizations are accomplished in control groups by administration of adjuvant with phosphate-buffered-saline. The groups are as follows:

1: Immunize/mock sensitize, with peptide 37b and 0.4% Alum

2: Immunize/sensitize, with peptide 37b and DNP-KLH

3: Mock immunize/sensitize, with Freunds and DNP-KLH

4: Immunize/mock sensitize, with peptide 38b and 0.4% Alum

5: Immunize/sensitize, with peptide 38b and DNP-KLH

Serum is collected on weeks 0, 5, 7, 9, 10, 11, 13, 16, and 20. Splenocytes are prepared from pairs of mice from each group on weeks 10 and 11.

IgG response to the peptide antigens and to DNP is monitored by conventional ELISA assays, using an anti-mouse IgG horseradish peroxidase conjugate, and microtiter plates whose wells are coated with unconjugated peptide 37 (mouse IgE-CH3 domain antigen peptide, SEQ ID NO:8) for peptide ELISA, and plates coated with DNP-BSA conjugate for DNP ELISA. Cross-reactivity of anti-37b antibodies with mouse IgE are monitored by a conventional IgG ELISA on plates coated with mouse monoclonal IgE SPE 7 (Sigma). IgG response to peptide immunogens is compared to mouse IgE crossreactivity among the groups throughout the 20 week course, to determine 1) primary and secondary responses, 2) the presence of undesirable immunosuppression of IgG responsiveness, and, 3) the occurrence of a desirable reduction in anti-IgE reactivity

during weeks 10-20 as evidence of reversibility and safety of the antibody response to the peptide composition of the invention.

On weeks 7, 9, 10, 11, 13, and 16, IgE response is monitored by whole IgE ELISA and by DNP-specific ELISA. On weeks 10 and 11 splenocyte B cells that secrete IgE with specificity for DNP are enumerated by DNP-specific ELISPOT assay. Also, because serum IgE levels may not be completely predictive of anaphylaxis, *i.e.*, IgE determinations may miss significant effects on *in vivo* sensitivity, sensitization of the mice is measured by Passive Percutaneous Anaphylaxis assay of mouse serum in rats (heterologous PCA). Heterologous PCA is preferred to autologous PCA assay in mice because rat skin mast cells are selectively cross-sensitized by mouse IgE as opposed to mouse IgG. Therefore, the heterologous mouse/rat PCA reaction is IgE-specific and is not confounded by IgG-mediated anaphylaxis which may occur in autologous mouse PCA assay (Maekawa and Ovary, *J Immunol Methods*, 1984; **71**:229-239).

ELISA, ELISPOT, and PCA results are compared between groups for immunosuppression of IgE responsiveness and for isotypic specificity of the immunosuppression. Experimental methods are described below.

Whole IgE ELISA

For an ELISA to measure total mouse IgE in serum, microtiter plates are coated with monoclonal rat anti-mouse IgE, R35-72 (Pharmingen), at 1 μg/ml. The plates are coated, washed and blocked as described. Serially diluted mouse sera are added to the plates and incubated.

Captured IgE is detected by reaction with biotinylated monoclonal rat anti-mouse IgE, R35-118 (Pharmingen), followed by sequential additions of streptavidin-horseradish peroxidase (Pierce) and OPD. A_{492} values are determined.

DNP-specific IgE ELISA

For an ELISA to determine DNP hapten-specific mouse IgE in serum from mice that have been sensitized with DNP-KLH, microtiter wells are coated with DNP-BSA conjugate (Molecular Probes, Inc.) at 5 μg/ml. Captured IgE with specificity for DNP hapten is detected as described above.

DNP-specific ELISPOT

For an ELISPOT assay to determine B cells that secrete DNP hapten-specific mouse IgE, DNP-BSA conjugate at 5 μg/ml is used to coat the wells of sterile microtiter plates whose wells are lined with 0.45 μm nitrocellulose filters, for example a MULTISCREEN HA Plate (Millipore Inc., cat. no. MAHAS4510). Serially diluted splenocytes, prepared from sensitized and control mice, are added to the wells and incubated overnight at 37° C under 5% CO_2. The cells are washed from the plates and IgE-secreting cells with specificity for DNP hapten are counted as localized spots on the filters following staining by alkaline phosphatase conjugated-rat monoclonal antibody R35-118 with 5-bromo-4-chloro-3-indoyl phosphate (Sigma) as colored substrate.

Heterologous PCA

Serial dilutions of sera from immunized/ sensitized and control mice are injected intradermally

into the shaved backs of adult male Sprague-Dawley rats. Anesthetized animals receive 10-12 injections of diluted serum into each of three parallel rows on the dorsal skin (50 µl/site). Each pattern of injections is replicated in duplicate animals. After a 24 hour latent period, for effective sensitization of skin mast cells, rats are challenged by intravenous injection of 1 mg of DNP-BSA in 1% Evans blue dye in PBS. In 30 minutes to 1 hour, rats are asphyxiated and skinned so that blueing reactions can be observed on the inside of the dorsal skin. A PCA titer is determined from the highest serum dilution which results in a readily definable spot.

EXAMPLE 6

IMMUNIZATION OF MICE AND INHIBITION OF PASSIVE CUTANEOUS ANAPHYLAXIS

To study the effect of immunization by an immunogenic peptide of the invention on an IgE-mediated inflammatory reaction, an antibody response was elicited to the mouse IgE-CH3 target antigenic site, SEQ ID NO:8, by immunizing mice with a peptide of the invention. The resulting mouse antiserum was then used to suppress the passive cutaneous anaphylaxis (PCA) triggered by the crosslinking of mouse IgE bound to rat mast cells.

Materials and methods

Balb/c mice were immunized with a peptide composition of the invention, SEQ ID NO:25, as described in Example 5, except that the subcutaneous injections were given on weeks 0, 3, and 6 only and the mice were not

sensitized. On week 8, mouse sera were collected and evaluated for crossreactivity to IgE by mouse IgE ELISA. The mouse IgE ELISA was as described for the human IgE ELISA in Example 1 except that microtiter wells were coated with 1 μg/ml of mouse anti-DNP IgE monoclonal antibody SPE7 (Sigma Chemical Co., St. Louis MO), and horseradish peroxidase(HRP)-labeled goat anti-mouse IgG (Kirkegaard and Perry Laboratories, Gaithersburg MD) was used for detection of captured mouse IgG. Thirteen out of 20 immunized mice had crossreactive antibodies for mouse IgE. Sera was pooled from seven mice showing ELISA titers against mouse IgE of $\geq \log_{10}$ 2.3 for use as the site-specific anti-IgE.

Another group of 10 balb/c mice was used to produce murine IgE. This group was sensitized by a single intraperitoneal administration of ovalbumin (Oa) on 0.4% Alum, 1.0 μg/0.2 ml. IgE content of the mouse sera was measured at day 20 by the whole IgE ELISA described in Example 5, except that captured IgE was detected by HRP-labeled sheep anti-mouse IgE supplied by The Binding Site Inc. (San Diego, CA). Out of the 10 mice, 7 had appreciable IgE responses of titer $\geq \log_{10}$ 1.6. These sera were pooled for use as the anti-Oa IgE working stock.

The IgE serum pool was serially diluted 1:62, 1:124 and 1:248 into PBS and then further diluted with an equal volume of the site-specific anti-IgE serum. Thus, final dilutions for mouse IgE were 1:124, 1:248, and 1:496 while mouse anti-IgE was diluted 1:2. Control dilutions of IgE were prepared having only PBS as diluent.

The IgE dilutions, with and without anti-IgE

serum, were incubated for 1 hour at 37° and 50 µl of each was taken for evaluation by heterologous PCA reaction.

Results

The 50 µl samples of diluted mouse IgE were injected intradermally into the shaved back of rats in a pattern that was a set of two rows of four injections. The rows were a row of three controls of IgE diluted 1:124, 1:248, and 1:496 in PBS only, in parallel with a row of the serially diluted IgE incubated with the site-specific anti-IgE. The fourth injection of each row was PBS only, as a control for the tissue trauma. The pattern was duplicated on two rats.

After 24 hours, PCA reactions were induced by intravenous injection of 1 mg of DNP-Oa conjugate in 1% Evans blue dye. One hour later, the rats were euthanized and skinned. The DNP-Oa allergen had crosslinked receptor-bound mouse anti-Oa IgE on the rat mast cells. The crosslinking triggered degranulation, increased permeability of the Evans blue dye, and the appearance of blue zones on the underside of the rat skins proportional to the extent of degranulation. However, wherever free IgE had been depleted by the site-specific murine anti-IgE, less was available to sensitize the rat mast cells and PCA reactions were suppressed. PCA reactions were evaluated by measuring the diameters of the blue zones on the undersides of the rat skins in two directions at right angles and taking the average. Results are shown in Table 7 for the duplicate inhibition of PCA determinations on two rats.

The rats differed by their inherent sensitivities to the mouse IgE so that control and anti-IgE inhibited PCA reactions should be compared only on the same rat. Mouse IgE-mediated PCA reactions were inhibited in both rats by the murine antiserum with specificity for the target antigenic site on mouse IgE. Thus, the antibody response that results from immunization by a peptide composition specific for the target antigenic site of a non-human IgE resulted in suppression of the inflammatory response mediated by the selfsame non-human IgE.

Table 1

Sequence	224 230 240 250 253b 260
Human ε (Seq ID No:1)	V C S R D F T P P T V K I L Q S S - C D G G G H F - P P T I Q L L C L V S G Y T P G T I N I
Dog ε (Seq ID No:2)	A C A L N F I P P T V K L F H S S - C N - P V G D T H T T I Q L L C L I S G Y V P G D M E V
Rat ε (Seq ID No:3)	A R P V N I T K P T V D L L H S S - C D - P N A F - H S T I Q L Y C F V Y G H I Q N D V S I
Mouse ε (Seq ID No:4)	V R P V T H S L S P P W S Y S I H R C D - P N A F - H S T I Q L Y C F I Y G H I L N D V S V
	270 280 290 300 310
Human ε (Seq ID No:1)	T W L E D G Q - V M D V D L S T A - S T T Q E G E L A S T Q S E L T L S Q K H W L S D R T Y
Dog ε (Seq ID No:2)	I W L V D G Q K A T N I F P Y T A P G T K - E G N V T S T H S E L N I T Q G E W V S Q K T Y
Rat ε (Seq ID No:3)	H W L M D D R K I Y D T H A Q N V - L I K E E G K L A S T Y S R L N I T Q Q Q W M S E S T F
Mouse ε (Seq ID No:4)	S W L M D D R E I T D T L A Q T V - L I K E E G K L A S T C S K L N I T E Q Q W M S E S T F
	320 330 340 350
Human ε (Seq ID:No:1)	T C Q V - T Y Q G H T F E D S T K K C A D S N P R G V S A Y L S R P S P F D L F I R K S P T
Dog ε (Seq ID:No:2)	T C Q G F T F K D E A R K - - - - - C S E S D P R G V T S Y L S P P S P L D L Y V H K A P K
Rat ε (Seq ID:No:3)	T C K V - T S Q G E N Y W A H T R R C S D D E P R G V I T Y L I P P S P L D L Y E N G T P K
Mouse ε (Seq ID:No:4)	T C R V - T S Q G C D Y L A H T R R C P D H E P R G A I T Y L I P P S P L D L Y Q N G A P K

Table 1 (cont'd)

	360	370	380	390
Human ε (Seq ID:No:1)	I T C L V V D L A P S K G T V N L T W S R A S G K P - V N H S T R K E E K Q R - N G T L T			
Dog ε (Seq ID:No:2)	I T C L V V D L A T M E G M - N L T W Y R E S K E P - V N P G P L N K - K D H F N G T I T			
Rat ε (Seq ID:No:3)	L T C L V L D L E S E E - N I T V T W V R E R K K S I G S A S Q R S T - K H H - N A T T S			
Mouse ε (Seq ID:No:4)	L T C L V V D L E S E - K N V N V T W N Q E - K K T S V S A S Q W Y T - K H H N N A T T S			

	400	410	420	430	440
Human ε (Seq ID:No:1)	V T S T L P V G T R D W I E G E T Y Q C R V T H P H L P R A L M R S T T K T - S G P R A A P				
Dog ε (Seq ID:No:2)	V T S T L P V N T N D W I E G E T Y Y C R V T H P H L P K D I V R S I A K A - P G K R A P P				
Rat ε (Seq ID:No:3)	I T S I L P V D A K D W I E G E G Y Q C R V D H P H F P K P I V R S I T K A - L G L R S A P				
Mouse ε (Seq ID:No:4)	I T S I L P V V A K D W I E G Y G Y Q C I V D R P D F P K P I V R S I T K T Q P G Q R S A P				

	450	460	470	480
Human ε (Seq ID:No:1)	E V Y A F A T P E W P G S R D K - R - T L A C L I Q N F M P E D I S V Q W L H N E V Q L P D			
Dog ε (Seq ID:No:2)	D V Y L F L P P E - E E Q G T K D R V T L T C L I Q N F F P A D I S V Q W L R N D S P I Q T			
Rat ε (Seq ID:No:3)	E V Y V F L P P E - E E E K N K - R - T L T C L I Q N F F P E D I S V Q W L Q D S K L I P K			
Mouse ε (Seq ID:No:4)	E V Y V F P P P E - E E S E D K - R - T L T C L I Q N F F P E D I S V Q W L G D G K L I S N			

Table 1 (Cont'd)

	490	500	510	520
Human ε (Seq ID:No:1)	A R H S T T Q - P R K T K G S - - G F F V F S R L E V T R A E W - Q E K D E F I C R A V H E			
Dog ε (Seq ID:No:2)	D Q Y - T T T G P H K V S G S R P A F F I F S R L E V S R V D W E Q - K N K F T C Q V V H E			
Rat ε (Seq ID:No:3)	S Q H S T T T - P L K T N G S N Q R F F I F S R L E V T K A L W T Q T K Q - F T C R V I H E			
Mouse ε (Seq ID:No:4)	S Q H S T T T - P L K S N G - N Q G F F I F S R L E V A K T L W T Q R K Q - F T C Q V I H E			

	530	540
Human ε (Seq ID:No:1)	A A S P S Q T V Q R A V S V N P G K	
Dog ε (Seq ID:No:2)	A L S G S R	
Rat ε (Seq ID:No:3)	A L R E P R	
Mouse ε (Seq ID:No:4)	A L Q K P R	

Table 2

Screening of IgE CH2/3 Peptides for Selection of Candidate IgE Antigens

IgE Derived Target Antigenic Site			Immunostimulatory sequence attached to Target Antigenic Site		Cross-reactivity with human IgE
Entry No.; Description†		Amino Acid Sequence			Log_{10} ELISA Titer vs HuIgE
1	CH2/3 (328-376) (C_{358}→S)	CADSNPRGVSAYLSRPSPFDLFIRKSPTITSLVVDLAPSKGTVNLTWSR (SEQ ID NO:28)	a	KLH	3.66
2	CH2/3 (317-376) (C_{358}→S)	QGHTFEDSTKKCADSNPRGVSAYLSRPSPFDLFIRKSPTITSLVVDLAPSKGTVNLTWSR (SEQ ID NO:29)	a	KLH	5.08
			b	1,4,9 Palindromic Th lib-GG	3.77
3	CH2/3 (313-376) (C_{358}→S)	QVTYQGHTFEDSTKKCADSNPRGVSAYLSRPSPFDLFIRKSPTITSLVVDLAPSKGTVNLTWSR (SEQ ID NO:30)	a	KLH	3.12
4	CH2/3 (301-376) (C_{358}→S)	QKHWLSDRTYTSQVTYQGHTFEDSTKKCADSNPRGVSAYLSRPSPFDLFIRKSPTITSLVVDLAPSKGTVNLTWSR (SEQ ID NO:31)	a	KLH	4.04
5	CH2/3 (328-362) (C_{358}→S)	CADSNPRGVSAYLSRPSPFDLFIRKSPTITSLVVD (SEQ ID NO:32)	a	KLH	4.40
6	CH2/3 (317-362) (C_{358}→S)	QGHTFEDSTKKCADSNPRGVSAYLSRPSPFDLFIRKSPTITSLVVD (SEQ ID NO:33)	a	KLH	4.30

Table 2 (continued)

IgE Derived Target Antigenic Site			Immunostimulatory sequence attached to Target Antigenic Site		Cross-reactivity with human IgE
Entry No.; Description†		Amino Acid Sequence			Log_{10} ELISA Titer vs HuIgE
7	CH2/3 (313-362) (C_{358}→S)	QVTYQGHTFEDSTKKCADSNPRGVSAYLSRPSPFDLFIRKSPTITSLVVD (SEQ ID NO:34)	a	KLH	3.92
8	CH2/3 (301-362) (C_{358}→S)	QKHWLSDRTYTSQVTYQGHTFEDSTKKCADSNPRGVSAYLSRPSPFDLFIRKSPTITSLVVD (SEQ ID NO:35)	a	KLH	3.37
9	CH2/3 (328-356)	CADSNPRGVSAYLSRPSPFDLFIRKSPTI (SEQ ID NO:36)	a	KLH	3.49
10	CH2/3 (317-356)	QGHTFEDSTKKCADSNPRGVSAYLSRPSPFDLFIRKSPTI (SEQ ID NO:37)	a	KLH	4.71
			b	HBs_{19-32}Th-GG	3.76
			c	Inv-GG-HBs_{19-32}Th-GG	2.94
11	CH2/3 (313-356)	QVTYQGHTFEDSTKKCADSNPRGVSAYLSRPSPFDLFIRKSPTI (SEQ ID NO:38)	a	KLH	4.31
12	CH2/3 (301-356) (C_{312}→S)	QKHWLSDRTYTSQVTYQGHTFEDSTKKCADSNPRGVSAYLSRPSPFDLFIRKSPTI (SEQ ID NO:39)	a	KLH	2.79
13	CH2/3 (301-376)	QKHWLSDRTYTCQVTYQGHTFEDSTKKCADSNPRGVSAYLSRPSPFDLFIRKSPTITCLVVDLAPSKGTVNLTWSR (SEQ ID NO:40)	a	KLH	3.77
14	(C)CH3 (391-398) (C)*	(C)KQRNGTLT(C) (SEQ ID NO:41)	b	HBs_{19-32}Th-GG	1.47
			C	Inv-GG-HBs_{19-32}Th-GG	0.77

Table 2 (continued)

IgE Derived Target Antigenic Site			Immunostimulatory sequence attached to Target Antigenic Site		Cross-reactivity with human IgE
Entry No.; Description†		Amino Acid Sequence			Log_{10} ELISA Titer vs HuIgE
			c	Inv-GG-HBs_{19-32}Th-GG	0.77
15	(C)CH3 (413-435)(C)* (C_{418}→S)	(C)GETYQSRVTHPHLPRALMRSTTK(C) (SEQ ID NO:5)	b	Syn Th (1,2,4)-GG	4.24
			c	Inv-GG-Syn Th (1,2,4)-GG	4.17
16	CH2/3 (301-345)	QKHWLSDRTYTCQVTYQGHTFEDSTKKCADSNPRGVSAYLSRPSP (SEQ ID NO:42)	b	HBs_{19-32}Th-GG	2.31
17	(C)CH3 (365-396)(C)*	(C)PSKGTVNLTWSRASGKPVNHSTRKEEKQRNGT(C) (SEQ ID NO:43)	b	HBs_{19-32}Th-GG	< 1.0
18	(C)CH3 (404-434)(C)*	(C)PVGTRDWIEGETYQCRVTHPHLPRALMRSTT(C) (SEQ ID NO:44)	b	HBs_{19-32}Th-GG	< 1
19	CH3 (432-445)	STTKTSGPRAAPEV (SEQ ID NO:45)	b	HBs_{19-32}Th-GG	2.725
20	(C)CH3(374-382-(C)-383-385)*	(C)WSRASGKPV(C)NHS (SEQ ID NO:46)	b	HBs_{19-32}Th-GG	3.976
21	CH3 (345-357)*	(C)PSPFDLFIRKSPT(C) (SEQ ID NO:83)	b	HBs_{19-32}Th-GG	< 1^{Δ}
			c	Inv-GG-HBs_{19-32}Th-GG	
22	(C)CH3 (343-360)*	(C)SRPSPFDLFIRKSPTITC (SEQ ID NO:47)	b	HBs_{19-32}Th-GG	< 1^{Δ}
			c	Inv-GG-HBs_{19-32}Th-GG	
23	(C)CH3 (404-413)(P)(C)*	(C)VGTRDWIEGE(P)(C) (SEQ ID NO:48)	b	HBs_{19-32}Th-GG	< 1^{Δ}

Table 2 (continued)

IgE Derived Target Antigenic Site			Immunostimulatory sequence attached to Target Antigenic Site		Cross-reactivity with human IgE
Entry No.; Description†		Amino Acid Sequence			Log_{10} ELISA Titer vs HuIgE
			c	Inv-GG-HBs_{19-32}Th-GG	
24	(C) (P) CH3 (403-413) (P) (C)*	(C) (P) PVGTRDWIEGE (P) (C) (SEQ ID NO:49)	b	HBs_{19-32}Th-GG	< 1^{Δ}
			c	Inv-GG-HBs_{19-32}Th-GG	
25	(C) CH3 (387-400) (C)*	(C) KEEKQRNGTLTVTS (C) (SEQ ID NO:50)	b	HBs_{19-32}Th-GG	< 1^{Δ}
			c	Inv-GG-HBs_{19-32}Th-GG	
26	CH3 (387-394)	KEEKQRNG (SEQ ID NO:51)	b	HBs_{19-32}Th-GG	< 1
			c	Inv-GG-HBs_{19-32}Th-GG	
27	(C) CH3 (373-381) (C)*	(C) WSRASGKPV (C) (SEQ ID NO:52)	b	HBs_{19-32}Th-GG	2.40^{Δ}
			c	Inv-GG-HBs_{19-32}Th-GG	
28	CH3 (354-373) (C)*	PTITCLVLDLAPSKGTVNLT (C) (SEQ ID NO:53)	b	HBs_{19-32}Th-GG	2.59
29	CH3 (354-369)	PTITCLVLDLAPSKGT (SEQ ID NO:54)	b	HBs_{19-32}Th-GG	2.39
30	CH3 (399-424)	TSTLPVGTRDWIEGETYQCRVTHPH (SEQ ID NO:55)	b	HBs_{19-32}Th-GG	4.01

Table 2 (continued)

IgE Derived Target Antigenic Site			Immunostimulatory sequence attached to Target Antigenic Site		Cross-reactivity with human IgE
Entry No.;	Description†	Amino Acid Sequence			Log_{10} ELISA Titer vs HuIgE
31	CH3 (354-368) (C)* (C_{358}→S) (D_{362}→C)	PTITSLVLCLAPSKG(C) (SEQ ID NO:56)	b	HBs_{19-32}Th-GG	< 1
32	(C)CH3 (370-390) (C)*	(C)VNLTWSRASGKPVNHSTRKEE(C) (SEQ ID NO:57)	b	HBs_{19-32}Th-GG	3.45
33	(C)CH3 (373-424)*	(C)TWSRASGKPVNHSTRKEEKQRNGTLTVTSTLPVGTRDWIEGETYQCRVIHPH (SEQ ID NO:58)	b	HBs_{19-32}Th-GG	2.33
34	CH4 (497-506)	KTKGSGFFVF (SEQ ID NO:59)	b	HBs_{19-32}Th-GG + $MVF_{288-302}$Th-GG + $PT_{149-176}$Th-GG	< 1

* = cyclized peptide

† = amino acid residue numbers from Table 1, SEQ ID No. 1

Δ = crossreactivity results are for a mixture of "b" and "c" peptides

(C) = cysteine introduced into native sequence for cyclization

C→S = Serine substituted for cysteine residue, D→C = cysteine substituted for aspartic acid residue.

Table 3

Evaluation of Anti-IgE Antibodies
for Inhibition of Histamine Release

IgE Antigen Entry No.	IgE Antigen Description (SEQ ID NO)	Immunogenic Elements Attached to IgE Antigen		% Inhibition of Histamine Release†
1	CH2/3 (328-376) (C_{358}→S) (SEQ ID NO:28)	a	KLH	0
2	CH2/3 (317-376) (C_{358}→S) (SEQ ID NO:29)	a	KLH	14%
		b	1,4,9 PALINDROMIC Th-GG-	17% and 0
5	CH2/3 (328-362) (C_{358}→S) (SEQ ID NO:32)	a	KLH	0
6	CH2/3 (317-362) (C_{358}→S) (SEQ ID NO:33)	a	KLH	0
7	CH2/3 (313-362) (C_{358}→S) (SEQ ID NO:34)	a	KLH	6%
8	CH2/3 (301-362) (C_{358}→S) (SEQ ID NO:35)	a	KLH	6%
11	CH2/3 (313-356) (SEQ ID NO:38)	a	KLH	6%
15	(C)CH3 (413-435)(C)* (C_{418}→S) (SEQ ID NO:5)	b	Syn Th(1,2,4)-GG	58%‡ and 71%-⊕
		c	Inv-GG-Syn Th(1,2,4)-GG-	
20	(C)CH3 (374-382-(C)-383-385)* (SEQ ID NO:46)	b	HBs_{19-32}Th-GG	0
30	CH3 (399-424) (SEQ ID NO:55)	b	HBs_{19-32}Th-GG-	9% and 0
32	(C)CH3 (370-390)(C)* (SEQ ID NO:57)	b	HBs_{19-32}Th-GG-	0

* Cyclized peptide

(C) Cysteine introduced into native sequence for cyclization

(C→S) Serine substituted for cysteine residue

‡ Results are shown for pooled anti-15b and anti-15c IgG's.

† Histamine release inhibition by antibodies to peptides, purified from serum collected at week 8, except as otherwise noted by⊕

⊕ Histamine release inhibition by antibodies to peptides, collected at week 12.

Table 4A

Representative Peptides of the Invention

IgE-CH3 antigen SEQ ID NO	Description, SEQ ID NO(S) of immunostimulatory sequence	Amino acid sequence and SEQ ID NO of peptide
SEQ ID NO:5	Syn Th(1,2,4)-GG-SEQ ID NO:9	KKKIITITRIITIITTIDGGCGETYQSRVTHPHLPRALMRSTTKC (SEQ ID NO:14)
SEQ ID NO:5	Inv-GG-Syn Th(1,2,4)-GG-SEQ ID NOS:13, 9	TAKSKKFPSYTATYQFGGKKKIITITRIITIITTIDGGCGETYQSRVTHPHLPRALMRSTTKC (SEQ ID NO:15)
SEQ ID NO:5	CT P11 Th-GG-Syn Th(1,2,4)1-GG-SEQ ID NOS:12, 9	TINKPKGYVGKEGGKKKIITITRIITIITTIDGGCGETYQSRVTHPHLPRALMRSTTKC (SEQ ID NO:17)
SEQ ID NO:5	IS(1,4,9 PALt)LF simplified Th-GG-SEQ ID NO:60	ISISEIKGVIVHKIEGILFGGCGETYQSRVTHPHLPRALMRSTTKC T RT TR T (SEQ ID NO:18)
SEQ ID NO:5	Inv-IS(1,4,9 PALt)LF simplified Th-GG-SEQ ID NOS:13, 60	TAKSKKFPSYTATQFGGISISEIKGVIVHKIEGILFGGCGETYQSRVTHPHLPRALMRSTTKC T RT TR T (SEQ ID NO:19)
SEQ ID NO:5	(CT P11 Th)-GG-IS(1,4,9 PALt)LF simplified Th-GG-SEQ ID NOS:12, 60	TINKPKGYVGKEGGISISEIKGVIVHKIEGILFGGCGETYQSRVTHPHLPRALMRSTTKC T RT TR T (SEQ ID NO:20)

Table 4A (continued)

SEQ ID NO:5	(1,4,9 PALt) Th-GG-SEQ ID NO:10	ISEIKGVIVHKIEGIGGCGETYQSRVTHPHLPRALMRSTTKC MT RT TRM TM L L V (SEQ ID NO:21)
SEQ ID NO:5	Inv-(1,4,9 PALt) Th-GG-SEQ ID NOS:13, 10	TAKSKKFPSYTATYQFGGISEIKGVIVHKIEGIGGCGETYQSRVTHPHLPRALMRSTTKC MT RT TRM TM L L V (SEQ ID NO:22)
SEQ ID NO:5	(CT P11 Th)-(1,4,9 PALt)Th-GG-SEQ ID NOS:12, 10	TINKPKGYVGKEGGISEIKGVIVHKIEGIGGCGETYQSRVTHPHLPRALMRSTTKC MT RT TRM TM L L V (SEQ ID NO:23)
SEQ ID NO:5	CTR11Th-GG-IS(1,4,9, PALt)LF simplified Th-GG- SEQ ID NOS: 12, 60	TINKPKGYVGKEGGISISEIKGVIVHKIEGILFGGCGETYQSRVTHPHLPRALMRSTTKC T RT TR T (SEQ ID NO:85)
SEQ ID NO:5	klh*-KKK-	[klh*]-KKKCGETYQSRVTHPHLPRALMRSTTKC
SEQ ID NO:8	klh*-KKK-	[klh*]-KKKCGYGYQSIVDRPDFPKPIVRSITKC
SEQ ID NO:8	IS(1,4,9 PALt)LF simplified Th-GG- SEQ ID NO:60	ISISEIKGVIVHKIEGILFGGCGYGYQSIVDRPDFPKPIVRSITKC T RT TR T (SEQ ID NO:24)
SEQ ID NO:8	Syn Th(1,2,4)-GG- SEQ ID NO:9	KKKIITITRIITIITTIDGGCGYGYQSIVDHPDFPKPIVRSITKC (SEQ ID NO:25)
SEQ ID NO:6	klh*-KKK-	[klh*]-KKKCGETYYSRVTHPHLPKDIVRSIAKC
SEQ ID NO:6	Syn Th(1,2,4)-GG- SEQ ID NO:9	KKKIITITRIITIITTIDGGCGETYYSRVTHPHLPKDIVRSIAKC (SEQ ID NO:26)

Table 4A (continued)

SEQ ID NO:6	IS(1,4,9 PALt)LF Th-GG-SEQ ID NO:11	ISISEIKGVIVHKIEGILFGGCGETYYSRVTHPHLPKDIVRSIAKC MT RT TRM TM L L V(SEQ ID NO:27)
SEQ ID NO:6	SMTPITh- K-Syn Th (1,2,3)- K-SEQ ID NOS:86,60	KWFKTNAPNGVDEKIRIεKKKKIITITRIITIITTIDεKCGETYYSRVTHPHLPKDIVRSIAKC (SEQ ID NO:87)
SEQ ID NO:6	CTP11Th-εK-Syn Th(1,2,4)-εK-SEQ ID NOS:12, 9	TINKPKGYVGKEεKKKKIITITRIITIITTIDεKCGETYYSRVTHPHLPKDIVRSIAKC (SEQ ID NO:88)
SEQ ID NO:6	ArtMVFTh-εK-SEQ ID NO:89	ISLTEIRTVIVTRLETVLFεKCGETYYSRVTHPHLPKDIVRSIAKC (SEQ ID NO:90)
SEQ ID NO:6	SMTPITh-εK-ArtMVFTh-εK-SEQ ID NOS:86, 89	KWFKTNAPNGVDEKIRIεKISLTEIRTVIVTRLETVLFεKCGETYYSRVTHPHLPKDIVRSIA KC (SEQ ID NO:91)

*klh = keyhole limpet hemocyanin, chemically linked (see Example 1)

†PAL = Palindromic

Table 4B

Immunogenicity of Representative Peptide Constructs of the Invention

SEQ ID NO of peptide contructs		Species immunized	Site-directed crossreactivity to IgE (Log_{10} titer)	% HR[c]	%HR[d] inhibition
Human IgE Target	SEQ ID NO:18	GP[a]	4.4[e]	1	96
	SEQ ID NO:85	GP[a]	4.2[e]	3	87
	SEQ ID NO:18	Pig[a]	4.1[e]	3	84
	SEQ ID NO:18	Baboon[a]	4.8[e]	8	53
Dog IgE Target	SEQ ID NO:87	GP[b]	3.4[f]	NT	NT
	SEQ ID NO:88	GP[b]	3.2[f]	NT	NT
	SEQ ID NO:90	GP[b]	3.2[f]	NT	NT
	SEQ ID NO:91	GP[b]	3.2[f]	NT	NT

[a] Guinea pigs, pigs and baboon were immunized with human IgE peptide constructs at 0, 3 and 6 weeks, with sera collected at 8 wpi for testing by human IgE ELISA and inhibition of HR.

[b] Guinea pigs were immunized with dog IgE peptide constructs at 0, 2 and 4 weeks with sera collected at 6 wpi for dog IgE ELISA.

[c] Average % HR.

[d] % HR inhibition = control - %HR/control x 100

GP: Guinea pig

NT: Not tested

Table 5
Amino Acid Sequences of
Foreign Pathogen-Derived Th Epitopes

Description of Th	SEQ ID NO	Amino Acid Sequences
$MVF_{288-302}$ Th	61	LSEIKGVIVHRLEGV
$MVF_{258-277}$ Th	62	GILESRGIKARITHVDTESY
$TT_{830-844}$ Th	63	KKQYIKANSKFIGITEL
$TT_{947-966}$ Th	64	KKFNNFTVSFWLRVPKVSASHL
$PT_{149-176}$ Th	65	KKLRRLLYMIYMSGLAVRVHVSKEEQYYDY
TT_{73-99} Th	66	YDPNYLRTDSDKDRFLQTMVKLFNRIK
PT_{18-41} Th	67	GAYARCPNGTRALTVAELRGNAEL
HBs_{19-32} Th	68	FFLLTRILTIPQSLD
$HBc_{120-140}$ Th	69	VSFGVWIRTPPAYRPPNAPIL
HBc_{21-40} Th	70	SDFFPSVRDLLDTASALYRE
HBc_{50-69} Th	71	PHHTALRQAILCWGELMTLA
$TT_{615-631}$ Th	72	WVRDIIDDFTNESSQKT
HIV gp41 Th_6 (N-)	73	RAGRAILHIPTRIRQGLER
HIV gp41 Th_6 (C-)	74	AVAEGTDRVIEVLQRAGRAIL
CT $A8_{106-130}$ Th	75	ALNIWDRFDVFTLGATSGYLKGNS
CT P11 Th	12	TINKPKGYVGKE
DT1 Th	76	DSETADNLEKTVAALSILPGHG
DT4 Th	77	EEIVAQSIALSSLMVAQAIPLVGELVDIGFAATNFVESC
PF Th	78	DIEKKIAKMEKASSVFNVVNS
SM Th	79	KWFKTNAPNGVDEKIRI
TraT1 Th	80	GLQGKIADAVKAKG
TraT4 Th	81	GLAAGLVGMAADAMVEDVN
TraT6 Th	82	STETGNQHHYQTRVVSNANK
SMTPITh	86	KWFKTNAPNGVDEKIRI

Table 6

Amino Acid Sequences of
Representative Artificial Th Epitopes and SSAL

Description of Th	SEQ ID NO:	Amino Acid Sequence
(1,4,9 PALINDROMIC) Th	10	ISEIKGVIVHKIEGI MT RT TRM TM L L V
Syn Th(1,2,4)	9	KKKIITITRIITIITTID
IS(1,4,9 PALINDROMIC)LF simplified Th	60	ISISEIKGVIVHKIEGILF T RT TR T
IS(1,4,9 PALINDROMIC)LF Th	11	ISISEIKGVIVHKIEGILF MT RT TRM TM L L V
ArtMVF Th	89	ISLTEIRTVIVTRLETVLF

Table 7
Inhibition of PCA Reaction

IgE Dilution	Rat #5		Rat #6	
	No Anti-IgE (mm)	Anti-IgE 1:2 (mm)	No Anti-IgE (mm)	Anti-IgE 1:2 (mm)
0	0	0	0	0
1:496	0	0	4.3	0
1:248	0	0	7.0	6.0
1:124	11	4*	13.0	12.7

* very pale blue

CLAIMS

We claim:

1. An IgE-CH3 domain antigen peptide between about 25 and about 29 amino acids in length containing two cysteine residues separated by about 23 amino acid residues, selected from the group consisting of SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:84, homologous sequences from the epsilon heavy chain of mammalian IgE-CH3, and crossreactive and immunologically functional analogs thereof.

2. An IgE-CH3 domain antigen peptide of claim 1 selected from the group consisting of SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, and SEQ ID NO:84.

3. A synthetic peptide of about 50 to about 90 amino acids, which comprises

(a) a helper T cell (Th) epitope,

(b) an IgE-CH3 domain antigen peptide according to claim 1;and

(c) an immunostimulatory invasin domain.

4. A peptide conjugate comprising a helper T cell epitope sequence (Th) covalently attached to an IgE-CH3 domain antigen peptide according to claim 1.

5. A peptide conjugate represented by the formula

$$(A)_n\text{-(IgE-CH3 domain antigen)-}(B)_o\text{-}(Th)_m\text{-}X$$

or

$(A)_n-(Th)_m-(B)_o-$(IgE-CH3 domain antigen)$-X$

wherein

each A is independently an amino acid or a general immunostimulatory sequence;

each B is chosen from the group consisting of amino acids, $-NHCH(X)CH_2SCH_2CO-$, $-NHCH(X)CH_2SCH_2CO(\varepsilon-N)Lys-$,

$-NHCH(X)CH_2S-$succinimidyl$(\varepsilon-N)Lys-$, and $-NHCH(X)CH_2S-$(succinimidyl)$-$;

each Th is independently a sequence of amino acids that constitutes a helper T cell epitope, or an immune enhancing analog or segment thereof;

IgE-CH3 domain antigen represents the sequence of an IgE-CH3 domain antigen peptide according to claim 1;

X is an amino acid $\alpha-COOH$ or $\alpha-CONH_2$;

n is from 0 to about 10;

m is from 1 to about 4; and

o is from 0 to about 10.

6. A peptide conjugate represented by the formula

(IgE-CH3 domain antigen)$-(B)_o-(Th)_m-(A)_n-X$

or

$(Th)_m-(B)_o-$(IgE-CH3 domain antigen)$-(A)_n-X$

wherein

each A is independently an amino acid or a general immunostimulatory sequence;

each B is chosen from the group consisting of amino acids, -NHCH(X)CH_2SCH_2CO-, -NHCH(X)CH_2SCH_2CO(ε-N)Lys-, -NHCH(X)CH_2S-succinimidyl(ε-N)Lys-, and -NHCH(X)CH_2S-(succinimidyl)-;

each Th is independently a sequence of amino acids that constitutes a helper T cell epitope, or an immune enhancing analog or segment thereof;

IgE-CH3 domain antigen represents the sequence of an IgE-CH3 domain antigen peptide according to claim 1;

X is an amino acid α-COOH or α-$CONH_2$;

n is from 0 to about 10;

m is from 1 to about 4; and

o is from 0 to about 10.

7. A peptide conjugate of any one of claims 4-6 wherein said Th is an SSAL.

8. A peptide conjugate of any one of claims 4-6 wherein said IgE-CH3 domain antigen peptide has an amino acid sequence selected from the group consisting of SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, and SEQ ID NO:84.

9. A peptide conjugate of claim 7 wherein said IgE-CH3 domain antigen peptide has an amino acid sequence selected from the group consisting of SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, and SEQ ID NO:84.

10. A peptide conjugate of any one of claims 4-6 wherein said Th has an amino acid sequence selected from the group consisting of SEQ ID NOS: 9-12 and SEQ ID NOS: 61-82 and 84.

11. A peptide conjugate of claim 7 wherein said Th has an amino acid sequence selected from the group consisting of SEQ ID NOS: 9-12 and SEQ ID NOS: 61-82 and 84.

12. A peptide conjugate of claim 8 wherein said Th has an amino acid sequence selected from the group consisting of SEQ ID NOS: 9-12 and SEQ ID NOS: 61-82 and 84.

13. A peptide conjugate of claim 9 wherein said Th has an amino acid sequence selected from the group consisting of SEQ ID NOS: 9-12 and SEQ ID NOS: 61-82 and 84.

14. A peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 14, 15, 17-27, 85, 87, 88, 90, 91.

15. A peptide conjugate of claim 5 or 6, wherein at least one A is an invasin domain.

16. A peptide conjugate of claim 5 or 6 wherein n is 3, and $(A)_3$ is (invasin domain)-Gly-Gly.

17. A peptide conjugate of claim 15 wherein said invasin domain has the amino acid sequence of SEQ ID NO:13.

18. A peptide conjugate of claim 16 wherein said invasin domain has the amino acid sequence of SEQ ID NO:13.

19. A peptide conjugate comprising a carrier protein covalently attached to one or more IgE-CH3 domain antigen peptides according to claim 1.

20. The peptide conjugate of claim 19 wherein the carrier protein is keyhole limpet hemocyanin.

21. A peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOS:14, 15, 26, 90.

22. A branched polymer comprising a lysine, trilysine, or heptalysine core, covalently attached to two, four, or eight peptide conjugates, respectively, of any one of claims 4-6 or 14.

23. A polymer comprising one or more peptide conjugates of any one of claims 4-6 or 14, cross-linked by a bifunctional crosslinking agent.

24. A pharmaceutical composition comprising an immunologically effective amount of a peptide or peptide conjugate of any one of claims 4-6 or 14, and a pharmaceutically acceptable carrier.

25. A pharmaceutical composition of claim 23, wherein said immunologically effective amount of said peptide or peptide conjugate is between about 0.5 μg and about 1 mg per kilogram body weight per dose.

26. A method for inducing anti-IgE antibody production in a mammal which comprises administering to said mammal a pharmaceutical composition of claim 23.

27. A method for inducing anti-IgE antibody production in a mammal which comprises administering to said mammal a pharmaceutical composition of claim 24.

28. A nucleic acid comprising a sequence which encodes a peptide of any one of claims 1-6.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: UNITED BIOMEDICAL INC., et al.

(ii) TITLE OF INVENTION: PEPTIDE COMPOSITION AS IMMUNOGEN FOR THE TREATMENT OF ALLERGY

(iii) NUMBER OF SEQUENCES: 91

(iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Morgan & Finnegan
(B) STREET: 345 Park Avenue
(C) CITY: New York
(D) STATE: NY
(E) COUNTRY: USA
(F) ZIP: 10154-0053

(v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: WORD 8.0

(vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER: To be assigned
(B) FILING DATE: 21-JUNE-1999
(C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: US 09/100,287
(B) FILING DATE: 20-JUN-1998
(C) CLASSIFICATION: 514

(viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: MARIA C.H.LIN
(B) REGISTRATION NUMBER: 29,323
(C) REFERENCE/DOCKET NUMBER: 1151-4153PC1

(ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: 212-758-4800
(B) TELEFAX: 212-751-6849

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 325 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) FEATURE:
(A) NAME/KEY: î chain of human IgE

(x) REFERENCE: Dorrington and Bennich, Immunol Rev, 1978, 41:3-25.

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

```
Val Cys Ser Arg Asp Phe Thr Pro Pro Thr Val Lys
 1               5                  10
Ile Leu Gln Ser Ser Cys Asp Gly Gly Gly His Phe
            15                  20
Pro Pro Thr Ile Gln Leu Leu Cys Leu Val Ser Gly
 25                  30                  35
Tyr Thr Pro Gly Thr Ile Asn Ile Thr Trp Leu Glu
             40                  45
Asp Gly Gln Val Met Asp Val Asp Leu Ser Thr Ala
     50                  55                  60
Ser Thr Thr Gln Glu Gly Glu Leu Ala Ser Thr Gln
                 65                  70
Ser Glu Leu Thr Leu Ser Gln Lys His Trp Leu Ser
            75                  80
Asp Arg Thr Tyr Thr Cys Gln Val Thr Tyr Gln Gly
 85                  90                  95
His Thr Phe Glu Asp Ser Thr Lys Lys Cys Ala Asp
             100                 105
```

Ser Asn Pro Arg Gly Val Ser Ala Tyr Leu Ser Arg
110 115 120
Pro Ser Pro Phe Asp Leu Phe Ile Arg Lys Ser Pro
125 130
Thr Ile Thr Cys Leu Val Val Asp Leu Ala Pro Ser
135 140
Lys Gly Thr Val Asn Leu Thr Trp Ser Arg Ala Ser
145 150 155
Gly Lys Pro Val Asn His Ser Thr Arg Lys Glu Glu
160 165
Lys Gln Arg Asn Gly Thr Leu Thr Val Thr Ser Thr
170 175 180
Leu Pro Val Gly Thr Arg Asp Trp Ile Glu Gly Glu
185 190
Thr Tyr Gln Cys Arg Val Thr His Pro His Leu Pro
195 200
Arg Ala Leu Met Arg Ser Thr Thr Lys Thr Ser Gly
205 210 215
Pro Arg Ala Ala Pro Glu Val Tyr Ala Phe Ala Thr
220 225
Pro Glu Trp Pro Gly Ser Arg Asp Lys Arg Thr Leu
230 235 240
Ala Cys Leu Ile Gln Asn Phe Met Pro Glu Asp Ile
245 250
Ser Val Gln Trp Leu His Asn Glu Val Gln Leu Pro
255 260
Asp Ala Arg His Ser Thr Thr Gln Pro Arg Lys Thr
265 270 275
Lys Gly Ser Gly Phe Phe Val Phe Ser Arg Leu Glu
280 285
Val Thr Arg Ala Glu Trp Gln Glu Lys Asp Glu Phe
290 295 300
Ile Cys Arg Ala Val His Glu Ala Ala Ser Pro Ser
305 310
Gln Thr Val Gln Arg Ala Val Ser Val Asn Pro Gly
315 320
Lys
325

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 312 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) FEATURE:
(A) NAME/KEY: î chain of dog IgE

(x) REFERENCE: Patel et al., Immunogenetics, 1995; 41:282-286.

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Ala Cys Ala Leu Asn Phe Ile Pro Pro Thr Val Lys
1 5 10
Leu Phe His Ser Ser Cys Asn Pro Val Gly Asp Thr
15 20
His Thr Thr Ile Gln Leu Leu Cys Leu Ile Ser Gly
25 30 35
Tyr Val Pro Gly Asp Met Glu Val Ile Trp Leu Val
40 45
Asp Gly Gln Lys Ala Thr Asn Ile Phe Pro Tyr Thr
50 55 60
Ala Pro Gly Thr Lys Glu Gly Asn Val Thr Ser Thr
65 70
His Ser Glu Leu Asn Ile Thr Gln Gly Glu Trp Val
75 80
Ser Gln Lys Thr Tyr Thr Cys Gln Gly Phe Thr Phe
85 90 95
Lys Asp Glu Ala Arg Lys Cys Ser Glu Ser Asp Pro
100 105
Arg Gly Val Thr Ser Tyr Leu Ser Pro Pro Ser Pro
110 115 120
Leu Asp Leu Tyr Val His Lys Ala Pro Lys Ile Thr
125 130
Cys Leu Val Val Asp Leu Ala Thr Met Glu Gly Met
135 140

```
Asn Leu Thr Trp Tyr Arg Glu Ser Lys Glu Pro Val
145                 150                 155
Asn Pro Gly Pro Leu Asn Lys Lys Asp His Phe Asn
            160                 165
Gly Thr Ile Thr Val Thr Ser Thr Leu Pro Val Asn
    170                 175                 180
Thr Asn Asp Trp Ile Glu Gly Glu Thr Tyr Tyr Cys
                185                 190
Arg Val Thr His Pro His Leu Pro Lys Asp Ile Val
        195                 200
Arg Ser Ile Ala Lys Ala Pro Gly Lys Arg Ala Pro
205                 210                 215
Pro Asp Val Tyr Leu Phe Leu Pro Pro Glu Glu Glu
            220                 225
Gln Gly Thr Lys Asp Arg Val Thr Leu Thr Cys Leu
    230                 235                 240
Ile Gln Asn Phe Phe Pro Ala Asp Ile Ser Val Gln
                245                 250

Trp Leu Arg Asn Asp Ser Pro Ile Gln Thr Asp Gln
        255                 260
Tyr Thr Thr Thr Gly Pro His Lys Val Ser Gly Ser
265                 270                 275
Arg Pro Ala Phe Phe Ile Phe Ser Arg Leu Glu Val
            280                 285
Ser Arg Val Asp Trp Glu Gln Lys Asn Lys Phe Thr
    290                 295                 300
Cys Gln Val Val His Glu Ala Leu Ser Gly Ser Arg
                305                 310
```

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 313 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) FEATURE:
(A) NAME/KEY: î chain of rat IgE

(x) REFERENCE: Steen et al., J Mol Biol, 1984; 177:19-32.

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

```
Ala Arg Pro Val Asn Ile Thr Lys Pro Thr Val Asp
 1               5                  10
Leu Leu His Ser Ser Cys Asp Pro Asn Ala Phe His
         15                  20
Ser Thr Ile Gln Leu Tyr Cys Phe Val Tyr Gly His
 25                  30                  35
Ile Gln Asn Asp Val Ser Ile His Trp Leu Met Asp
             40                  45
Asp Arg Lys Ile Tyr Asp Thr His Ala Gln Asn Val
     50                  55                  60
Leu Ile Lys Glu Glu Gly Lys Leu Ala Ser Thr Tyr
                 65                  70
Ser Arg Leu Asn Ile Thr Gln Gln Gln Trp Met Ser
         75                  80
Glu Ser Thr Phe Thr Cys Lys Val Thr Ser Gln Gly
 85                  90                  95
Glu Asn Tyr Trp Ala His Thr Arg Arg Cys Ser Asp
             100                 105
Asp Glu Pro Arg Gly Val Ile Thr Tyr Leu Ile Pro
    110                 115                 120
Pro Ser Pro Leu Asp Leu Tyr Glu Asn Gly Thr Pro
                125                 130
Lys Leu Thr Cys Leu Val Leu Asp Leu Glu Ser Glu
        135                 140
Glu Asn Ile Thr Val Thr Trp Val Arg Glu Arg Lys
145                 150                 155
Lys Ser Ile Gly Ser Ala Ser Gln Arg Ser Thr Lys
            160                 165
His His Asn Ala Thr Thr Ser Ile Thr Ser Ile Leu
    170                 175                 180
Pro Val Asp Ala Lys Asp Trp Ile Glu Gly Glu Gly
                185                 190
```

```
Tyr Gln Cys Arg Val Asp His Pro His Phe Pro Lys
        195                 200
Pro Ile Val Arg Ser Ile Thr Lys Ala Leu Gly Leu
205                 210                 215
Arg Ser Ala Pro Glu Val Tyr Val Phe Leu Pro Pro
            220                 225
Glu Glu Glu Glu Lys Asn Lys Arg Thr Leu Thr Cys
    230                 235                 240
Leu Ile Gln Asn Phe Phe Pro Glu Asp Ile Ser Val
                245                 250
Gln Trp Leu Gln Asp Ser Lys Leu Ile Pro Lys Ser
        255                 260
Gln His Ser Thr Thr Thr Pro Leu Lys Thr Asn Gly
265                 270                 275
Ser Asn Gln Arg Phe Phe Ile Phe Ser Arg Leu Glu
            280                 285
Val Thr Lys Ala Leu Trp Thr Gln Thr Lys Gln Phe
    290                 295                 300
Thr Cys Arg Val Ile His Glu Ala Leu Arg Glu Pro
                305                 310
Arg
```

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 313 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) FEATURE:
(A) NAME/KEY: î chain of mouse IgE

(x) REFERENCE: Ishida et al., EMBO, 1982; 1:1117-1123

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

```
Val Arg Pro Val Thr His Ser Leu Ser Pro Pro Trp
 1               5                  10
Ser Tyr Ser Ile His Arg Cys Asp Pro Asn Ala Phe
            15                  20
His Ser Thr Ile Gln Leu Tyr Cys Phe Ile Tyr Gly
 25                  30                  35
His Ile Leu Asn Asp Val Ser Val Ser Trp Leu Met
             40                  45
Asp Asp Arg Glu Ile Thr Asp Thr Leu Ala Gln Thr
     50                  55                  60
Val Leu Ile Lys Glu Glu Gly Lys Leu Ala Ser Thr
                 65                  70
Cys Ser Lys Leu Asn Ile Thr Glu Gln Gln Trp Met
            75                  80
Ser Glu Ser Thr Phe Thr Cys Arg Val Thr Ser Gln
 85                  90                  95
Gly Cys Asp Tyr Leu Ala His Thr Arg Arg Cys Pro
            100                 105
Asp His Glu Pro Arg Gly Ala Ile Thr Tyr Leu Ile
    110                 115                 120
Pro Pro Ser Pro Leu Asp Leu Tyr Gln Asn Gly Ala
                125                 130
Pro Lys Leu Thr Cys Leu Val Val Asp Leu Glu Ser
            135                 140
Glu Lys Asn Val Asn Val Thr Trp Asn Gln Glu Lys
145                 150                 155
Lys Thr Ser Val Ser Ala Ser Gln Trp Tyr Thr Lys
            160                 165
His His Asn Asn Ala Thr Thr Ser Ile Thr Ser Ile
    170                 175                 180
Leu Pro Val Val Ala Lys Asp Trp Ile Glu Gly Tyr
                185                 190
Gly Tyr Gln Cys Ile Val Asp Arg Pro Asp Phe Pro
            195                 200
Lys Pro Ile Val Arg Ser Ile Thr Lys Thr Pro Gly
205                 210                 215
Gln Arg Ser Ala Pro Glu Val Tyr Val Phe Pro Pro
            220                 225
Pro Glu Glu Glu Ser Glu Asp Lys Arg Thr Leu Thr
    230                 235                 240
```

```
Cys Leu Ile Gln Asn Phe Phe Pro Glu Asp Ile Ser
                245                 250
Val Gln Trp Leu Gly Asp Gly Lys Leu Ile Ser Asn
        255                 260
Ser Gln His Ser Thr Thr Thr Pro Leu Lys Ser Asn
265                 270                 275
Gly Asn Gln Gly Phe Phe Ile Phe Ser Arg Leu Glu
            280                 285
Val Ala Lys Thr Leu Trp Thr Gln Arg Lys Gln Phe
    290                 295                 300
Thr Cys Gln Val Ile His Glu Ala Leu Gln Lys Pro
                305                 310
Arg
```

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

```
Cys Gly Glu Thr Tyr Gln Ser Arg Val Thr His Pro
  1               5                  10
His Leu Pro Arg Ala Leu Met Arg Ser Thr Thr Lys
          15                  20
Cys
 25
```

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Cys Gly Glu Thr Tyr Tyr Ser Arg Val Thr His Pro
1 5 10
His Leu Pro Lys Asp Ile Val Arg Ser Ile Ala Lys
15 20
Cys
25

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

Cys Gly Glu Gly Tyr Gln Ser Arg Val Asp His Pro
1 5 10
His Phe Pro Lys Pro Ile Val Arg Ser Ile Thr Lys
15 20
Cys
25

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

Cys Gly Tyr Gly Tyr Gln Ser Ile Val Asp Arg Pro
1 5 10
Asp Phe Pro Lys Pro Ile Val Arg Ser Ile Thr Leu
15 20
Cys
25

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

Lys Lys Lys Ile Ile Thr Ile Thr Arg Ile Ile Thr
1 5 10
Ile Ile Thr Thr Ile Asp
15

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 1

(D) OTHER INFORMATION: /note= "Ile, Met or Leu"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 2
(D) OTHER INFORMATION: /note= "Ser or Thr"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 5
(D) OTHER INFORMATION: /note= "Lys or Arg"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 6
(D) OTHER INFORMATION: /note= "Gly or Thr"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 10
(D) OTHER INFORMATION: /note= "His or Thr"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 11
(D) OTHER INFORMATION: /note= "Lys or Arg"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 12
(D) OTHER INFORMATION: /note= "Ile, Met or Leu"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 14
(D) OTHER INFORMATION: /note= "Gly or Thr"

(ix) FEATURE:
(A) NAME/KEY: Modified-site

(B) LOCATION: 15
(D) OTHER INFORMATION: /note= "Ile, Met or Val"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

Xaa Xaa Glu Ile Xaa Xaa Val Ile Val Xaa Xaa Xaa
1 5 10
Glu Xaa Xaa
15

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 3
(D) OTHER INFORMATION: /note= "Ile, Met or Leu"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 4
(D) OTHER INFORMATION: /note= "Ser or Thr"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 7
(D) OTHER INFORMATION: /note= "Lys or Arg"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 8
(D) OTHER INFORMATION: /note= "Gly or Thr"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 12
(D) OTHER INFORMATION: /note= "His or Thr"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 13
(D) OTHER INFORMATION: /note= "Lys or Arg"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 14
(D) OTHER INFORMATION: /note= "Ile, Met or Leu"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 16
(D) OTHER INFORMATION: /note= "Gly Or Thr"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 17
(D) OTHER INFORMATION: /note= "Ile, Met or Val"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

Ile Ser Xaa Xaa Glu Ile Xaa Xaa Val Ile Val Xaa
1 5 10
Xaa Xaa Glu Xaa Xaa Leu Phe
15

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

Thr Ile Asn Lys Pro Lys Gly Tyr Val Gly Lys Glu
1 5 10

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

Thr Ala Lys Ser Lys Lys Phe Pro Ser Tyr Thr Ala
1 5 10
Thr Tyr Gln Phe
15

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 45 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

Lys Lys Lys Ile Ile Thr Ile Thr Arg Ile Ile Thr
1 5 10
Ile Ile Thr Thr Ile Asp Gly Gly Cys Gly Glu Thr
15 20

```
Tyr Gln Ser Arg Val Thr His Pro His Leu Pro Arg
 25                  30                  35
Ala Leu Met Arg Ser Thr Thr Lys Cys
             40                  45
```

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 63 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

```
Thr Ala Lys Ser Lys Lys Phe Pro Ser Tyr Thr Ala
  1               5                  10
Thr Tyr Gln Phe Gly Gly Lys Lys Lys Ile Ile Thr
          15                  20

Ile Thr Arg Ile Ile Thr Ile Ile Thr Thr Ile Asp
 25                  30                  35
Gly Gly Cys Gly Glu Thr Tyr Gln Ser Arg Val Thr
             40                  45
His Pro His Leu Pro Arg Ala Leu Met Arg Ser Thr
      50                  55                  60
Thr Lys Cys
```

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

Pro Pro Xaa Pro Xaa Pro
1 5

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 59 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

Thr Ile Asn Lys Pro Lys Gly Tyr Val Gly Lys Glu
1 5 10
Gly Gly Lys Lys Lys Ile Ile Thr Ile Thr Arg Ile
15 20
Ile Thr Ile Ile Thr Thr Ile Asp Gly Gly Cys Gly
25 30 35
Glu Thr Tyr Gln Ser Arg Val Thr His Pro His Leu
40 45
Pro Arg Ala Leu Met Arg Ser Thr Thr Lys Cys
50 55

(2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 46 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 4

(D) OTHER INFORMATION: /note= "Ser or Thr"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 7
(D) OTHER INFORMATION: /note= "Lys or Arg"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 8
(D) OTHER INFORMATION: /note= "Gly Or Thr"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 12
(D) OTHER INFORMATION: /note= "His Or Thr"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 13
(D) OTHER INFORMATION: /note= "Lys or Arg"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 16
(D) OTHER INFORMATION: /note= "Gly Or Thr"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

```
Ile Ser Ile Xaa Glu Ile Xaa Xaa Val Ile Val Xaa
 1               5                  10

Xaa Ile Glu Xaa Ile Leu Phe Gly Gly Cys Gly Glu
        15                  20

Thr Tyr Gln Ser Arg Val Thr His Pro His Leu Pro
 25                  30                  35

Arg Ala Leu Met Arg Ser Thr Thr Lys Cys
            40                  45
```

(2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 63 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 21
(D) OTHER INFORMATION: /note= "Ser or Thr"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 24
(D) OTHER INFORMATION: /note= "Lys or Arg"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 25
(D) OTHER INFORMATION: /note= "Gly Or Thr"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 29
(D) OTHER INFORMATION: /note= "His Or Thr"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 30
(D) OTHER INFORMATION: /note= "Lys or Arg"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 33
(D) OTHER INFORMATION: /note= "Gly Or Thr"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

```
Thr Ala Lys Ser Lys Lys Phe Pro Ser Tyr Thr Ala
 1               5                  10
Thr Gln Phe Gly Gly Ile Ser Ile Xaa Glu Ile Xaa
            15                  20
Xaa Val Ile Val Xaa Xaa Ile Glu Xaa Ile Leu Phe
 25                  30                  35
Gly Gly Cys Gly Glu Thr Tyr Gln Ser Arg Val Thr
                40                  45
His Pro His Leu Pro Arg Ala Leu Met Arg Ser Thr
     50                  55                  60
Thr Lys Cys
```

(2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 60 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 18
(D) OTHER INFORMATION: /note= "Ser or Thr"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 21
(D) OTHER INFORMATION: /note= "Lys or Arg"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 22
(D) OTHER INFORMATION: /note= "Gly or Thr"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 26

(D) OTHER INFORMATION: /note= "His or Thr"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 27
(D) OTHER INFORMATION: /note= "Lys or Arg"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 30
(D) OTHER INFORMATION: /note= "Gly or Thr"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

```
Thr Ile Asn Lys Pro Lys Gly Tyr Val Gly Lys Glu
 1               5                  10
Gly Gly Ile Ser Ile Xaa Glu Ile Xaa Xaa Val Ile
        15                  20
Val Xaa Xaa Ile Glu Xaa Ile Leu Phe Gly Gly Cys
 25                 30                  35
Gly Glu Thr Tyr Gln Ser Arg Val Thr His Pro His
            40                  45
Leu Pro Arg Ala Leu Met Arg Ser Thr Thr Lys Cys
 50                 55                  60
```

(2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 42 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "Ile, Met or Leu"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 2
(D) OTHER INFORMATION: /note= "Ser or Thr"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 5
(D) OTHER INFORMATION: /note= "Lys or Arg"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 6
(D) OTHER INFORMATION: /note= "Gly or Thr"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 10
(D) OTHER INFORMATION: /note= "His or Thr"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 11
(D) OTHER INFORMATION: /note= "Lys or Arg"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 12
(D) OTHER INFORMATION: /note= "Ile, Met or Leu"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 14
(D) OTHER INFORMATION: /note= "Gly or Thr"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 15
(D) OTHER INFORMATION: /note= "Ile, Met or Val"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

```
Xaa Xaa Glu Ile Xaa Xaa Val Ile Val Xaa Xaa Xaa
 1               5                  10
Glu Xaa Xaa Gly Gly Cys Gly Glu Thr Tyr Gln Ser
        15                  20
Arg Val Thr His Pro His Leu Pro Arg Ala Leu Met
 25                  30                  35
Arg Ser Thr Thr Lys Cys
            40
```

(2) INFORMATION FOR SEQ ID NO:22:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 60 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 19
(D) OTHER INFORMATION: /note= "Ile, Met or Leu"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 20
(D) OTHER INFORMATION: /note= "Ser or Thr"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 23
(D) OTHER INFORMATION: /note= "Lys or Arg"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 24
(D) OTHER INFORMATION: /note= "Gly or Thr"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 28
(D) OTHER INFORMATION: /note= "His or Thr"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 29
(D) OTHER INFORMATION: /note= "Lys or Arg"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 30
(D) OTHER INFORMATION: /note= "Ile, Met or Leu"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 32
(D) OTHER INFORMATION: /note= "Gly or Thr"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 33
(D) OTHER INFORMATION: /note= "Ile, Met or Val"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

```
Thr Ala Lys Ser Lys Lys Phe Pro Ser Tyr Thr Ala
 1               5                  10
Thr Tyr Gln Phe Gly Gly Xaa Xaa Glu Ile Xaa Xaa
            15                  20
Val Ile Val Xaa Xaa Xaa Glu Xaa Xaa Gly Gly Cys
 25                  30                  35
Gly Glu Thr Tyr Gln Ser Arg Val Thr His Pro His
                40                  45
Leu Pro Arg Ala Leu Met Arg Ser Thr Thr Lys Cys
     50                  55                  60
```

(2) INFORMATION FOR SEQ ID NO:23:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 56 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 15
D) OTHER INFORMATION: /note= "Ile, Met or Leu"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 16
(D) OTHER INFORMATION: /note= "Ser or Thr"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 19
(D) OTHER INFORMATION: /note= "Lys or Arg"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 20
(D) OTHER INFORMATION: /note= "Gly or Thr"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 24
(D) OTHER INFORMATION: /note= "His or Thr"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 25
(D) OTHER INFORMATION: /note= "Lys or Arg"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 26
(D) OTHER INFORMATION: /note= "Ile, Met or Leu"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 28
(D) OTHER INFORMATION: /note= "Gly or Thr"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 29
(D) OTHER INFORMATION: /note= "Ile, Met, or Val"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

Thr Ile Asn Lys Pro Lys Gly Tyr Val Gly Lys Glu
1 5 10
Gly Gly Xaa Xaa Glu Ile Xaa Xaa Val Ile Val Xaa
15 20
Xaa Xaa Glu Xaa Xaa Gly Gly Cys Gly Glu Thr Tyr
25 30 35
Gln Ser Arg Val Thr His Pro His Leu Pro Arg Ala
40 45
Leu Met Arg Ser Thr Thr Lys Cys
50 55

(2) INFORMATION FOR SEQ ID NO:24:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 46 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 4

(D) OTHER INFORMATION: /note= "Ser or Thr"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 7
(D) OTHER INFORMATION: /note= "Lys or Arg"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 8
(D) OTHER INFORMATION: /note= "Gly or Thr"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 12
(D) OTHER INFORMATION: /note= "His or Thr"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 13
(D) OTHER INFORMATION: /note= "Lys or Arg"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 16
(D) OTHER INFORMATION: /note= "Gly or Thr"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

```
Ile Ser Ile Xaa Glu Ile Xaa Xaa Val Ile Val Xaa
 1               5                  10

Xaa Ile Glu Xaa Ile Leu Phe Gly Gly Cys Gly Tyr
            15                  20
Gly Tyr Gln Ser Ile Val Asp His Pro Asp Phe Pro
 25                  30                  35
Lys Pro Ile Val Arg Ser Ile Thr Lys Cys
             40                  45
```

(2) INFORMATION FOR SEQ ID NO:25:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 45 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

Lys Lys Lys Ile Ile Thr Ile Thr Arg Ile Ile Thr
1 5 10
Ile Ile Thr Thr Ile Asp Gly Gly Cys Gly Tyr Gly
15 20
Tyr Gln Ser Ile Val Asp His Pro Asp Phe Pro Lys
25 30 35
Pro Ile Val Arg Ser Ile Thr Lys Cys
40 45

(2) INFORMATION FOR SEQ ID NO:26:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 45 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

Lys Lys Lys Ile Ile Thr Ile Thr Arg Ile Ile Thr
1 5 10
Ile Ile Thr Thr Ile Asp Gly Gly Cys Gly Glu Thr
15 20

Tyr Tyr Ser Arg Val Thr His Pro His Leu Pro Lys
25 30 35

Asp Ile Val Arg Ser Ile Ala Lys Cys
40 45

(2) INFORMATION FOR SEQ ID NO:27:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 46 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "Met or Leu"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 2
(D) OTHER INFORMATION: /note= "Thr"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 7
(D) OTHER INFORMATION: /note= "Arg"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 8
(D) OTHER INFORMATION: /note= "Thr"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 12
(D) OTHER INFORMATION: /note= "Thr"

(ix) FEATURE:
(A) NAME/KEY: Modified-site

(B) LOCATION: 13
(D) OTHER INFORMATION: /note= "Arg"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 14
(D) OTHER INFORMATION: /note= "Met or Leu"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 16
(D) OTHER INFORMATION: /note= "Thr"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 17
(D) OTHER INFORMATION: /note= "Met or Val"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

```
Ile Ser Ile Ser Glu Ile Lys Gly Val Ile Val His
 1               5                  10
Lys Ile Glu Gly Ile Leu Phe Gly Gly Cys Gly Glu
            15                  20
Thr Tyr Tyr Ser Arg Val Thr His Pro His Leu Pro
 25                  30                  35
Lys Asp Ile Val Arg Ser Ile Ala Lys Cys
             40                  45
```

(2) INFORMATION FOR SEQ ID NO:28:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 49 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

```
Cys Ala Asp Ser Asn Pro Arg Gly Val Ser Ala Tyr
 1               5                  10
Leu Ser Arg Pro Ser Pro Phe Asp Leu Phe Ile Arg
            15                  20
Lys Ser Pro Thr Ile Thr Ser Leu Val Val Asp Leu
 25                  30                  35

Ala Pro Ser Lys Gly Thr Val Asn Leu Thr Trp Ser
             40                  45
Arg
```

(2) INFORMATION FOR SEQ ID NO:29:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 60 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

```
Gln Gly His Thr Phe Glu Asp Ser Thr Lys Lys Cys
 1               5                  10
Ala Asp Ser Asn Pro Arg Gly Val Ser Ala Tyr Leu
            15                  20
Ser Arg Pro Ser Pro Phe Asp Leu Phe Ile Arg Lys
 25                  30                  35
Ser Pro Thr Ile Thr Ser Leu Val Val Asp Leu Ala
             40                  45
Pro Ser Lys Gly Thr Val Asn Leu Thr Trp Ser Arg
 50                  55                  60
```

(2) INFORMATION FOR SEQ ID NO:30:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 64 amino acids

(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

```
Gln Val Thr Tyr Gln Gly His Thr Phe Glu Asp Ser
 1               5                  10
Thr Lys Lys Cys Ala Asp Ser Asn Pro Arg Gly Val
            15                  20
Ser Ala Tyr Leu Ser Arg Pro Ser Pro Phe Asp Leu
 25                  30                  35
Phe Ile Arg Lys Ser Pro Thr Ile Thr Ser Leu Val
             40                  45
Val Asp Leu Ala Pro Ser Lys Gly Thr Val Asn Leu
 50                  55                  60
Thr Trp Ser Arg
```

(2) INFORMATION FOR SEQ ID NO:31:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 76 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

```
Gln Lys His Trp Leu Ser Asp Arg Thr Tyr Thr Ser
 1               5                  10
Gln Val Thr Tyr Gln Gly His Thr Phe Glu Asp Ser
            15                  20
Thr Lys Lys Cys Ala Asp Ser Asn Pro Arg Gly Val
 25                  30                  35
Ser Ala Tyr Leu Ser Arg Pro Ser Pro Phe Asp Leu
             40                  45
Phe Ile Arg Lys Ser Pro Thr Ile Thr Ser Leu Val
 50                  55                  60
```

Val Asp Leu Ala Pro Ser Lys Gly Thr Val Asn Leu
65 70
Thr Trp Ser Arg
75

(2) INFORMATION FOR SEQ ID NO:32:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 35 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

Cys Ala Asp Ser Asn Pro Arg Gly Val Ser Ala Tyr
1 5 10
Leu Ser Arg Pro Ser Pro Phe Asp Leu Phe Ile Arg
15 20
Lys Ser Pro Thr Ile Thr Ser Leu Val Val Asp
25 30 35

(2) INFORMATION FOR SEQ ID NO:33:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 46 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

Gln Gly His Thr Phe Glu Asp Ser Thr Lys Lys Cys
1 5 10
Ala Asp Ser Asn Pro Arg Gly Val Ser Ala Tyr Leu
15 20

Ser Arg Pro Ser Pro Phe Asp Leu Phe Ile Arg Lys
25 30 35
Ser Pro Thr Ile Thr Ser Leu Val Val Asp
40 45

(2) INFORMATION FOR SEQ ID NO:34:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 50 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

Gln Val Thr Tyr Gln Gly His Thr Phe Glu Asp Ser
1 5 10

Thr Lys Lys Cys Ala Asp Ser Asn Pro Arg Gly Val
15 20
Ser Ala Tyr Leu Ser Arg Pro Ser Pro Phe Asp Leu
25 30 35
Phe Ile Arg Lys Ser Pro Thr Ile Thr Ser Leu Val
40 45
Val Asp
50

(2) INFORMATION FOR SEQ ID NO:35:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 62 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:

```
Gln Lys His Trp Leu Ser Asp Arg Thr Tyr Thr Ser
 1               5                  10
Gln Val Thr Tyr Gln Gly His Thr Phe Glu Asp Ser
            15                  20
Thr Lys Lys Cys Ala Asp Ser Asn Pro Arg Gly Val
        25                  30                  35
Ser Ala Tyr Leu Ser Arg Pro Ser Pro Phe Asp Leu
                40                  45
Phe Ile Arg Lys Ser Pro Thr Ile Thr Ser Leu Val
    50                  55                  60
Val Asp
```

(2) INFORMATION FOR SEQ ID NO:36:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:

```
Cys Ala Asp Ser Asn Pro Arg Gly Val Ser Ala Tyr
 1               5                  10
Leu Ser Arg Pro Ser Pro Phe Asp Leu Phe Ile Arg
            15                  20
Lys Ser Pro Thr Ile
        25
```

(2) INFORMATION FOR SEQ ID NO:37:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 40 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:

```
Gln Gly His Thr Phe Glu Asp Ser Thr Lys Lys Cys
 1               5                  10
Ala Asp Ser Asn Pro Arg Gly Val Ser Ala Tyr Leu
         15                  20
Ser Arg Pro Ser Pro Phe Asp Leu Phe Ile Arg Lys
 25                  30                  35
Ser Pro Thr Ile
             40
```

(2) INFORMATION FOR SEQ ID NO:38:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 44 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:

```
Gln Val Thr Tyr Gln Gly His Thr Phe Glu Asp Ser
 1               5                  10
Thr Lys Lys Cys Ala Asp Ser Asn Pro Arg Gly Val
         15                  20
Ser Ala Tyr Leu Ser Arg Pro Ser Pro Phe Asp Leu
 25                  30                  35
Phe Ile Arg Lys Ser Pro Thr Ile
             40
```

(2) INFORMATION FOR SEQ ID NO:39:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 56 amino acids

(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:

```
Gln Lys His Trp Leu Ser Asp Arg Thr Tyr Thr Ser
 1               5                  10
Gln Val Thr Tyr Gln Gly His Thr Phe Glu Asp Ser
            15                  20
Thr Lys Lys Cys Ala Asp Ser Asn Pro Arg Gly Val
 25                  30                  35
Ser Ala Tyr Leu Ser Arg Pro Ser Pro Phe Asp Leu
            40                  45
Phe Ile Arg Lys Ser Pro Thr Ile
 50                  55
```

(2) INFORMATION FOR SEQ ID NO:40:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 76 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:

```
Gln Lys His Trp Leu Ser Asp Arg Thr Tyr Thr Cys
 1               5                  10
Gln Val Thr Tyr Gln Gly His Thr Phe Glu Asp Ser
            15                  20
Thr Lys Lys Cys Ala Asp Ser Asn Pro Arg Gly Val
 25                  30                  35
Ser Ala Tyr Leu Ser Arg Pro Ser Pro Phe Asp Leu
            40                  45
Phe Ile Arg Lys Ser Pro Thr Ile Thr Cys Leu Val
 50                  55                  60
```

Val Asp Leu Ala Pro Ser Lys Gly Thr Val Asn Leu
65 70
Thr Trp Ser Arg
75

(2) INFORMATION FOR SEQ ID NO:41:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:

Cys Lys Gln Arg Asn Gly Thr Leu Thr Cys
1 5 10

(2) INFORMATION FOR SEQ ID NO:42:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 45 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:

Gln Lys His Trp Leu Ser Asp Arg Thr Tyr Thr Cys
1 5 10
Gln Val Thr Tyr Gln Gly His Thr Phe Glu Asp Ser
15 20
Thr Lys Lys Cys Ala Asp Ser Asn Pro Arg Gly Val
25 30 35
Ser Ala Tyr Leu Ser Arg Pro Ser Pro
40 45

(2) INFORMATION FOR SEQ ID NO:43:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:

Cys Pro Ser Lys Gly Thr Val Asn Leu Thr Trp Ser
1 5 10
Arg Ala Ser Gly Lys Pro Val Asn His Ser Thr Arg
15 20
Lys Glu Glu Lys Gln Arg Asn Gly Thr Cys
25 30

(2) INFORMATION FOR SEQ ID NO:44:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:

Cys Pro Val Gly Thr Arg Asp Trp Ile Glu Gly Glu
1 5 10
Thr Tyr Gln Cys Arg Val Thr His Pro His Leu Pro
15 20
Arg Ala Leu Met Arg Ser Thr Thr Cys
25 30

(2) INFORMATION FOR SEQ ID NO:45:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:45:

Ser Thr Thr Lys Thr Ser Gly Pro Arg Ala Ala Pro Glu Val
1 5 10

(2) INFORMATION FOR SEQ ID NO:46:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:46:

Cys Trp Ser Arg Ala Ser Gly Lys Pro Val Cys Asn His Ser
1 5 10

(2) INFORMATION FOR SEQ ID NO:47:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:47:

Cys Ser Arg Pro Ser Pro Phe Asp Leu Phe Ile Arg
1 5 10
Lys Ser Pro Thr Ile Thr Cys
15

(2) INFORMATION FOR SEQ ID NO:48:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:48:

Cys Val Gly Thr Arg Asp Trp Ile Glu Gly Glu Pro Cys
1 5 10

(2) INFORMATION FOR SEQ ID NO:49:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:49:

Cys Pro Pro Val Gly Thr Arg Asp Trp Ile Glu Gly
1 5 10
Glu Pro Cys
15

(2) INFORMATION FOR SEQ ID NO:50:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:50:

Cys Lys Glu Glu Lys Gln Arg Asn Gly Thr Leu Thr
1 5 10

Val Thr Ser Cys
15

(2) INFORMATION FOR SEQ ID NO:51:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 8 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:51:

Lys Glu Glu Lys Gln Arg Asn Gly
1 5

(2) INFORMATION FOR SEQ ID NO:52:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:52:

Cys Trp Ser Arg Ala Ser Gly Lys Pro Val Cys
1 5 10

(2) INFORMATION FOR SEQ ID NO:53:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:53:

Pro Thr Ile Thr Cys Leu Val Leu Asp Leu Ala Pro
1 5 10
Ser Lys Gly Thr Val Asn Leu Thr Cys
15 20

(2) INFORMATION FOR SEQ ID NO:54:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:54:

Pro Thr Ile Thr Cys Leu Val Leu Asp Leu Ala Pro
1 5 10
Ser Lys Gly Thr
15

(2) INFORMATION FOR SEQ ID NO:55:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:55:

Thr Ser Thr Leu Pro Val Gly Thr Arg Asp Trp Ile
1 5 10
Glu Gly Glu Thr Tyr Gln Cys Arg Val Thr His Pro
15 20
His
25

(2) INFORMATION FOR SEQ ID NO:56:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:56:

Pro Thr Ile Thr Ser Leu Val Leu Cys Leu Ala Pro
1 5 10
Ser Lys Gly Cys
15

(2) INFORMATION FOR SEQ ID NO:57:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 amino acids

(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:57:

```
Cys Val Asn Leu Thr Trp Ser Arg Ala Ser Gly Lys
 1               5                  10
Pro Val Asn His Ser Thr Arg Lys Glu Glu Cys
          15                  20
```

(2) INFORMATION FOR SEQ ID NO:58:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 53 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:58:

```
Cys Thr Trp Ser Arg Ala Ser Gly Lys Pro Val Asn
 1               5                  10

His Ser Thr Arg Lys Glu Glu Lys Gln Arg Asn Gly
          15                  20
Thr Leu Thr Val Thr Ser Thr Leu Pro Val Gly Thr
 25                  30                  35
Arg Asp Trp Ile Glu Gly Glu Thr Tyr Gln Cys Arg
             40                  45
Val Thr His Pro His
     50
```

(2) INFORMATION FOR SEQ ID NO:59:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:59:

Lys Thr Lys Gly Ser Gly Phe Phe Val Phe
1 5 10

(2) INFORMATION FOR SEQ ID NO:60:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 4
(D) OTHER INFORMATION: /note= "Ser or Thr"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 7
(D) OTHER INFORMATION: /note= "Lys or Arg"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 8
(D) OTHER INFORMATION: /note= "Gly or Thr"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 12

(D) OTHER INFORMATION: /note= "His or Thr"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 13
(D) OTHER INFORMATION: /note= "Lys or Arg"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 16
(D) OTHER INFORMATION: /note= "Gly or Thr"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:60:

Ile Ser Ile Xaa Glu Ile Xaa Xaa Val Ile Val Xaa
1 5 10
Xaa Ile Glu Xaa Ile Leu Phe
15

(2) INFORMATION FOR SEQ ID NO:61:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:61:

Leu Ser Glu Ile Lys Gly Val Ile Val His Arg Leu
1 5 10
Glu Gly Val
15

(2) INFORMATION FOR SEQ ID NO:62:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:62:

Gly Ile Leu Glu Ser Arg Gly Ile Lys Ala Arg Ile
1 5 10
Thr His Val Asp Thr Glu Ser Tyr
15 20

(2) INFORMATION FOR SEQ ID NO:63:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:63:

Lys Lys Gln Tyr Ile Lys Ala Asn Ser Lys Phe Ile
1 5 10
Gly Ile Thr Glu Leu
15

(2) INFORMATION FOR SEQ ID NO:64:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:64:

```
Lys Lys Phe Asn Asn Phe Thr Val Ser Phe Trp Leu
 1               5                  10
Arg Val Pro Lys Val Ser Ala Ser His Leu
            15                  20
```

(2) INFORMATION FOR SEQ ID NO:65:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:65:

```
Lys Lys Leu Arg Arg Leu Leu Tyr Met Ile Tyr Met
 1               5                  10
Ser Gly Leu Ala Val Arg Val His Val Ser Lys Glu
            15                  20
Glu Gln Tyr Tyr Asp Tyr
 25                  30
```

(2) INFORMATION FOR SEQ ID NO:66:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:66:

```
Tyr Asp Pro Asn Tyr Leu Arg Thr Asp Ser Asp Lys
 1               5                  10
```

Asp Arg Phe Leu Gln Thr Met Val Lys Leu Phe Asn
15 20
Arg Ile Lys
25

(2) INFORMATION FOR SEQ ID NO:67:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:67:

Gly Ala Tyr Ala Arg Cys Pro Asn Gly Thr Arg Ala
1 5 10
Leu Thr Val Ala Glu Leu Arg Gly Asn Ala Glu Leu
15 20

(2) INFORMATION FOR SEQ ID NO:68:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:68:

Phe Phe Leu Leu Thr Arg Ile Leu Thr Ile Pro Gln
1 5 10
Ser Leu Asp
15

(2) INFORMATION FOR SEQ ID NO:69:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:69:

Val Ser Phe Gly Val Trp Ile Arg Thr Pro Pro Ala
1 5 10
Tyr Arg Pro Pro Asn Ala Pro Ile Leu
15 20

(2) INFORMATION FOR SEQ ID NO:70:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:70:

Ser Asp Phe Phe Pro Ser Val Arg Asp Leu Leu Asp
1 5 10
Thr Ala Ser Ala Leu Tyr Arg Glu
15 20

(2) INFORMATION FOR SEQ ID NO:71:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:71:

Pro His His Thr Ala Leu Arg Gln Ala Ile Leu Cys
1 5 10
Trp Gly Glu Leu Met Thr Leu Ala
15 20

(2) INFORMATION FOR SEQ ID NO:72:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:72:

Trp Val Arg Asp Ile Ile Asp Asp Phe Thr Asn Glu
1 5 10
Ser Ser Gln Lys Thr
15

(2) INFORMATION FOR SEQ ID NO:73:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:73:

Arg Ala Gly Arg Ala Ile Leu His Ile Pro Thr Arg
1 5 10

Ile Arg Gln Gly Leu Glu Arg
15

(2) INFORMATION FOR SEQ ID NO:74:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:74:

Ala Val Ala Glu Gly Thr Asp Arg Val Ile Glu Val
1 5 10

Leu Gln Arg Ala Gly Arg Ala Ile Leu
15 20

(2) INFORMATION FOR SEQ ID NO:75:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:75:

Ala Leu Asn Ile Trp Asp Arg Phe Asp Val Phe Ser
1 5 10
Thr Leu Gly Ala Thr Ser Gly Tyr Leu Lys Gly Asn
15 20
Ser
25

(2) INFORMATION FOR SEQ ID NO:76:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:76:

```
Asp Ser Glu Thr Ala Asp Asn Leu Glu Lys Thr Val
 1               5                  10
Ala Ala Leu Ser Ile Leu Pro Gly His Gly
            15                  20
```

(2) INFORMATION FOR SEQ ID NO:77:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 39 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:77:

```
Glu Glu Ile Val Ala Gln Ser Ile Ala Leu Ser Ser
 1               5                  10
Leu Met Val Ala Gln Ala Ile Pro Leu Val Gly Glu
            15                  20
Leu Val Asp Ile Gly Phe Ala Ala Thr Asn Phe Val
 25                  30                  35
Glu Ser Cys
```

(2) INFORMATION FOR SEQ ID NO:78:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:78:

Asp Ile Glu Lys Lys Ile Ala Lys Met Glu Lys Ala
1 5 10
Ser Ser Val Phe Asn Val Val Asn Ser
15 20

(2) INFORMATION FOR SEQ ID NO:79:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:79:

Lys Trp Phe Lys Thr Asn Ala Pro Asn Gly Val Asp
1 5 10

Glu Lys Ile Arg Ile
15

(2) INFORMATION FOR SEQ ID NO:80:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:80:

Gly Leu Gln Gly Lys Ile Ala Asp Ala Val Lys Ala
1 5 10
Lys Gly

(2) INFORMATION FOR SEQ ID NO:81:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:81:

Gly Leu Ala Ala Gly Leu Val Gly Met Ala Ala Asp
1 5 10
Ala Met Val Glu Asp Val Asn
15

(2) INFORMATION FOR SEQ ID NO:82:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:82:

Ser Thr Glu Thr Gly Asn Gln His His Tyr Gln Thr
1 5 10
Arg Val Val Ser Asn Ala Asn Lys
15 20

(2) INFORMATION FOR SEQ ID NO:83:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:83:

Cys Pro Ser Pro Phe Asp Leu Phe Ile Arg Lys Ser
1 5 10
Pro Thr Cys
15

(2) INFORMATION FOR SEQ ID NO:84:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:84:

Cys Gly Glu Thr Tyr Lys Ser Thr Val Ser His Pro
1 5 10
Asp Leu Pro Arg Glu Val Val Arg Ser Ile Ala Lys
15 20
Cys
25

(2) INFORMATION FOR SEQ ID NO:85:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 60 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide
(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 18
(D) OTHER INFORMATION: /note= "Thr"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 21
(D) OTHER INFORMATION: /note= "Arg"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 22
(D) OTHER INFORMATION: /note= "Thr"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 26
(D) OTHER INFORMATION: /note= "Thr"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 27
(D) OTHER INFORMATION: /note= "Arg"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 30
(D) OTHER INFORMATION: /note= "Thr"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:85:

Thr Ile Asn Lys Pro Lys Gly Tyr Val Gly Lys Glu
1 5 10

Gly Gly Ile Ser Ile Ser Glu Ile Lys Gly Val Ile
15 20
Val His Lys Ile Glu Gly Ile Leu Phe Gly Gly Cys
25 30 35
Gly Gly Thr Tyr Gln Ser Arg Val Thr His Pro His
40 45
Leu Pro Arg Ala Leu Met Arg Ser Thr Thr Lys Cys
50 55 60

(2) INFORMATION FOR SEQ ID NO:86:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:86:

Lys Trp Phe Lys Thr Asn Ala Pro Asn Gly Val Asp
1 5 10
Glu Lys Ile Arg Ile
15

(2) INFORMATION FOR SEQ ID NO:87:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 62 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:87:

Lys Trp Phe Lys Thr Asn Ala Pro Asn Gly Val Asp
1 5 10
Glu Lys Ile Arg Ile Lys Lys Lys Lys Ile Ile Thr
15 20

Ile Thr Arg Ile Ile Thr Ile Ile Thr Yhr Ile Asp
25 30 35
Lys Cys Gly Glu Thr Tyr Tyr Ser Arg Val Thr His
40 45
Pro His Leu Pro Lys Asp Ile Val Arg Ser Ile Ala
50 55 60
Lys Cys

(2) INFORMATION FOR SEQ ID NO:88:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 57 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:88:

Thr Ile Asn Lys Pro Lys Gly Tyr Val Gly Lys Glu
1 5 10
Lys Lys Lys Lys Ile Ile Thr Ile Thr Arg Ile Ile
15 20
Thr Ile Ile Thr Tyr Ile Asp Lys Cys Gly Glu Thr
25 30 35
Tyr Tyr Ser Arg Val Thr His Pro His Leu Pro Lys
40 45
Asp Ile Val Arg Ser Ile Ala Lys Cys
50 55

(2) INFORMATION FOR SEQ ID NO:89:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:89:

Ile Ser Leu Thr Glu Ile Arg Thr Val Ile Val Thr
1 5 10
Arg Leu Glu Thr Val Leu Phe
15

(2) INFORMATION FOR SEQ ID NO:90:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 45 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:90:

Ile Ser Leu Thr Glu Ile Arg Thr Val Ile Val Thr
1 5 10
Arg Leu Glu Thr Val Leu Phe □Lys Cys Gly Glu Thr
15 20
Tyr Tyr Ser Arg Val Thr His Pro His Leu Pro Lys
25 30 35
Asp Ile Val Arg Ser Ile Ala Lys Cys
40 45

(2) INFORMATION FOR SEQ ID NO:91:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 63 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:91:

```
Lys Trp Phe Lys Thr Asn Ala Pro Asn Gly Val Asp
 1               5                  10
Glu Lys Ile Arg Ile □Lys Ile Ser Leu Thr Glu Ile
            15                  20
Arg Thr Val Ile Val Thr Arg Leu Glu Thr Val Leu
 25                  30                  35
Phe □Lys Cys Gly Glu Thr Tyr Tyr Ser Arg Val Thr
             40                  45
His Pro His Leu Pro Lys Asp Ile Val Arg Ser Ile
 50                  55                  60
Ala Lys Cys
```

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/13959

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :C07K 16/46; A61K 39/44
US CL :530/387.1, 403; 424/180.1, 193.1
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 530/387.1, 403; 424/180.1, 193.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	BURT, D. S. et al., Analysis of the interaction between rat immunoglobulin E and rat mast cells using anti-peptide antibodies, Molecular Immunology, 1987, Vol. 24, No. 4, pages 379-389.	1-27
Y	BURT, D. S. et al., Inhibition of binding of rat IgE to rat mast cells by synthetic IgE peptides, Eur. J. Immunol., 1987, Vol. 17, pages 437-440, see entire document.	1-27
Y	VERCELLI, D. et al., The B-cell binding site of human immunoglobulin E, LETTERS TO NATURE , 20 April 1989, Vol. 338, pages 649-651, see entire document.	1-27

[X] Further documents are listed in the continuation of Box C. [ ] See patent family annex.

*	Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A"	document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E"	earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O"	document referring to an oral disclosure, use, exhibition or other means		
"P"	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search 28 SEPTEMBER 1999	Date of mailing of the international search report 07 OCT 1999
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer THOMAS CUNNINGHAM Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet)(July 1992)*

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/13959

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	HELM, B. et al., The mast cell binding site of human immunoglobulin E, Nature, 14 January 1988, vol. 331, pages 180-183, see entire document.	1-27
Y	WO 93/04173 A1 (GENENTECH INC) 04 March 1993, see entire document.	1-27

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/13959

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-27

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/13959

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING
This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

I. Group I, claims 1-27, directed to peptides, peptide conjugates, polymeric peptide products and methods of using such products to induce antibodies.

II. Group II, claim 28, directed to nucleic acids encoding the peptide products of Group I.

In view of conversations with the Applicant's attorney it is presumed that the inventive concept hinges on the identity of the IgE-CH3 domain and not on the T helper epitope to which it is attached. The T helper epitopes such as those recited by SEQ ID NOS: 9-12, 61-82 and 84 are therefore considered to have the same or corresponding technical features.

The inventions listed as Groups I and II do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: Group I is directed to peptide products which lack the same or corresponding structural and functional features of Group II which is directed to nucleic acids.